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Abstract 
Aim: Pre-eclampsia (PE) is a multifactorial pregnancy related disorder and a major cause of 
perinatal mortality. Mothers who develop PE present with clinical symptoms akin to experimentally 
induced elevated histamine. Maternal blood histamine is elevated, while Diamine Amine Oxidase 
(DAO) level is diminished in PE. The abnormalities in placental development and functions linked 
to aetiology of PE have similarities with effects of elevated histamine in other tissues, yet the 
effects of the elevated histamine on placental function were not directly investigated. Therefore, a 
series of studies were undertaken and published to increase our knowledge and elucidate our 
understanding on: (1) the functionality of elevated histamine in the placenta; (2) the causes of the 
elevated histamine in PE placentae, and (3) of the effects of the elevated histamine on placental 
gene expression and the implications for PE. 
 
Methods: A series of published high-throughput methodologies have been critically discussed in 
this commentary. Molecular biotechnology and bioinformatics methodologies such as, ex vivo 
elevated histamine placental explant model, gene cloning, RT-qPCR, In situ hybridization, 
microarrays, enzymological analysis, ELISA, Immunohistochemistry, RNA expression array assay 
analysis, integrated meta-gene analyses, Gene Set Enrichment Analysis, Gene Ontology and 
biological pathway analyses, Leading Edge Metagene analysis, Systematic Reviews with Meta-
analysis and Causal effect analysis have been discussed. The rationale for the appropriate use of 
these methods to investigate the topological expression of placental histamine receptors, 
regulation of histamine synthesis and production, the effects of elevated histamine on gene 
expression, and functional roles of the elevated histamine regulated genes in human placenta is 
also critically discussed. 
 
Results: The findings show that defective Histamine-DAO-Axis (dHDA) underpins PE, and this 
defect may be precipitated in early pregnancy, thus predating the onset of the clinical 
manifestation of PE in mothers who later develop the complication; histamine receptors H1 and 
H2, and DAO messages are expressed in juxtapositions at the foeto-maternal interface, Histidine 
Decarboxylase (HDC) HDC activity is elevated in PE placentae; and while elevated histamine up-
regulates the proteins for Th1-like cytokines, it also down-regulates DAO message expression 
after prolonged exposure in the placenta. The findings further show that lipopolysaccharides and 
pro-inflammatory cytokines including IL-10 and INF- increase histamine production in the 
placenta; and the histamine has a positive feedback loop regulatory relation with the pro-
inflammatory cytokines.  
 
Furthermore, the validation of Elevated Histamine Model (EHM), an in vitro model designed for 
studying histamine effect in placenta showed that placental micro explants (∼50 mg) in long-term 
culture (explants that have undergone syncytiotrophoblast regeneration) at the liquid-gas interface 
in 8% oxygen is an optimum culture condition to study effects of histamine in the placenta. EHM 
produced RNA with quality akin to time zero pre-culture explants.  
 
The works also led to the identifications of a core set of significant genes that are consistently 
expressed in both normal (NP) in PE placentae but at varying levels, and a further subset of 
significant genes expressed consistently only in PE placentae (PE specific genes). Comparison of 
EHM significant genes with the PE specific genes confirmed the presence of 270 consistently 
expressed genes that appear to underpin the effects of elevated histamine in the placenta with 
implications for PE pathogenesis. Further analyses of these EHM genes in PE placentae showed 
that the natural process by which pre-eclampsia develops is affected by the amount of histamine 
in the maternal blood and placenta, and the natural process by which pre-eclampsia develops is 
indirectly affected by histamine via covariate functional groups regulated by specific histamine 
regulated PE placental genes. 
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Conclusion:  Histamine receptor genes are expressed at the foeto-maternal interface; DAO 
genes are expressed in the placenta; HDC activity levels are increased in PE placentae; there is 
cross-talk between histamine, DAO and cytokines in the placenta; elevated histamine regulated 
the expression of specific genes in the placenta and these genes are abnormally expressed in PE 
placentae; the functions of the histamine regulated genes also identified in PE placentae are 
involved in tissue morphology and possibly poor placentation, metabolic defects, endothelial 
dysfunction, inflammation, immunologic response, angiogenic and anti-angiogenic response in PE 
placentae. Therefore it is reasonable to conclude that the elevated histamine observed in PE 
would have pathophysiological roles in PE and early detection leading to effective control of 
maternal blood histamine levels has survival values and it’s thus recommended. 
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                                        Chapter 1
                                              Introduction 
1.1 Background  
Pre-eclampsia (PE) is a major cause of perinatal mortality and it complicates up to 
8% of all pregnancies in Western countries (Khan et al. 2006, Duley 2009, WHO 
2014). It is one of the top 4 causes of maternal mortality and morbidity worldwide, 
causing 10 to 15% of maternal deaths (Duley 2009, Say et al. 2014, WHO 2014). PE 
is characterised by new hypertension (blood pressure of >140/90 mmHg) on two 
separate readings at least 6 hours apart presenting after 20 weeks' gestation in 
conjunction with clinically relevant proteinuria (>300mg) per 24 hours and/or with 
symptoms, and/or biochemical and/or haematological impairment (Tranquilli et al. 
2014, NICE 2017).  
 
The symptoms, biochemical and haematological impairment are related to maternal 
organ dysfunction including renal insufficiency (creatinine >90 µmol/L; 1.02 mg/ 
dL); liver involvement (elevated transaminases – at least twice upper limit of normal 
± right upper quadrant or epigastric abdominal pain); neurological complications 
(examples include eclampsia, altered mental status, blindness, stroke, or more 
commonly hyperreflexia when accompanied by clonus, severe headaches when 
accompanied by hyperreflexia, and persistent visual scotomata); haematological 
complications (thrombocytopenia – platelet count below 150,000/dL, DIC, 
haemolysis) (Tranquilli et al. 2014). 
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PE is a multifactorial disease, and while there is a cautious acceptance of links 
between familial concordance and maternal polymorphism in the pathogenesis of the 
disorder (Sutherland et al. 1981, Chesley & Cooper 1986, Arngrimsson et al. 1990, 
Cincotta & Brennecke 1998, Esplin et al. 2001, Nilsson et al. 2004, Buurma et al. 
2013, Sitras et al. 2015), the placenta is suggested as the primary cause of PE 
(Myatt 2002, Matsuo et al. 2007). 
 
The notion denoting the placenta as the main cause of PE is embedded in the fact 
that the delivery of the placenta is the only known intervention that cures PE (Matsuo 
et al. 2007). Therefore, the links between PE and placentation is well investigated. 
Placentation is basically the process of formation and growth of the placenta and it 
involves tight regulation of trophoblast proliferation, differentiation and invasion. It is 
initiated shortly after implantation, when the blastocyst makes contact with the 
epithelial lining of the uterus (Damsky et al. 1997, Genbacev & Miller 2000). The 
process enables the trophoblast cells to breach and colonise uterine epithelia, the 
endometrium and surrounding vasculature to allow nutrient supply to the developing 
foetus (Pijnenborg 1988, Castellucci et al. 1990, Genbacev & Miller 2000, Reynolds 
et al. 2010).  
 
The invasion process involves differentiation of the villous cytotrophoblast. Placental 
villi consisting of inner mesenchymal cells surrounded by a monolayer of 
mononuclear villous cytotrophoblast stem cells develop (Fisher & Damsky 1993, 
Meekins et al. 1994, Lyall 2006, Salamonsen et al. 2009). The cytotrophoblast layer 
differentiates by either fusing to form the overlying multinucleated 
syncytiotrophoblast or develops into extravillous trophoblasts (EVT) in anchoring villi 
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(Nelson et al. 1986, Irving et al. 1995, Damsky et al. 1997, James et al. 2005, 
Baczyk et al. 2006). The EVT which migrates away from the placenta differentiates 
further to form invasive extravillous trophoblast (iEVT) (Fisher & Damsky 1993, Zhou 
et al. 1997, Norwitz et al. 2001).  
 
It seems that a major outcome of invading EVT is the adaptation of the decidua to 
sustain pregnancy through remodeling of uterine spiral arteries in readiness for 
increased blood supply required in the second and third trimesters, and 
sequestration of this blood supply from maternal vasoconstriction (Pijnenborg 1988, 
Meekins et al. 1994, Naicker et al. 2003, James et al. 2006, Pringle et al. 2010). The 
invading EVT thus remodel spiral arterioles by replacing maternal endothelium 
(Meekins et al. 1994, Lyall 2003, Pijnenborg et al. 2006a, Pijnenborg et al. 2006b, 
Harris et al. 2010, Pringle et al. 2010), and this morphogenesis is suggested to 
increase the diameter and compliance of the spiral arteries to permit a 12-fold 
increase in uterine blood flow to meet the demands of the growing foetus in later 
gestations (Martin 1965, Pringle et al. 2010). It is during the process of placentation 
that it is believed defective histamine regulation could lead to a cascade of events 
that trigger PE and some trophoblast related complications of human pregnancy. 
 
1.2 Theories of Pre-eclampsia Pathophysiology and the Role of Histamine 
Several theoretical concepts (Figure 1-1A) including abnormal angiogenic and anti-
angiogenic factors, poor placentation, defective immunologic response, metabolic 
disorders, inflammation, and endothelial dysfunction have been proposed to explain 
the pathogenesis of PE (Mol et al. 2016). The conceptualisation of these theories as 
proposed to explain the pathophysiology of PE is complex (Redman 2014). Thus to 
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help with the understanding of the pathophysiology of PE, a two-stage model has 
been advocated (Redman 1991, Sargent et al. 2006, Gammill & Roberts 2007). 
Stage 1 speculates that the initiating perturbation of PE is a relative deficient 
placentation. The deficient placentation when established is suggested to lead to the 
precipitation of systemic inflammatory response that consequently results in the 
maternal pathophysiology of PE (Stage 2) (Redman et al. 1999, Roberts & Hubel 
2009).  
 
Figure 1-1: Theoretical Concepts for Pre-eclampsia Pathogenesis 
Figure A: This is a theoretical conceptualisation of the pathophysiological changes associated with 
pre-eclampsia (PE); Figure B depicts the missing link in the pathophysiology of PE. Figure A is based 
on Redman 1991, Redman et al. 1999, Sargent et al. 2006, Gammill & Roberts 2007, Roberts & 
Hubel 2009, Redman 2014, Ilekis et al. 2016, Mol et al. 2016. Figure B is based on my re-
interpretation of Figure A. 
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While it is accepted that the pathogenesis of PE is multifactorial and defective 
placentation plays critical role in the origins of PE (Ilekis et al. 2016), the changes or 
factors that link the pathophysiological presentations in the placenta to the clinical 
manifestation of PE have not been fully understood. In other words, it is 
acknowledged that stage 1 events are not sufficient to cause the stage 2 
downstream maternal syndrome (Roberts & Hubel 2009), and that there must be a 
missing link with plausible functions to interact with both placental and maternal 
events (genetic, morphological changes, physiological adaptation, behavioural, 
environmental) to precipitate the clinical manifestation of PE (Figure 1-1B). It was 
upon the basis of this proposition that it was hypothesised histamine could be the 
missing link in the pathophysiology of PE, and therefore the ensuing studies 
commenced.  
1.3 How could Histamine be the missing link in Pre-eclampsia Pathogenesis? 
It was observed that trophoblast related complications of human pregnancy including 
pre-eclampsia, preterm labour (PL), spontaneous abortion (SA) and hyperemesis 
gravidarum (HG) present with elevated blood histamine and perilous but varying 
pregnancy and maternal outcomes (Kapeller-Adler 1941, Kapeller-Adler 1949, 
Southren et al. 1963, Beaven et al. 1975, Dubois et al. 1977, Minagawa et al. 1999, 
Redman et al. 1999). Histamine has a well-characterised role in the pathogenesis of 
emesis (Brunton 1996), and experimental elevation of histamine in humans causes 
nausea and vomiting with a clear relationship between dosage of infused histamine 
and severity of nausea and vomiting (Kapeller-Adler 1941, Ind et al. 1982). In 
addition to emesis, intravenous infusion of histamine dose dependently causes rise 
in heart (pulse) rate, temperature and flushing, or fall in diastolic pressure, and 
feeling of constriction in the head, headache (minor and severe depending on dose) 
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with or without visual disturbances, cyanosis, inspiratory dyspnoea, convulsions and 
unconsciousness (Kapeller-Adler 1941, Ind et al. 1982, Kaliner et al. 1982). These 
symptoms are common in HG and PE, however no further commentary will be 
provided on the links between histamine and HG. Similarly, pre-term labour presents 
with elevated histamine (Kirkel' et al. 1983, Caldwell et al. 1988, Riedel et al. 1989, 
Donahue et al. 1995, Kramer et al. 1995, Wen et al. 2001). While the 
pathophysiology of pre-term labour involves inflammatory processes similar to PE, 
the aetiology of pre-term labour is different from PE (Bytautiene et al. 2004a, Steel et 
al. 2005, Romero et al. 2014), and therefore no further consideration is also given to 
it in this commentary. Indeed, these complications of human pregnancy have in 
common precipitation of histamine-like inflammatory response as underlying 
pathogenesis (Regan 1992, Sacks et al. 1998, Minagawa et al. 1999, Sacks et al. 
1999), nonetheless, due to major differences in the respective aetiology further 
discussion is herewith focused on histamine and PE. 
 
Histamine is a pleiotropic amine, which appears in tissues of most vertebrates and 
invertebrates, and the histamine forming capacity of tissues with a net whole blood 
histamine flow within 0.1M range (plasma equivalent in 2.0nM range) is associated 
with various physiological functions such as gastric acid secretion, immuno-
modulation, cell proliferation and differentiation, tissue growth and wound healing 
(Beaven 1982, Falus & Meretey 1992, Kahlson et al. 1960a, Rivera et al. 2000, 
Tetlow & Woolley 2003). In humans, the normal blood histamine follows a bio-
rhythmic change (Rehn et al. 1987), which is maintained by a balanced (Section 
2.2.2 below) between the activities of the synthesising enzyme histidine 
decarboxylase (HDC 4.1.1.22), and the metabolising agents including the copper 
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containing diamine amine oxidase (DAO: EC 1.4.3.6), histamine N-methyltransferase 
(HNMT: EC 2.1.1.8) and plasma ascorbic acid (Beaven 1982, Clemetson 1980, 
Kahlson & Rosengren 1971, Wantke et al. 1998) (section 2.2.3 below).  
 
The elevated blood histamine presents with both clinical symptoms and pathological 
effects including: oedema, hypertension, proteinuria, nausea & vomiting, headaches, 
platelet coagulation, endothelial damage, oxidative stress, dysregulation of glucose 
and lipid metabolism and immune reaction (summarised in Figure 1-2)  (Horakova et 
al. 1977, Beaven 1978, el-Gendi et al. 1988, Shterental' et al. 1991, Thomas et al. 
1991, Ebeigbe & Talabi 2014). These histamine effects are akin to maternal clinical 
manifestation or symptoms of PE. 
 
Figure 1-2: Summary of Systemic Effects of Elevated Histamine  
Figure shows known effects of elevated histamine in human tissues  
 
Also, randomised clinical trials of histamine augmentation confirmed that elevated 
histamine prevents inhibition of T cells and natural killer cells by monocyte-derived 
reactive oxygen metabolites and synergizes with IL-2 to up-regulates Th1 cell 
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responses in patients with melanoma (Asemissen et al. 2005). This report was 
revelatory, because it not only confirmed that ligand overload triggers dose 
dependent histamine post-receptor cascade of immunological responses but also 
supported a previous argument that elevated histamine up-regulates in vivo, thymic 
and pro-inflammatory cytokines as key pathological pathways (Falus & Meretey 
1992, Arad et al. 1996, Panina-Bordignon et al. 1997, van der Pouw Kraan et al. 
1998, Darmochwal-Kolarz et al. 1999, Hellstrand et al. 2000, Jutel et al. 2001).  
 
Considering that Natural Killer (NK) and extrathymic T cells are abundant in the 
human placenta, and numerical changes and functional activation of NK and T cells 
are more prominent in the blood and urine of patients with PE than in normal 
pregnant women (Regan 1992, Sacks et al. 1998, Darmochwal-Kolarz et al. 1999, 
Minagawa et al. 1999, Redman et al. 1999, Saito et al. 1999); and that the activation 
of granulocytes, NK cells, and extrathymic T cells are suggested as essential for the 
maintenance of pregnancy but the over-activation thereof may be responsible for the 
onset of pregnancy disorders (Wegmann et al. 1993, Minagawa et al. 1999, Saito et 
al. 1999, Weetman 1999, Saito & Sakai 2003). It was asked whether the elevated 
histamine in PE could have effects, similar to that observed in peripheral tissues 
(Figure 1-2) and thus plausibly function as the missing link in the PE pathophysiology.  
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Figure 1-3: Conceptual Framework for Histamine in Pre-eclampsia Pathogenesis 
Figure depicts the theoretical framework linking histamine to PE pathophysiology 
 
To answer this question, it was hypothesised that for histamine to have effects in the 
placenta, histamine receptors should be expressed at the foeto-maternal interface, 
and the histamine receptors thus expressed would regulate placental gene 
expression (Figure 1-3). It was further hypothesised that for histamine to be 
established as the missing link in the pathophysiology of PE, elevated histamine 
would regulate specific genes that are also expressed in pre-eclamptic placentae, 
and the ontologies of these genes would be associated with pathophysiological 
changes implicated in pathogenesis of pre-eclampsia. 
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1.4 Academic Biography  
With over 29 years’ experience in healthcare and higher education (HE) including at 
least 16 years in senior positions in HE, I have made notable contributions to 
healthcare workforce development through both undergraduate and postgraduate 
biomedical science, nursing and medical workforce training. I studied Human 
Physiology and Pharmacology at the University Hertfordshire and later, Human 
Reproductive Biology at the Imperial College London. Clinically, I undertook training 
in nursing, midwifery and clinical andrology, and worked for over 10 years in both 
public and private healthcare institutions in London including St Samaritan’s Hospital 
for women, London, Edgware General Hospital London, St Mary’s Hospital 
Paddington, London and the NHS Direct.  
 
Except for a brief period of time working as a visiting researcher at the then Institute 
of Obstetrics and Gynaecology of the former Royal Postgraduate Medical School in 
Queen Charlotte's and Chelsea Hospital, I have over the past 20 years worked 
sorely in HEI, mainly at the University of West London with a focus on teaching and 
research. My early career in HE started as basic science tutor for pre-registration 
nurses, focusing on teaching Physics and Chemistry as applied to Nursing and later 
as a lecturer in Life and Applied Sciences at Wolfson Institute of Health and Human 
Science. In later years, my teaching is mainly focused on precision and personalised  
medicine, genomics, bioinformatics, service design and improvement in healthcare,  
 
I focus my technical expertise in two predominant areas: in the identification of novel 
diagnostic biomarkers and therapeutic targets for complications of human pregnancy 
and in development of high quality pedagogy to provide accessible world class 
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education. In these areas, I have authored other research and scholarly articles 
including technical reports, research, systematic reviews, and conference 
proceedings; some of which are presented here for the award of PhD by publication.  
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1.5 Portfolio of Publications 
The following papers were therefore published from the investigations undertaken to 
answer the questions above and they form the basis for the award of PhD by 
Published work. The publications fall under the discipline of Genomics and 
Bioinformatics. The citations are numbered in the order in which they appear in the 
commentary rather than by year of publication. 
1. Brew O, Sullivan MH. (2006) The links between maternal histamine levels 
and complications of human pregnancy. J Reprod Immunol. Dec;72(1-2):94-
107 
2. Brew, O., Sullivan, M.H. & Woodman, A. (2016) Comparison of Normal and 
Pre-Eclamptic Placental Gene Expression: A Systematic Review with Meta-
Analysis. PloS One, 11(8), p.e0161504. 
3. Brew, O., Nikolopoulou, E., Hughes, A., Christian, M., Lee, Y., Oduwole, O., 
Sullivan, M.H.F. & Woodman, A. (2016) Quality of placental RNA: Effects of 
explant size and culture duration. Placenta, 46, p.45-48. 
4. Brew, O. & Sullivan, M.H.F. (2017) Oxygen and tissue culture affect placental 
gene expression. Placenta, 55, p.13-20.  
5. Brew O, Lakasing L, Sullivan M. (2007) Differential Activity of Histidine 
Decarboxylase in Normal and Pre-eclamptic Placentae. Placenta. May-
Jun;28(5-6):585-7. 
6. Brew O, Sullivan, M. H., Roller S (2005), "Regulatory loops between 
cytokines and histamine in the human placenta", Placenta, vol. 26, no. 8-9, p. 
A.52  
7. Brew, OB & Sullivan MH (2001) Localisation of mRNAs for diamine oxidase 
and histamine receptors H1 and H2, at the foeto-maternal interface of human 
pregnancy, Inflammation Research, 50(9): 449-452 
8. Brew, O. & Sullivan, M.H.F. (2007) Histamine regulates placental diamine 
oxidase mrna expression - Evidence for a feedback loop decreasing 
histamine production in pregnancy? Placenta, 28(8 - 9), p.A71. 
9. Brew O, Sullivan MHF (2015) Placental Gene Expression in Response to 
Histamine and Oxygen, Gene Expression Omnibus. Series accession number 
GSE74446 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE74446)  
10. Brew O, Sullivan M. (2017) Elevated Histamine Model: A Protocol for an ex 
vivo model for in vitro study of histamine effect on placenta. Protocols.io 
dx.doi.org/10.17504/protocols.io.jigckbw 
11. Brew O, Sullivan MHF. Comparison of elevated histamine model and pre-
eclamptic placental gene expression, Unpublished 
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Rationale for the inclusion of Publication items #6, #8 and #11 
All articles submitted here are currently published as original research except items 
#6, #8, and #11. Items #6 and #8 were originally published as conference 
proceedings respectively at the International Federation of Placental Association 
(IFPA) in 2005 Glasgow, UK, and 2007, Kingston, Ontario, Canada. The abstracts 
from these conference proceedings are published as indicated in the citations. In this 
document, the findings from these studies are discussed in more detail to provide 
context to the work assembled herein. Particularly, item #6 supports publications 
items #5 and #7. Publication item #5 reported on the findings that HDC activity is 
increased in PE relative to normal placentae. Item #7 on the other hand shows that 
histamine receptors are expressed in the placenta. Studies reported in item #6 were 
conducted to test whether elevated histamine has effect in human placenta. The 
findings are thus discussed in detail in this context to provide unequivocal evidence 
that elevated histamine regulates the expression of key cytokines implicated in PE.  
Similarly, findings from item #8 are discussed below in this context of publications 
items #9 and #10 to collaboratively demonstrate the evidence that elevated 
histamine in the placenta not only affect the regulation of key placental proteins but 
also perturb the expression DAO genes. Item #11 is currently undergoing revision 
following submission for publication, and the content of this paper is discussed to 
provide depth and breadth, and contextualisation of the evidence herewith indicated.  
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1.6 Themes for Commentary 
Commentary is hereby provided with four themes to show the links and coherence 
between the published works. The themes provide an account for originality of the 
works at the time of each project or publication, and identify my contributions to the 
subject of placental genomics, the regulatory roles of histamine and implications in 
pre-eclampsia. The commentary also provides reappraisal of the originality of the 
work and reflection about my professional development as a research practitioner 
and suggestions for future developments. The themes for the commentary are: 
1. Histamine links with Pre-eclampsia: Evidence from Systematic Reviews 
 
2. Methodological Considerations- Model for studying ex vivo placental 
gene expression in response to histamine 
 
3. Understanding causes of elevated Histamine in Pregnancy and Pre-
eclampsia 
 
4. Effects of histamine on placental genes expression: Implications for pre-
eclampsia 
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                                                                                         Chapter 2
Theme 1: Histamine links with Pre-eclampsia: Evidence from 
Systematic Reviews 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In this chapter:  
 The commentary is based on the findings from publication item #1: 
 
Brew O, Sullivan MH. (2006), The links between maternal histamine levels 
and complications of human pregnancy. J Reprod Immunol. Dec;72(1-2):94-
107 
 
 The results from systematic review of evidence that clarified our 
understanding of modalities of histamine production and regulation in human 
pregnancy are discussed. 
Highlights: 
 The placenta is the major source of maternal blood histamine during 
pregnancy. 
 Maternal blood histamine level in normal early pregnancy (up to gestational 
week 8) is similar to pre-pregnancy levels.  
 Direct oxidative deamination metabolic pathway by DAO, indirect deamination 
involving HNMT and DAO and hydroxylation involving ascorbic acid are the 
active histamine metabolic pathways during pregnancy. 
 Histamine oxidative deamination by DAO is the dominant metabolic pathway 
in pregnant compared to non-pregnant women.  
 In normal pregnancy maternal plasma DAO activity exponentially increase 
from gestational week 8, and peaks at mid-trimester (~gestational week 24). 
Concurrently, maternal blood histamine levels progressively decline also from 
gestational week 8 with a mid-trimester (~gestational week 24) nadir, and this 
forms a normal Histamine-DAO-Axis (HDA). 
 In PE, there is an apparent failure of the HDA and this is termed defective 
Histamine-DAO-Axis (dHDA). 
 dHDA presents with a failure of maternal plasma DAO activity to exponentially 
rise from gestation week 8, leading to diminished DAO activity and elevated 
maternal blood histamine. 
 Regression analysis of maternal blood histamine in PE suggests first and 
second trimesters histamine levels are significantly higher in PE compared to 
levels in normal pregnancy. 
 The ratio of histamine oxidative deamination to methylation metabolites 
concentrations in maternal blood or urine has predictive value for early 
identification of PE.  
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2.1 Introduction  
Account of originality at the time of publication  
In 1910, Dale and Laidlaw published their seminal work on the effect of histamine on 
pregnancy outcome (Dale & Laidlaw 1910). This work showed for the first time that 
elevated histamine in uterine tissues: in this case, subcutaneous injection of 
histamine into cats in late pregnancy causes strong periodic uterine contractions of 
the tonic type with no expulsive value but strong enough to cause premature 
placental separation and intrauterine death of litters (Dale & Laidlaw 1910). Several 
publications since this seminal work showed associations between increasing 
maternal blood histamine and specific pregnancy complications such as PE.  
 
Phylogenetically, histamine appears in tissues of most vertebrates and invertebrates, 
and the histamine forming capacity of tissues seemingly correlates with various 
physiological functions such as gastric acid secretion, immuno-modulation, cell 
proliferation and differentiation, tissue growth and wound healing (Kahlson et al. 
1960a, Tasaka 1991, Falus & Meretey 1992, Rivera et al. 2000).  At the point of 
initiating the systematic reviews, evidence that histamine was produced during 
pregnancy was not disputed. However, the sources and significance of the amine in 
human pregnancy was unclear. There was also no previous systematic review of the 
evidence to demonstrate coherent links between the varying histamine levels and 
specific complications of human pregnancy. Therefore, a series of systematic 
reviews with narrative synthesis and or meta-analysis were conducted. Databases 
(Medline, Pubmed, EMBASE) were searched with keywords histamine, diamine 
oxidase, pregnancy, pre-eclampsia and their variants in Jan 2005 and repeated in 
April 2006. A total of 208 articles were reviewed to examine the level and extent of 
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associations between maternal blood histamine and specific pregnancy outcomes to 
answer the following questions: 
1. During pregnancy, does elevated maternal blood histamine originate from the 
maternal issues as compared to foetal tissues? 
2. In pregnant women, does elevated blood histamine cause clinical symptoms? 
3. Does blood histamine levels and metabolism during pregnancy differ between 
women with normal pregnancy and those who develop PE? 
 
2.2 Contributions made by the reviews to the understanding of the impact of 
Maternal Blood Histamine on pre-eclamptic pregnancy outcome 
2.2.1 The Roles of Pre-formed and De Novo Histamine in Pregnancy  
The first set of reviews was conducted to determine the sources and the type, i.e., 
pre-formed and de novo histamine in human pregnancy. It was observed that the 
nature of histamine production in both vertebrates and invertebrates indicates two 
main sources for histamine appearance in tissues: pre-formed  histamine from 
storage cells e.g., mast cells, basophils, and platelets; and nascent histamine or 
histamine produced de novo by induction of histidine decarboxylase (HDC) activity 
(Beaven 1982, Kahlson & Rosengren 1971). In both cases the pyridoxal phosphate 
dependent HDC enzyme metabolises histidine to produce histamine (Reite 1972, 
Beaven 1982), and its activity mostly serves as a rate-limiting step for histamine 
production (Kahlson et al. 1958a, Nilsson et al. 1959). It was also clear that diamine 
oxidase (DAO), histamine methyl transferase (HMT), Pyridoxal phosphate (PLP), 
and ascorbic acid (AA) were established as important metabolising agents for both 
nascent and pre-formed histamine (Cooper & Schayer 1956, Schayer & Karjala 
1956, Nandi et al. 1974, Chatterjee et al. 1975). 
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Using thematic analysis, the review revealed that the pre-formed histamine functions 
more as a stereoadaptive-defence agent, where in both vertebrates and 
invertebrates it is mainly involved with immediate defence response attack as in 
antigeneic or predatory invasion (Reite 1972, Beaven 1982). In these instances the 
review further showed that pre-formed histamine commonly occurs in secretory 
glands and in their secretions, e.g. in many poisonous glands; in gastric mucosa, 
gastric glands and gastric secretions of most eutherians and ancestral vertebrates of 
the cyclostomes and cartilaginous fish types, like hagfish and dogfish respectively; 
and in salivary glands of octopus and squid (Reite 1972). These initial findings 
prompted a subsequent review to establish the most common type of histamine 
produced during human pregnancy.  
 
The subsequent results showed that: (1) Pre-formed  histamine is produced and 
stored in mast cells in both male and female reproductive apparatus e.g. human 
testes, seminal vesicles, prostate glands, uterine tissues, placenta and ovaries 
(Wicksell 1949, Purcell & Hanahoe 1991, Purcell 1992, Szelag et al. 2002a, Szelag 
et al. 2002b); (2) That the rate of turnover of pre-formed histamine in maternal uterus 
and the placenta is quite slow and therefore suggests that pre-formed histamine may 
have minor physiological roles in early pregnancy or during human pregnancy 
(Beaven 1982); (3) That de novo synthesised histamine characterised by HDC 
activity is prominent in pregnancy and is localised in cleaving embryo, fallopian tube 
and at implantation sites (Blanco et al. 1970, Bronson & Wallach 1977, Shrivastav et 
al. 1988, Cocchiara et al. 1987, Cocchiara et al. 1992, Menezo et al. 1993, 
Cocchiara et al. 1996, Sawin et al. 1997, Jankovic et al. 1998); (4) While the pre-
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formed  histamine in uterine and endometrial tissues has been associated with 
muscle contraction and immuno-protection of uterine or endometrial milieu 
(Bytautiene et al. 2003, Bytautiene et al. 2004b, Purcell & Hanahoe 1991, Thomson 
et al. 2000, Wicksell 1949, King et al. 2003), de novo histamine synthesised by 
endometrial epithelia is shown in animal models and human cell lines to initiate 
implantation, functions in anabolic processes like regenerative growth, cell 
differentiation and proliferation, imuno-modulation, placentation, and foetal 
development (Kahlson et al. 1958a, Kahlson et al. 1958b, Kahlson et al. 1960b, 
Connolly et al. 1962, Johnson & Dey 1980, Dey & Hubbard 1981, Hine et al. 1985, 
Cocchiara et al. 1987, Rivera et al. 2000, Zhao et al. 2000, Dey et al. 2004, Liu et al. 
2004), and hence could have similar roles in human pregnancy. 
 
2.2.2 The Sources of Histamine during Pregnancy  
It became clear that histamine thus observed in human pregnancy could originate 
from the uterus, foetal membranes and or from the placenta. Therefore, a further 
review question was conducted to clarify the source of increasing histamine in 
human pregnancy.  For this review, attention was focused on human studies which 
have investigated in vivo metabolism of 14C-histamine, labelled at the 2nd position of 
the imidazole ring in women including during pregnancy.  
 
Narrative synthesis was used to summarise the findings from the included studies 
(Schayer 1952b, Cooper & Schayer 1956, Nilsson et al. 1959, Schayer 1959, 
Lindberg 1963b, Lindberg 1963a, Lindberg et al. 1963a, Lindberg et al. 1963b, 
Lindberg & Tornqvist 1966). The synthesis showed that (1) when labelled histamine 
was injected directly into maternal cubital vein, less than 5% of the histamine was 
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detected in umbilical vein; (2) when labelled histamine was injected into umbilical 
artery, less than 0.3% of the histamine was detected in maternal urine; (3) when the 
labelled histamine was injected into the uterus of pregnant and non-pregnant 
women, 49% as compared to 36% of histamine was metabolised during uterine 
passage into maternal blood respectively in pregnant and non-pregnant women; and 
(4) that M-methyl imidazole acetic acid (MIAA) resulting from methylation of the 
nitrogen on the imdazole ring remote from the amine side chain was secreted into 
maternal circulation from the placenta. These findings therefore suggested that the 
placenta, and not the uterus or the foetus is the major source of increasing histamine 
in maternal blood during pregnancy, and thus focused our attention on the placenta 
as the potential medium where histamine could exert effect on pregnancy outcome. 
 
2.2.3 Histamine Metabolism in Pre-eclampsia  
After establishing that the placenta is the main source of elevated blood histamine 
during human pregnancy, a critical question about what causes the elevated 
histamine in PE pregnancy however remained unclear. Therefore, a further review 
was undertaken to determine if there was any association between histamine 
metabolism and pre-eclamptic pregnancy outcome.  
 
Generally, histamine is metabolised via 2 major pathways: methylation and 
deamination pathways. In the methylation pathway histamine is metabolised via 
methylation at the imidazole nitrogen furthest from the ethylamine side chain (termed 
tele-N or Nt) by the enzyme histamine-N-methyltransferase (HNMT) to N-Methyl-
histamine (NMH), and monoamine oxidase (MAO) then metabolises the NMH to M-
methyl imidazole acetic acid (MIAA) (Schayer 1952b, Cooper & Schayer 1956, 
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Schayer 1956, Schayer & Karjala 1956, Rothschild & Schayer 1958, Schayer & 
Reilly 1975). In the deamination pathway, DAO metabolises histamine to imidazole 
acetic acid (ImAA) (Schayer 1952b).  
 
Using narrative synthesis, the review showed that the methylation and deamination 
of histamine pathways accounts for about 80% of histamine metabolism during 
human pregnancy, and hydroxylation of histamine into hydantoin propionic acid by 
ascorbic acid (Figure 2-1) could account for between 10 -20% (Ahlmark 1944, 
Wicksell 1949, Kapeller-Adler 1952a, Kapeller-Adler 1952b, Cooper & Schayer 1956, 
Schayer & Karjala 1956, Lindberg 1963a, Bjuro et al. 1964, Kapeller-Adler 1965, 
Nandi et al. 1974, Chatterjee et al. 1975).  
Figure 2-1: Metabolism of histamine by ascorbic acid 
Figure 2-1 was written in 2006 based on the systematic review of metabolic effect of ascorbic acid on histamine. 
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The results also showed that the relative metabolism differed between maternal and 
non-pregnant women. Table 2-1 summarises the relative concentrations of histamine 
metabolites from the deamination and methylation pathways. The data (Table 2-1) 
shows an approximate 33% increase in histamine metabolism via direct deamination 
by DAO and 58% decrease in histamine metabolism via HNMT methylation during 
pregnancy compared to non-pregnant women, thus confirming that DAO is the 
dominant histamine metabolic pathway during pregnancy. 
 
Table 2-1: Deamination and Methylation Metabolic Rates in Pregnancy  
Histamine Metabolites Non-pregnant 
women levels 
Pregnant women 
levels 
Average Change in 
Pregnancy 
 
MIAA 32 – 59% 20 – 41% -57.69% 
ImAA 25 – 37% 26 – 53%, 32.7% 
(Schayer 1952b, Nilsson et al. 1959, Lindberg 1963a); MIAA = M-methyl imidazole acetic acid; ImAA 
= imidazole acetic acid.  
 
 
Somehow, the confirmation that DAO is the major histamine metabolising enzyme 
during human pregnancy was pedestrian. Nonetheless, a regression analysis 
revealed that the deamination to methylation ratio (DMR) of histamine metabolites in 
maternal blood has predictive value for pregnancy outcome, and this was novel 
(Table 2-2). Using a comparative analysis of the metabolites from pregnant and non-
pregnant women, it was observed that the ratio of deaminated histamine metabolites 
(imidazole acetic acid) and the methylated metabolites (n-methyl-histamine, and 
methyl-imidazole acetic acid) were 4 and 2 folds respectively in pregnant and non-
pregnant women arterial or venous blood (Table 2-2), and this was highly informative 
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of maternal blood capacity to control histamine within range associated with good 
pregnancy outcome prognosis. 
Table 2-2: Deamination to Methylation Ratio 
Relative abundance of Histamine Metabolites in Maternal Blood and Urine from Diamine Oxidase and Histamine N-
Methyltransferase Activities 
 
Radio-labelled 
histamine metabolite 
Sampling and radio-labelled histamine metabolite analysis count (cpm/ml) 
Brachial Artery Cubital Vein Uterine Vein 
 
Umbilical 
Vein 
Urine  
 
  
Values in blood sample taken from 6 pregnant women (a) 
From 4 pregnant women 
(b) 
Ratio of ImAA ÷  
(NMH + MIAA) 
2.21 
 
1.98 
 
2.28 
 
1.90 
 
1.31 
  
Values in blood samples from 4 non-pregnant women (a) 
From 3 non-pregnant 
women (b) 
 
Ratio of ImAA ÷  
(NMH + MIAA) 
0.51 0.71 0.34 -  0.75 
cpm = Counts per minutes; N-Methyl-histamine = NMH, Methyl-imidazole acetic acid = MIAA, Imidazole 
Acetic Acid = ImAA, (a) from (Lindberg 1963a), (b) from (Nilsson, LINDELL, Schayer, & Westling 1959) 
 
The analysis further showed that whilst the measurement of individual histamine 
metabolites in urine was erratic and non-predictive of pregnancy outcomes, the 
assessment of the ratio of the metabolites in urine or blood could provide a measure 
or competence of maternal blood to control histamine levels during pregnancy, and 
thus could predict plausible variations associated with PE as a plausible non-
invasive model. Further work using prospective longitudinal studies however, is 
needed to test this emerging hypothesis. 
 
In effect, these outputs suggested that there are three instead of two major histamine 
metabolic pathways during human pregnancy: (a) Direct DAO oxidative deamination 
metabolic pathway (b) indirect deamination pathway involving HNMT and DAO and 
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(c) hydroxylation pathway involving ascorbic acid. The work also suggested that a 
further review to examine the variations between maternal histamine metabolism in 
normal and complicated pregnancies could provide additional information to 
contribute to explaining the association between maternal blood histamine levels and 
PE. Therefore a further review was conducted to examine the mechanisms of 
histamine regulation during normal and complicated human pregnancies.  
 
2.2.4 Association of diminished maternal DAO activity and increasing blood histamine 
with Pre-eclampsia 
A further review using comparative analysis was conducted to examine the 
characteristics and profiles of maternal blood histamine and plasma DAO activity 
during normal and PE pregnancy. Twelve studies met the inclusion criteria for this 
analysis (Connolly et al. 1962, Southren et al. 1966a, Tryding & Willert 1968, Achari 
et al. 1971, Vanina et al. 1971, Beaven et al. 1975, Dubois et al. 1977, Sharma et al. 
1981, Morgan & Hytten 1984, Sharma et al. 1984, Hine et al. 1985, Caldwell et al. 
1988). The data synthesis was separated into animal and human profiles. The 
review showed that during normal pregnancy, maternal blood histamine levels 
gradually decrease below values found in healthy non-pregnant women (Figure 2-2), 
and this characteristic decline of gestational blood histamine was conserved in 
rodent models (Figure 2-3). In human normal pregnancy, the progressive decrease 
in maternal blood histamine (Figure 2-2) reaches a nadir at mid-gestation (weeks 20 
and 24) and this was associated with a concurrent exponential rise in maternal 
plasma DAO activity from gestational week 8 onwards in normal pregnancies with a 
peak also at mid-gestational (weeks 20 and 24)  (Southren et al. 1966a, Tryding & 
Willert 1968, Achari et al. 1971, Beaven et al. 1975, Dubois et al. 1977).  
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Figure 2-2: Mean plot of normal maternal blood histamine levels  
(Southren et al. 1966a, Tryding & Willert 1968, Achari et al. 1971, Beaven et al. 1975, Dubois et al. 
1977, Sharma et al. 1981, Sharma et al. 1984, Caldwell et al. 1988) 
 
 
 
Figure 2-3: Rodent Oestrous and Gestational Histamine 
Figure shows the profile of histamine production in rodent reproductive tissues across the oestrous cycle (eDay) 
and gestation (gDay). Data is mean plot of histamine levels pooled from rodent studies (Connolly et al. 1962, 
Hine et al. 1985). 
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The significance of the low histamine levels in mid-gestation is unclear; however the 
coincidence with DAO peak activity and the period of uterine tranquillity (Morgan & 
Hytten 1984) appears to support the hypothesis that tight control of maternal blood 
histamine is required for normal pregnancy outcome. Therefore, the review further 
examined the links between hyper-histaminemia occurring in specific gestational 
complications including preeclampsia, spontaneous abortion, preterm labour and 
hyperemesis gravidarum.  In the case of PE, it was revealed that the complication 
presents with clinical symptoms similar to those observed in experimentally induced 
elevation of blood histamine in humans (Table 2-3).  
 
Table 2-3: Clinical Symptoms of High Blood Histamine and Pre-eclampsia 
Symptoms of Experimentally Induced High 
Blood Histamine in normal healthy human 
volunteers 
Common Symptoms of PE 
Dizziness 
Light-headedness 
Fainting 
Tachycardia 
Pyrexia  
Palpitation 
Continuous headache 
Severe headache 
Nervousness  
Convulsions (seizures) 
Difficulty breathing 
Flushing or redness of face 
Blue discoloration of face 
Blurred vision 
Chest discomfort or pain 
Hypotension 
Hypertension 
Diarrhoea 
Nausea 
Vomiting 
Metallic taste 
Oedema 
Abdominal or stomach spasm or cramps 
Proteinuria 
Severe headaches 
Blurred vision  
Seeing flashing lights 
Severe heartburn 
Upper abdominal pain just below the ribs 
Nausea   
Vomiting 
Excessive weight gain 
Decreased urine output (fluid retention)  
Feeling very unwell 
Oedema  
Proteinuria 
Light sensitivity 
Decreased levels of platelets in your blood 
(thrombocytopenia) 
Impaired liver function 
Shortness of breath, 
(Ind et al. 1982, Kaliner et al. 1982, Ind et al. 1983, Pollock et al. 1991, Thomas et al. 1991, Schmetterer et al. 
1997, Akerman et al. 2002, Lassen et al. 2003, NICE 2008, NICE 2011) 
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Interestingly, the review also showed that the average maternal blood histamine 
levels in early normal gestation is similar to levels found in non-pregnant women 
(Table 2-4), but the levels in normal pregnancy decrease from gestational week 8 
onwards to values below that found in healthy non-pregnant women (Figure 2-4 – 
Figure 2-6). In contrast, a logarithm regression of 3rd trimester maternal blood 
histamine level in PE suggests a significantly higher early maternal blood histamine 
levels compared to normal pregnancy for matched gestational ages (Figure 2-4). The 
average difference between NP and PE 3rd trimester blood histamine was 18.42%. 
Table A-1 & Table A-2 (appendix 1) provide further information on the differences 
and significance level between normal pregnancy and PE maternal blood histamine. 
Similar level of magnitude of change in histamine levels was observed in maternal 
urine histamine concentration after reanalysis of experimental inhibition of DAO 
activity with aminoguanidine data (Table A-3; Appendix 1). In this instance, the 
percentage rise in trimester 1 maternal urine histamine after inhibition of DAO with 
aminoguanidine was 18.73%. 
 
Table 2-4: Normal Histamine and Pregnancy Histamine Levels  
Histamine levels in Pregnancy and PE   
Condition  Histamine levels Range 
(ng/ml) 
Histamine levels (ng/ml) 
(Mean ± SEM) 
Reference  
Normal Blood  25 – 65.0 56.7 ± 1.85  [1,2] 
Normal Pregnancy:    
Trimester 1 58 – 70.0 64.0 ± 6.0  [3] 
Trimester 2 30 – 50.0 43.3 ± 6.7 [3,4] 
Trimester 3 35 – 74.3 52.9 ± 1.4 [3,5-11] 
Pre-eclampsia: Trimester 3 49 – 94.3 69.7 ± 1.9 [8,10] 
    
[1]: (Pfeiffer et al. 1970); [2]:(Lorenz et al. 1972); [3]:(Dubois et al. 1977); [4]: (Clemetson & Cafaro 1981); [5]: 
Effkemann & Werle 1940, [6]: Kapeller-Adler 1949; [7]: (Gunther & Glick 1967); [8]: (Achari et al. 1971); [9]: 
(Sharma et al. 1981), [10]: (Sharma et al. 1984); [11]: (Sharma et al. 1985). 
 
 
 39 
 
Figure 2-4: Normal and PE Maternal Blood Histamine levels superimposed 
Figure is a plot of grand mean of blood histamine levels to depict the pattern of maternal blood 
histamine in normal (NP) and pre-eclampsia (PE) pregnancies. Black line shows predicted levels of 
early pregnancy maternal blood histamine in mother who later developed PE. Average rise of early 
pregnancy blood histamine in PE is projected to be 18.42% above normal. The pattern of gestational 
dependent variation in blood histamine is similar in both normal and PE pregnancies. (Southren et al. 
1966a, Tryding & Willert 1968, Achari et al. 1971, Beaven et al. 1975, Dubois et al. 1977, Sharma et 
al. 1981, Sharma et al. 1984, Caldwell et al. 1988) 
 
 
 
Figure 2-5: Normal Trimesters and Pre-eclamptic Maternal Blood Histamine  
NP = Normal Pregnancy, PE = Pre-eclampsia 
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Figure 2-6: Normal and PE Maternal Blood Histamine levels Compared 
Provide pooled analysis blood histamine means based on: (Achari et al. 1971, Dubois et al. 1977, 
Sharma et al. 1981, Sharma et al. 1984, Caldwell et al. 1988) 
 
These findings showed that although the placenta is a major source of histamine, it 
also releases active diamine amine oxidase into the maternal circulation, which 
metabolises histamine (Purcell & Hanahoe 1991).  The placental derived DAO once 
deported into maternal blood breaks down the histamine released from the placenta 
in normal pregnancy, leading to physiological levels of histamine in normal 
pregnancy. Clinically, the activity of the deported placental DAO in maternal blood 
increases a 1000 fold by mid-gestation in normal pregnancy to form a normal 
histamine-DAO-axis (Southren et al. 1966b, Beaven et al. 1975, Dubois et al. 1977). 
In PE, the DAO activity from the placenta is decreased thus, forming a defective 
histamine-DAO-axis (dHDA). This results in less histamine metabolism in the 
maternal circulation and higher systemic histamine levels in PE (Achari et al. 1971, 
Vanina et al. 1971, Beaven et al. 1975). Thus, normal Histamine-DAO-Axis (HDA) in 
pregnancy was defined as the concurrent exponential rise of maternal plasma DAO 
activity levels from gestational week 8 onwards with a peak at mid-trimester 
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(~gestational week 24), and progressive decline of maternal blood histamine levels 
below pre-pregnancy levels from gestational week 8 onwards with a mid-trimester 
(~gestational week 24) nadir. Defective Histamine-DAO-Axis (dHDA) in pregnancy 
on the other hand was defined as the failure of maternal plasma DAO activity to 
exponentially rise from gestation week 8, leading to diminished DAO activity and 
elevated maternal blood histamine akin to pre-pregnancy levels. 
 
2.3 Conclusion 
The series of reviews provided comprehensive knowledge and in-depth 
understanding of the links between histamine and PE. In summary, the studies 
broadened our understanding on the sources of elevated histamine in pregnancy by 
revealing that the placenta and not the uterus or the foetus is the major source of 
increasing histamine in maternal blood during pregnancy. The evidence reviewed 
was conclusive that methylation and deamination pathways accounts for about 80% 
of histamine metabolism during pregnancy, and hydroxylation of histamine into 
hydantoin propionic acid by ascorbic acid accounts for between 10 -20%. The work 
also affirmed that relative metabolic pathways differed between maternal and non-
pregnant women, and DAO is the dominant histamine metabolic pathway during 
pregnancy. The work further showed that maternal blood histamine levels in early 
gestation are similar to levels found in non-pregnant women, and the levels in normal 
pregnancy decrease below values found in healthy non-pregnant women from 
around gestational week 8 onwards. However, in specific complication of pregnancy 
such as PE, DAO activity levels diminish after gestational week 8 and histamine 
levels remain elevated at levels similar to pre-gestational levels, thus forming a 
defective histamine-DAO-axis (dHDA). 
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                                                                                         Chapter 3
Theme 2: Methodological Considerations- Model for studying ex 
vivo placental gene expression in response to histamine 
 
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In this chapter: 
 
 The commentary is based on methods used to investigate the works that underpin 
publication items # 2 – 11.  
 The commentary discusses the rationale and challenges for using specific 
methodologies rather than a detailed discussion or report of the methods in general. 
 
 
Highlights: 
 Placental explant size (micro or macro) and duration of culture affect explant RNA 
quality. 
 Micro explants (∼50 mg) in optimum long-term culture (have undergone 
syncytiotrophoblast regeneration) at 8% oxygen produced RNA with quality akin to pre-
culture explants. 
 Quality of RNA from explants in early cultures (48 hours), presumably undergoing 
syncytiotrophoblast degeneration is compromised. 
 Macro explants (∼200 mg) after culture produced poor quality RNA and should be 
avoided. 
 Gene expression patterns differ between pre-culture and cultured explants 
 Atmospheric Oxygen Concentration up-regulates HIF1A transcription target gene set 
 Atmospheric Oxygen Concentration regulated genes that favour apoptosis and 
inflammation  
 Tissue culture up-regulates apoptosis and response to stress genes in placenta 
 Tissue culture per se induces expression of genes with preponderance towards 
apoptosis, inflammation and tissue response to stress irrespective of culture oxygen 
concentration. 
 Explant culture at Atmospheric Oxygen Concentration exacerbates tissue expression of 
stress and programmed cell death genes in placenta. 
 Oxygen and tissue culture generally precipitate down-regulation of placental genes. 
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3.1 Introduction:  
It is widely accepted that prudent evaluation and informed selection of choiced 
research methods are the most appropriate and cost effective approach to answer a 
research question. The selection of methods and the implementation thereof, are 
however influenced not only by the research question but also by practical 
considerations, such as the availability of resources, including the type of data 
available and the knowledge and skills of the persons undertaking the research, 
access to funds and time constraints. This chapter likewise, discusses key factors 
that impacted on decisions, selection, applications and implementation of methods 
used to investigate the genomic impact of histamine in human placenta. The 
discussions in this chapter are therefore based on rationales for: (1) Patients and the 
Placental choices; (2) Transition from Single Gene Analysis to Multi-gene Analysis; 
(3) Microarrays: Study Design Considerations and Rationale, and (4) Bioinformatics 
analyses. This chapter is therefore organised into three sub-sections as follows: 
 In sub-section 1, the commentary focuses on addressing specific questions 
as: What was the need to be selective about patients? Why use placental 
explants instead of cell lines? What was the need for sampling tissues? Was 
the use of short term explant culture appropriate model for ex vivo 
investigation of histamine effect on the placenta? Blocking of DAO with 
aminoguanidine disulphate: what was the need?  
 In sub-section 2, the focus shifts onto addressing the impact of Technological 
advancement on the research agenda. Specifically, the section addresses 
questions related to the need to reshape the research approach in line with 
evolution of technology from single gene expression analysis to multiplex, and 
then microarray.  
 In sub-section 3, issues related to explant viability after culture and selection 
of an appropriate baseline control are discussed to show the respective 
contribution to the knowledge and understanding of placental explant culture.  
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3.2 Sub-section (1): Contributions made to the knowledge and understanding 
of Patients, the Placenta and Tissue Culture (#2 - #11) 
3.2.1 The Patient  
Human pregnancy has multiple outcomes including spontaneous abortion, PE, and 
pre-term labour. Therefore, defining the patients involved in the investigations was 
important to embed the findings in the context of specific complications of human 
pregnancy. Placental samples were taken from women whose pregnancy outcomes 
were classified as a first trimester social abortion, normal term, or PE (Table 3-1). 
Clinically diagnosed PE was defined in terms of WHO criteria (updated in 2014) as 
new hypertension (raised diastolic pressure to >90 mmHg on two occasions, 1–4 
hours apart) presenting after 20 weeks with proteinuria (>30mg/dL or +1 or more on 
a single sample).  
 
Table 3-1: Characteristics of Placentae 
Clinical Condition 
of Placenta 
Gestation 
(weeks) 
Number of 
placenta 
Delivery  
Method  
Foetal birth 
weight 
Normal  8 – 10  3 SA NA 
Normal  38 – 40  40 C/S ≥2.5kg ≤ 4.0kg 
Pre-eclampsia 38 – 39  10 C/S ≥2.5kg ≤ 4.0kg 
C/S = Caesarean Section; SA = Social Abortion  
 
Thus, all placentae from normal pregnancies had no history of gestational 
hypertension or pre-existing hypertension, proteinuria, infection, glucosuria and other 
pregnancy related complications such as intra-uterine growth restriction. 
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3.2.2 Justification for using Placental Explants 
The placenta is implicated in specific complications of human pregnancy such as PE 
(Myatt 2002, Matsuo et al. 2007). The mature human placenta is a discoid organ 20-
25 cm in diameter, 3 cm thick and weighing 400-600g. Internally, it consists of a 
foetal villous tree bathed directly by maternal blood (Castellucci & Kaufmann 1982). 
The cells making up the internal of the mature placenta consists of several cell types 
including cytotrophoblast, syncytiotrophoblast, stromal, endothelial cells, pericytes, 
smooth muscle cells, erythrocytes and macrophages (Hofbauer cells) (Castellucci & 
Kaufmann 1982).  
 
Various in vitro models including: choriocarcinoma cell lines such as BeWo, Jeg-3 
and Jar cells; isolated primary trophoblast cells, placental mesenchymal stromal cell 
lines, and villous parenchyma (placental) explants have been used to investigate 
placental physiology, pharmacology and other functions (Miller et al. 2005, Bode et 
al. 2006, Orendi et al. 2011, Daoud et al. 2016, Qin et al. 2016). Of all the models 
however, placental explant is reported to closely mimic in vivo conditions to support 
ex vivo study of placental functions including cellular uptake, production and release 
of secretory components, cell interactions, proliferation, growth and differentiation, 
gene delivery, pharmacology, toxicology, and disease processes (Miller et al. 2005, 
Orendi et al. 2011).   
 
Of particular importance to histamine effects, caesarean delivered explants were the 
first choice of tissue for investigating the roles of histamine in the placenta. This was 
principally important because, it is observed that placentae with uterine contractile 
activity produce varying levels of histamine: less in decidua from maternal side, and 
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high levels in tissues from foetal side (Szukiewicz et al. 1995). It is also established 
that tissue damage and stress destabilise histamine production (Schayer 1952a, 
Norn 1968, Neugebauer & Lorenz 1982, Sooranna et al. 2004, Mohan et al. 2007): 
thereby, making the study of histamine in placentae that have undergone uterine 
contraction less suitable for mimicking in vivo conditions. Furthermore, the cross-talk 
between the trophectoderm derived (trophoblasts) and mesenchymal derived cells in 
the placenta (Lewis et al. 1996) is difficult to mimic or practically absent in cell line 
models. Also, the cell line models generically show increased baseline expression of 
pro-inflammatory receptors such as Toll-like receptors and cytokines (Kauma et al. 
1992, Lonsdale et al. 1996, Gierman et al. 2015). Thus, rendering cell lines as less 
attractive model in favour of placental villous tissue explants to investigate the 
genomic response of the placenta to histamine.  
 
3.2.3 Tissue sampling 
Fresh placental samples were collected from singleton pregnancies. Placentae were 
collected from the Imperial College NHS Trust following informed consent from 
mothers. Ethics permission was granted by the Hammersmith and Queen Charlotte’s 
& Chelsea Hospitals Research Ethics Committee.  Samples were taken from non-
smoking mothers without gestational diabetes or other complications (except PE), 
who were delivered by elective Caesarean section. Each placenta was visually 
inspected for signs of excessive tears, necrosis, and infarction, and samples taken 
from healthy looking areas about 5 cm away from the placental cord with sterile 
sharp scissors. Approximately 2 cm3 of the placental tissue were randomly cut with 
sterile scissors from three different sampling sites. Each sample was carefully 
excised to include an intact chorionic plate, villous parenchyma, basal plate and 
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decidua.  All samples were collected from the maternity operating theatre, washed in 
phosphate-buffered saline (PBS) solution (pH 7.4) containing 10% penicillin, 
streptomycin and L-glutamine (Sigma) to remove excess blood and blood clots and 
transported in 150 ml sterile pots containing warm PBS with 10% penicillin, 
streptomycin and L-glutamine immediately to the laboratory. The placental explants 
were then aseptically dissected from the villous parenchyma of each sample, 
fragmented with scissors and incubated within 30 minutes of delivery.  
 
3.2.4 Effects of Culture Duration, Explant Size and Oxygen on Explant Morphology 
(Publication #3) 
The use of placental explants as model to investigate placental physiology is 
complicated by intrinsic variances related to the viability of the tissues in organ 
culture, duration of the organ culture, oxygen concentration of the culture media and 
the size of the explants (Miller et al. 2005). Concerning placental culture oxygen, 
different concentrations (atmospheric oxygen concentration (AOC) and Physiological 
oxygen concentrations (POC)) have generally been used during culture of term 
placentae. It has been argued that POC (8%) reflects in vivo physiology, and 
provides optimal culture conditions for term placental villous explants than AOC 
(20%) (Damsky et al. 1993, Genbacev et al. 1996, Caniggia et al. 2000, Huppertz et 
al. 2003, Miller et al. 2005, Burton et al. 2006).  
 
Some studies have also reported increased deterioration of placental explant viability 
within 24 hours of culture (Palmer et al. 1997, Sooranna et al. 1999) while others 
have demonstrated its viability for more than 7 days in organ culture (Tao & Hertig 
1965, Taylor & Hancock 1973, Faye et al. 2005). Moreover, placental explant 
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syncytiotrophoblast (STB) cell population are completely regenerated in the course 
of days in organ culture (Taylor & Hancock 1973, Palmer et al. 1997, Siman et al. 
2001). Therefore, the establishment of an appropriate duration and condition for 
explant culture was crucial, as was determining the baseline control samples for 
reasons related to the plausible impact of syncytial degeneration on explant RNA 
quality. Thus, it was aimed to determine whether syncytial degeneration and 
regeneration could affect the interpretation of results, and also to establish an 
appropriate explant size, duration of culture and optimum oxygen concentration for 
the study of histamine effect on human placenta.  
In order to evaluate the impact of placental explant size, culture method, culture 
oxygen concentration and duration of culture on explant viability and quality of RNA 
placental micro and macro explant in different culture settings were compared. 
Placental macro explants (approximately 200 mg wet weight) and micro explants 
(<50 mg wet weight) were cultured to time 0h, 24h, 48h, 72h, 96h, 120h and 144h 
(publication #3). Microcapillary electrophoretic RNA separation and analysis of 
automatically generated signal measurements was performed on RNA extracted 
from placental explants incubated at Physiological Oxygen Concentration (8%) or 
AOC in standard or optimum culture (publication #3). Explant viability was indirectly 
assessed with immunohistochemistry for the STB integrity.  
 
Previous studies have established very clearly that placental tissue, particularly 
placental explants (Taylor & Hancock 1973, Watson et al. 1995, Tao & Hertig 1965) 
show loss of the STB layer during initial culture (2-4 days), followed by regeneration 
of the syncytium over longer culture periods (5 – 11 days) (Palmer et al. 1997, Siman 
et al. 2001). Therefore, STB integrity was measured by the extent of degeneration 
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and regeneration of the STB layer. STB degeneration was defined as the presence 
of small, dense and rounded nuclei, irregular syncytial layer with disintegration of the 
integrity of the apical membrane; detachment and sloughing off of the original 
syncytial layer in culture (Tao & Hertig 1965, Palmer et al. 1997).  STB regeneration 
was on the other hand, defined according Siman et al (2001) as the progressive 
replacement of the original STB by a newly formed layer, evidenced by gradual 
thickening of the new STB as the original syncytium is sloughed off and lost. 
 
The findings (publication #3) showed that integrity of RNA in the macro samples 
irrespective of oxygen concentration and micro explants cultured in AOC was poor 
throughout the culture period, whereas in the micro explants cultured in optimal 
media in POC, the RNA quality was transiently poor, and then improved by day 6 of 
culture. Thus, suggesting that micro explants cultured at POC have the best RNA 
quality and tissue structure whereas, macro explants were less viable after long-term 
culture. The findings also showed that placental explants undergoing syncytial 
degeneration produced poor quality RNA and should be avoided. The findings 
further showed that the RNA quality generically declined in tandem with STB 
degeneration, suggesting also that the STB viability could be a proxy measure of 
explant quality for high throughput experiments. In view of these, short term culture, 
macro explants and explants cultured in AOC were avoided in favour of micro 
explants in POC cultured at the gas interface to 6 days. 
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3.2.5 Modelling Defective Histamine-DAO-Axis (publications #9 - #11) 
Ex-vivo defective histamine – DAO – axis (dHDA) also referred to Elevated 
Histamine Model (EHM) was modelled in human placental explants to identify genes 
that are affected by elevated histamine in the placenta and examined their functions 
in PE. Diamine oxidase (DAO; EC 1.4.3.22) also known as copper-containing-amine 
oxidase; histaminase; amiloride binding protein-1, was first discovered as a 
histamine-inactivating enzyme (Best 1929). This enzyme catalyzes the oxidative 
deamination of histamine to an aldehyde, ammonia, and hydrogen peroxide (Zeller 
1938, Schayer 1959). DAO is mostly expressed in tissues (e.g., intestines, kidney, 
thymus, kidney cortex, seminal vesicles, placenta, and in the plasma of pregnant 
women), that transport large quantities of histamine (Marcou et al. 1938, Gunther & 
Glick 1967, Tryding & Willert 1968, Beaven & Shaff 1975). And in publication #7, it 
was demonstrated that DAO is localized densely at the foeto-maternal interface to 
the cross borders between maternal (decidual) and foetal (trophoblastic) tissues, 
thereby confirming previous postulates about the topological orientation of the 
enzyme in human placenta (Buffoni 1966, Gunther & Glick 1967, Tornqvist 1969).  
 
In normal human pregnancy, the parallel increase in DAO activity in the placenta and 
in maternal blood along with gestational age creates an effective histamine-DAO-
axis (HDA), with DAO activity present throughout the course of pregnancy. In the 
pregnancies with normal HDA, maternal plasma DAO activity levels spontaneously 
rise exponentially to a 1000 fold from gestational week 8 and peaks at gestational 
weeks 20 and 24 (Ahlmark 1944, Southren et al. 1966b, Gunther & Glick 1967, 
Weingold & Southren 1968, Tufvesson 1978, Beaven et al. 1975, Dubois et al. 
1977). In contrast, the spontaneous exponential rise of DAO activity is abrogated 
from gestational week 8 onwards thus, leading to a defective histamine-DAO-axis in 
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pregnancies such as PE that present with high blood histamine (Southren et al. 
1966b, Achari et al. 1971, Beaven et al. 1975, Legge & Duff 1981).  
 
Thus, modelling the EHM was crucial to deciphering the functions of increasing 
histamine in PE. This was achieved by inhibiting DAO enzyme activity in regenerated 
syncytiotrophoblast placental explants with aminoguanidine to mimic in vivo 
condition. The explants were incubated at the liquid-gas interface in 8% oxygen, 
37°C in basic media for 5 days (the culture media were changed at days 2 and 4) to 
allow for syncytiotrophoblast degeneration and regeneration. This was followed by a 
final media change on day 5, containing 100nM histamine in the presence of 
aminoguanidine (10-4 M final concentration) for 24 hours histamine treatment, or 
basic media without aminoguanidine for control samples. Endogenous placental 
DAO metabolises histamine in 1g of placental explant at a rate of 45.54 µg/hr 
(Kapeller-Adler 1952b). Therefore, to be able to observe the effect of the exogenous 
histamine, DAO activity was blocked with aminoguanidine in the treatment samples. 
Aminoguanidine is a specific inhibitor of DAO enzyme activity (Tamura et al. 1989). 
This culture method therefore enabled us to create an ex vivo elevated histamine 
model (EHM) with some parallel features of an in vivo defective histamine-DAO-axis 
system. 
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3.3 Sub-section 2: Justification for evolution of methodological techniques and 
contributions knowledge: - Transition from Single Gene to Multi-gene Analysis 
  
Detailed analyses of biological processes that underpin health are identified by most 
UK research funding bodies (e.g., MRC) as key step in the search for new ways of 
treating disease. Thus post-genome research focus is shifted to the accurate 
annotation of genomic sequences and the interplay between genes and proteins, 
and high throughput analysis of genetic variability between patients and susceptibility 
to disease or failed therapy. In tandem, methodological approach for the study of 
histamine role in placental gene expression evolved from a pre-genome approach 
focusing on single index genes using Polymerase Chain Reaction (PCR) technique 
through real time multiplex PCR to post genome high throughput techniques such as 
microarrays.  
 
The changes to the technical approaches were necessary because of the multiple 
foci of the research agenda. First, a major focus of the study was to investigate the 
interplay between genes and proteins. Databases containing large numbers of 
genetic sequences and polymorphisms were available to facilitate the investigations 
however the method of investigation significantly influenced the rate of progress and 
dissemination. Similarly, to be able to significantly contribute towards faculty 
research output required maximisation of limited research time to decipher parallel 
gene expression profiles of normal and disease tissues in different clinical states. 
Thus, there was an inherent need to maximise potentials and resources through 
technological advancement. 
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Cost effective analysis of the project in year Jan 2005 showed that it was extremely 
laborious, costly and time consuming to use low throughput techniques to investigate 
effect of histamine on placental gene expression. For example, in the year 2000, 
using conventional PCR technique, working 11 hours per day, five days a week for 6 
months, enabled the study of the expression characteristic of 4 genes only. In 
contrast, the expression characteristics of 6 genes were studied over 3 weeks (7 
hours per day; 3 days per week) in December 2004, with real-time multiplex qPCR 
technology at a fraction of the consumable cost for the year 2000 work. Moreover, 
the evolution of new high throughput technologies to quantify the expression of 
specific genes eliminated the need for some time-consuming and hazardous steps 
such as radio-labelling, scintillation counting, and post PCR analysis using 
carcinogenic chemicals such as ethidium bromide in gel electrophoresis. Thus on the 
grounds of cost effectiveness, expediency and safety, it was justified that application 
of high throughput technique to study histamine effects on placental gene expression 
was the best value for money option to significantly enhance the rate of data 
turnover and discoveries.  
 
 
3.4 Sub-section 3: Microarrays and Bioinformatics: Considerations, 
Rationale and Contributions to Knowledge of Placental Gene Expression 
3.4.1 Microarray Hybridisation (Publications #4, #9 and #11) 
In publications #4, #9 and #11, placental RNA hybridised onto Affymetrix microarrays 
were used to investigate the effects of oxygen and histamine in human placentae. In 
brief, RNA was extracted from micro explants with TRIZOL (Invitrogen, UK) and 
quality assessed. Total RNA was processed into labelled cDNA with NuGEN™ 
Ovation™ RNA Amplification System V2 and FL-Ovation™ cDNA Biotin Module V2 
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(Nugen). The resultant fragmented and labelled cDNA was added to the 
hybridisation cocktail in accordance with the NuGEN™ guidelines for microarray 
hybridisation onto Affymetrix GeneChip® Human Genome U133 Plus 2.0 arrays: one 
sample per array, (Figure 3-1) in Affymetrix GeneChip® Hybridisation Oven 640 for 
18 hours at 45°C. Features that retained bound labelled cRNA after washing were 
visualized using the GeneChip® Scanner 3000 (Affymetrix).  
 
 
 
 
 
 
 
 
 
 
Figure 3-1: Microarray Experiment Culture flowchart 
Total RNA from term placental explants were hybridised to Affymetrix Human Genome U133 Plus 2.0 
Array. Explants were incubated for 6 days in POC or AOC. Half of the explants RNA under each of 
the ambient oxygen were treated with histamine and aminoguanidine in the last 24 hours of organ 
culture. Non-histamine & aminoguanidine treated samples served as the respective control samples.  
 
3.4.2 Rationale for using Loop microarray design (Publications #4, #9 and #11) 
A critical component of microarray studies is to design the experiment to make the 
analysis of the data and the interpretation of the results as uncomplicated but as 
powerful as possible, given the purpose of the experiment and the constraints of the 
experimental material (Yang et al. 2002, Yang & Speed 2002). Thus, two main 
microarray experiment designs: single factor or one-way experiment, and multi-
factorial experimental designs (Yang & Speed 2002, Peng & Stromberg 2003) were 
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considered for the study to investigate the effects of histamine and oxygen in 
placental explants. Single factor designs typically include studies that investigate the 
differences in expression between two or more time points following treatment (time-
course experiments), or different regions or subtypes of tissues such as normal and 
pre-eclamptic placentae (Kerr & Churchill 2001, Simon et al. 2002, Yang & Speed 
2002, Blalock 2003).  The microarray experimental designs that have two or more 
factors to be considered jointly, where each factor in turn may have two or more 
levels are normally considered multi-factorial (Yang & Speed 2002, Wit & McClure 
2004).  
 
Within the multi-factorial array designs, there are at least two basic types: a design 
with common reference or loop baselines (controls) (Kerr et al., 2000; Kerr & 
Churchill, 2001b; Yang & Speed, 2002; Wit & McClure, 2004; Kerr & Churchill, 
2007). A loop design (Figure 3-2a) describes the method where samples are directly 
compared by direct pairing of sample array slides, usually based on scientific aim or 
biological interest of the study, whereas a common reference design describes the 
method where all samples are indirectly compared by referring to a single reference 
sample (Figure 3-2b) usually a pre-culture time-zero sample (Kerr & Churchill, 
2001a; Yang & Speed, 2002; Wit & McClure, 2004). In effect, loop design uses direct 
comparison between slides without a common reference so that the choice of a 
baseline control depends on the experimental question. 
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Figure 3-2: Microarray Experiment Design 
 
Previous comparative work reporting on the appropriateness of loop design (Yang & 
Speed 2002) showed that loop design gave the smallest confounding variance for 
estimating differential expression between the main effects, whereas common 
reference usually derived from time zero samples (e.g., Figure 3-2b), by far gave the 
worst variance for estimating the interaction in both 2 X 2 factorial and single factor 
time-course experiments (Yang & Speed 2002). Thus, in our loop design (Figure 
3-2a), samples were compared with each other in a loop order according the 
biological or experimental questions. Our direct loop order was driven by 3 main 
scientific questions aimed at determining whether: (1) gene expression between 
explants cultured for 6 days in POC or AOC differ, (2) the effect of histamine on 
placental explants gene expression differ between those cultured in POC and AOC; 
and (3) gene expression in cultured explants with diminished DAO activity but 
treated with histamine differ from cultured explants without diminished DAO and 
histamine treatment. Therefore the loop design allowed for direct comparison of time 
equivalent controls with treated sample. For example, in order to determine relative 
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changes in gene expression between explants cultured in POC and AOC, slide A 
was compared with B where slide A was made the control (Figure 3-2A). Therefore, 
based on the biological interests posed by the experimental questions a loop design 
was deemed more appropriate to enhance the biological relevance of the results.  
 
3.4.3 Dealing with the impacts of variances (Publications #4, #9 and #11) 
While it is well demonstrated that one of the best designs to limit confounding 
variance in multi-factorial microarray experiment is loop design instead of common 
reference design (Kerr et al., 2000; Kerr & Churchill, 2001b; Yang & Speed, 2002; 
Wit & McClure, 2004; Kerr & Churchill, 2007), there are constraints associated with 
this type of experimental designs. Often, the constraints are linked to strategies to 
deal with inherent variances that may affect data interpretation. In this instance, the 
documented sources of variance have broadly been classified either as biological or 
technical variance (Blalock 2003). At the beginning of the studies, it was clear that 
both biological and technical variances in microarray studies could be effectively 
contained with judicious statistically based experimental design to account for four 
basic factors: control, randomisation, replicates and balance (Peng & Stromberg 
2003, Schena 2003, Wit & McClure 2004). 
 
Replicates in microarray studies are deemed highly important in creating a degree of 
variation in measurements to provide independence of data, and to offer the benefits 
of averaging log expressions to infer external validity (Lee et al. 2000, Yang & Speed 
2002, Peng & Stromberg 2003). The two types of replicates (biological and technical) 
described in microarray experiments appear to have different degrees of impact on 
variance in gene expression. The technical replicate refers to replication in which the 
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target mRNA is from the same pool or extraction, whereas biological replicate refers 
to hybridizations that involve mRNA from different extractions or different samples of 
cells from a particular cell line or tissue; or from target mRNA, which comes from 
different individuals or different versions of a cell line (Lee et al. 2000, Yang & Speed 
2002).  
 
Of these, it is suggested that technical replicates generally involve a smaller degree 
of variation in measurements than the biological replicates, and therefore do not 
provide a greater deal of impact on external validity (Lee et al. 2000, Yang & Speed 
2002, Peng & Stromberg 2003). In contrast, the literature suggests that external 
validity of microarray findings can be improved with meticulous prediction of 
biological replicates to ascertain appropriate sample size to detect statistical 
differences in gene expression along with appropriate use of control samples to 
establish baseline expression (Yang & Speed 2002, Wright & Simon 2003, Dobbin & 
Simon 2005). Analysis of variance distribution incorporating random variance model 
to estimate the within-class variance for each gene in the human genome to predict 
sample size (Wright & Simon 2003, Dobbin & Simon 2005) was therefore performed 
in Chipster v1.4.7. Consequently, biological replicates of 6 per class was predicted to 
identify differentially expressed genes at Type 1 error = 0.05, (Power = 70%, 
hypothesized mean difference in log2 expression between classes = 1). 
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3.4.4 Validation of the Microarray Design: Biological Relevance of Pre-culture explant 
as baseline control for histamine treated cultured explants (Publication #3 & #4) 
To validate the loop design, the effects of tissue culture and oxygen on placental 
gene expression were examined to ascertain the biological relevance of studying 
histamine effects in POC or AOC, and also for using pre-culture explants as control 
for the cultured explants. It was argued that pre-culture (time zero) placental explant 
expression was needed as a common reference baseline control to put the cultured 
explant microarray expression into perspective as opposed to using cultured non-
treated explants as baseline for the cultured treated samples. Therefore, the 
hypotheses that (1) entropy of gene expression of pre-culture time zero explant and 
explants that have been cultured and undergone STB regeneration were mutually 
meaningful and biologically relevant; (2) oxygen concentration and tissue culture per 
se do not affect the explant gene expression and the interpretations thereof were 
tested.  
3.4.4.1 Biological Relevance between Pre-culture and cultured Explants for RGE (#4, 9, 11) 
To answer the question of using time zero explants as common reference baseline 
for the cultured explants, biological relevance network analysis was performed with 
placental micro explants cultured for 6 days in POC (4 biological replicate arrays), in 
AOC (6 biological replicate arrays) and pre-culture time zero explant (5 biological 
replicates) microarrays. All placentae were delivered by elective caesarean sections. 
 
The biological relevant networks analysis was performed by computing the entropy 
of gene expression patterns between the microarray samples to provide mutual 
information (information content) for RNA expression patterns from each hybridised 
explant sample (Butte & Kohane, 2000). The correlation coefficient between explants 
was measured by comparing the expression pattern of genes on each slide to that of 
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every other gene. Minimum Pearson correlation (R2) threshold was set as 
0.7700514, and maximum Pearson correlation (R2) threshold at 1.0. To observe all 
true relevance networks, highest entropy filter was also set to 100%. 
 
The analysis showed 55 biologically relevant clusters or links (Figure 3-3), with two 
mutually exclusive relevance subnets. Subnet 1 contained 10 experiments entirely 
from explants cultured for 6 days, while subnet 2 contained 5 experiments 
exclusively from pre-culture (time zero) explants. The percentages of biologically 
relevant networks in each subnet were respectively 67% and 33% for subnet 1 and 
2. The explants were represented as nodes in the network and lines were drawn 
between the nodes (Figure 3-3) to show the link was biologically relevant when the 
respective correlation coefficient was R2 >0.77. All gene expression entropies for the 
15 microarrays were linked through comprehensive pair-wise mutual information 
analysis, but no biologically relevant network was identified between pre-culture time 
zero explants and 6 days cultured explants. The findings suggested that the links 
between gene expression in pre-culture time-zero and explants cultured to 6 days 
were not biologically relevant to support direct comparison. Thus, indicating that the 
use of pre-culture time-zero explants as a baseline control for 6 days culture time-
point placental microarray experiment could complicate interpretation of results. 
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Figure 3-3: Biological Relevance Network Analysis of Time zero, POC and AOC 
treated Explants 
Fifteen placental explant microarrays from 11 elective caesarean normal placentae (pre-culture explants = red 
nodes, n = 5; explants cultured in POC for 6 days = green nodes, n = 4; explants cultured in AOC for 6 days = 
blue nodes, n = 6) were analysed to identify biologically relevant networks (BRN) between each pair of 
samples. A total of 55 BRNs were identified. (a) = true links between cultured explants (green nodes = POC 
explants; blue nodes = AOC explants); (b) true links between pre-culture explants (orange nodes). No BRN 
were found between pre-culture and cultured explants at minimum Pearson Correlation R
2
 = 0.77. Networks 
(lines) coloured in red represent elements that are positively correlated while networks coloured in blue 
represent elements that are negatively correlated. 
 
3.4.4.2 Impact of Tissue Culture and Oxygen on Explant Gene Expression (#4) 
To further examine the implication of the lack of biologically relevant links between 
pre-culture and 6 days cultured explants on the interpretation of results, the 
differences in placental transcriptomic changes in response to tissue culture and 
oxygen, and the relevance of genetic alterations and pathways associated with POC 
and AOC culture were investigated. Placental explants were collected from normal 
term (38-39 weeks of gestation) placentae with no previous uterine contractile 
activity. Placental gene expression profile was evaluated with analysis of GeneChip® 
Human Genome U133 Plus 2.0 arrays (Affymetrix). 
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Absolute gene expression (AGE) analysis was performed using One Class 
RankProd statistics to identify ‘consistently high expressed’ (CHE) and ‘consistently 
low expressed’ (CLE) significant genes respectively in Time Zero (pre-culture) 
explants (designated as T0), and explants cultured in POC and AOC for 6 days. FDR 
Confidence (1-alpha) was set at 99.9% (FDR <0.001). The analysis identified a total 
of 635, 1207 and 1760 significant genes that were consistently expressed in pre-
culture (T0); POC and AOC cultured explants respectively (Figure 3-4).  Of these, 
224 genes were exclusively expressed in pre-culture samples. In contrast, 69 genes 
(1 CHE and 68 CLE) were exclusively expressed in POC and 574 genes (292 CHE, 
and 282 CLE) in AOC cultured explants only.  
 
The analysis also identified a further 48 genes that were expressed in both pre-
culture and AOC treated explants but not in POC treated explants. In addition, it was 
observed that the CHE genes appeared insensitive to POC, but rather to tissue 
culture and AOC. In that, all CHE genes (except SIGLEC6) expressed in POC 
explants were also expressed consistently at high levels in AOC explants. 
Furthermore, there was a core set of 770 significant genes that were expressed in 
both POC and AOC treated samples only, and appeared to be genes suggestively 
responding to tissue culture per se. No genes were exclusively expressed 
consistently between pre-culture and POC treated samples only. However, using 
class prediction modelling incorporating Leave-one-out cross-validation and ROC 
curves analysis, the study identified the expression of 134 genes that were 
significantly (p<0.01, AUC = 0.82(CCP), 0.81(DLDA), 0.81(BCCP)) associated with 
prolonged explant culture at AOC.  
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Figure 3-4:  Expressed genes in POC and AOC explants 
Figure A shows overlap of consistent high level expressed (CHE) genes between pre-culture, and explants 
culture at AOC and POC. Figure B shows overlap between pre-culture CHE genes and cultured explants 
consistent low expressed (CLE) genes. Figure C shows a volcano plot of 157 significant genes (blue dots). 
Random variance model parameters at a= 1.31652, b= 17.03489, Kolmogorov-Smirnov statistic= 0.01 and a 
nominal significance level (dotted line) of each univariate test at p< 0.05 (210 exact permutations). Figure D 
shows the ROC curve from the Bayesian Compound Covariate Predictor for AOC associated genes. S1 – S8 = 
Gene Sub-sets 1 – 8; T0 = Pre-culture CHE genes; AOC = Atmospheric Oxygen Concentration; POC = 
Physiologic Oxygen Concentration; +ve = CHE; -ve = CLE. 
 
Subsequently, through analysis of the gene ontologies and pathways enriched by the 
pre-culture, POC and AOC significant gene sets it was shown that the preserved set 
of genes that appeared to respond to tissue culture irrespective of oxygen 
concentration were significantly involved in programmed cell death, cell death, death, 
stress response, protein metabolic process, electron transport activity, RNA 
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translation and oxidoreductase activity, regulation of cytosol, cytoplasmic and 
organelle parts of the placental cells. These therefore suggested that tissue culture 
per se induces the expression of genes that regulate a cluster of cathartic functions 
in the placenta. 
 
The work was thus extended to examine the effects of culture oxygen concentration 
on Transcription Factor Target gene sets (TFTs) expression. It was observed that 
culture at AOC down-regulated specific TFTs including REL, ETV4, ATF3, STAT1, 
JUND and STAT5B. Through text mining analysis, these TFTs were identified to be 
involved in cell growth, proliferation, invasion, regeneration, differentiation, 
transformation, tissue viability, protection from apoptosis, and glands development. 
Conversely, AOC up-regulated TFTs such as HIF1A, PPARA, CEBPD, STAT3, and 
CEBPE, that are associated with oxygen regulation, immune and inflammation 
responses; leptin mediated response; lipid metabolism; suppression and mis-
regulation of cell growth and proliferation; cell morphogenesis; induction of 
apoptosis; and oxygen regulation. These findings collectively suggested that: 
 
1. Gene expression patterns differ between pre-culture and cultured explants 
2. Placental explants’ responses to tissue culture per se induce expression of 
genes with preponderance towards apoptosis, inflammation and tissue 
response to stress irrespective of culture oxygen concentration.  
3. The magnitude of the tissue response to stress and programmed cell death in 
placenta is sensitive to AOC.  
4. Explants culture at AOC exacerbates tissue response to stress and 
programmed cell death in placenta. 
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5. AOC up-regulates HIF1A transcription target gene set 
6. Oxygen and tissue culture generally precipitate down-regulation of a sub-set 
of placental genes 
 
Overall, the findings suggested that the lack of biologically relevant links between 
pre-culture and 6 days cultured explants was underpinned by critical biological 
variance, and that the use of pre-culture time zero explants as baseline for 6 days 
cultured explants could complicate the interpretation rather than offer meaningful 
baseline. The findings also confirmed previous reports (Thompson et al. 2007, 
Fajardy et al. 2009) that culture per se affects explant gene expression. It further 
showed that irrespective of oxygen concentration, tissue culture per se down-
regulates more genes but the effect is exacerbated in explants cultured under AOC. 
Therefore, it was acknowledged that in a time point (not time series) experiment 
variances introduced by explant culture including syncytial degeneration and 
regeneration and differential gene expression would complicate the interpretation of 
gene expression induced by histamine after long-term culture, and hence pre-culture 
explant was deemed unsuitable as baseline control for relative gene expression 
analysis (RGE). 
3.4.5 Rationale for Bioinformatics methodologies (Publications #2, #4 and #11) 
Bioinformatics analyses were performed to transform gene expression data into 
biological information. R Bioconductor statistics were used within R Studio (RStudio 
2015), BRB ArrayTools (Simon et al 2007), Gene Ontology Tree Machine (GOTM, 
(Zhang et al. 2004)), "WEB-based GEne SeT AnaLysis Toolkit (WebGestalt, (Wang 
et al. 2013)), MEV4 (Saeed et al. 2006), Reactome (Fabregat et al. 2016), Chipster 
(Tuimala et al. 2008), INMEX (Xia et al. 2013) and NetworkAnalyst (Xia et al. 2015) 
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to process microarrays and also to probe the Gene Ontology, Kyoto Encyclopedia of 
Genes and Genomes (KEGG), BIOCARTA and Molecular Signature Database 
(MSigDB) data bases to assess the biological relevance and significance of genes 
according to similarity in function, participation in signalling pathways, and protein 
domains. 
 
3.4.5.1 Gene Findings: AGE and RGE (#2, #4, #11) 
The usual approach to finding significantly expressed genes from microarray 
experiments relies on relative gene expression (RGE), which is defined as the 
relative quantitation of the differences in the expression level of a gene between the 
case and control samples (Xia et al. 2013). Traditionally, this approach is suggested 
as highly suitable for candidate gene discovery or class prediction studies, but 
limited in its ability to find genes that are significantly expressed consistently at low 
or high levels in the same class or phenotype (Schena et al. 1995, Dudley et al. 
2002, Simon et al. 2002). To find such regulated genes would require absolute gene 
expression (AGE) analysis, but existing methods for microarray AGE relied on 
common reference methods (Seita et al. 2012). In the common reference method, 
microarray data were normalized individually with the common reference and 
averaged. These averaged values were then mapped onto the probeset meta-profile 
in order to obtain the population’s percentile and expression value for each probeset 
(Seita et al. 2012). While this methodology was helpful if the objective was to 
compare a probeset value against existing values, the value thus computed was 
relative and arbitrary; and subject to changes to the pooled value. It was therefore 
proposed that RankProd analysis method could be used to perform AGE without 
reliance on a common reference. 
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RankProd analysis is a non-parametric statistic originally modelled for RGE (Breitling 
et al. 2004). It combines the gene rank from the different arrays together instead of 
using actual expression data to select genes that are consistently ranked high or low 
(Breitling et al. 2004, Hong & Breitling 2008). The product ranks from all samples are 
then calculated as the test statistic in100X permutations with a nominated False 
Discovery Rate (FDR), for example, confidence at 1 – alpha = 95.0% or 99.9%. The 
RankProd analysis generates three pools of data classified as Negative Significant, 
Positive Significant and Non-significant. In the context of intra-class AGE, negative 
significant gene pool contains genes that are consistently expressed at low levels 
(CLE) across the libraries from the same class, and are thus classified as down-
regulated (Saeed et al. 2003). Positive significant gene pool on the other hand 
contains genes that are consistently expressed at high levels (CHE) across all 
libraries from the same class (up-regulated) (Saeed et al. 2003). Genes that have 
very low expression below the present call or background threshold cut-off point, and 
genes that have inconsistent expression across all libraries from same class are 
classified as non-significant (Saeed et al. 2003).  
 
In contrast, positive significant genes (up-regulated) identified from RGE are genes 
that are more highly expressed in treatment group relative to the expression in 
control class or libraries; and negative significant genes (down-regulated) are the 
genes that are more highly expressed in the control class relative to treatment class. 
Both RGE and AGE methods have been used at different stages in the work to 
answer different questions. For example, in paper #2, AGE methodology was for the 
first time used successfully to identify comprehensive gene-signature that included 
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genes with consistently low or high expression in both pre-eclamptic and normal 
placentae. The findings showed that the use of AGE analysis enables independent 
description of a comprehensive, globally and consistently expressed genes in the 
case and control samples. On the other hand, the findings showed that overt use of 
RGE analysis to the disadvantage of AGE could limit gene sets and our 
understanding of the real time and complexities of changes that could occur in a 
case or disease state.  
 
The findings also confirmed earlier reports (Simon et al. 2003, Breitling et al. 2004) 
that RGE not only identifies limited candidate genes but could also exclude large 
proportion of genes that may be of relevance in characterising the molecular 
pathology of a disease including those with biologically relevant low level expression 
and genes with similar levels of expression in both the case and control samples. 
The findings further suggested that RGE could inherently identify genes whose 
expression patterns may be inconsistent but might have large differential expression 
between control and case samples.  
 
3.4.5.2 Finding Biological Relevance of Genes (#2, #4 & #11) 
For interpreting the expression results in terms of higher order of biological 
processes or molecular pathways, Gene Set Analysis methodology (GSA) method 
(Efron & Tibshirani 2007), Gene Set Enrichment Analysis ((GSEA), (Subramanian et 
al. 2005)), Over-representation analysis, Paroto Analysis for Vital Few Genes 
 and Leading Edge Metagene ((LEM), (Subramanian et al. 2007)) analysis were 
used to identify over-represented, enriched and leading edge genes from Gene 
Ontology (GO) term, genetic pathways, transcription factor target gene sets.  
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3.4.5.3 GSA and GSEA  (#2, #4 & #11) 
GSEA is a computational method that determines whether a priori defined set of 
genes shows statistically significant, concordant differences between two biological 
states (e.g. phenotypes) (Subramanian et al. 2005). GSA was mostly used in the 
studies that focused on deciphering the differential enrichment of pathways between 
experimental and control samples. The Efron-Tibshirani's GSA uses the maxmean 
statistics, a modification of the GSEA procedure (Subramanian et al. 2005) for 
assessing significance and direction of regulation of pre-defined gene-sets. The 
maxmean statistic identifies the direction of regulation of the gene set by a measure 
of the absolute value of the positive or negative part of gene scores di in the gene 
set (Efron & Tibshirani 2007). In this analysis, all gene scores di in the gene set were 
taken to set all of the negative ones to zero.  Average of the positive scores were 
then taken to give a positive part average = avpos. Similarly, gene ‘scores di’ in the 
gene set were taken to set all of the positive ones to zero and then average for the 
negative side were taken to give the negative part average avneg (Efron & Tibshirani 
2007, Simon et al. 2007). Thus, the overall score for the gene set was avpos (up-
regulated) if |avpos| > |avneg|, or otherwise it is avneg (down-regulated) (Simon et 
al. 2007). Consequently, transcription factor target gene sets and biochemical 
pathways analyses were performed.  
 
3.4.5.4 Leading Edge Metagene (#11) 
LEM is build-up of the GSEA to find the leading-edge subset in a gene set. Leading-
edge subset in a gene set are those genes that appear in a ranked list at or before 
the point at which the running sum reaches its maximum deviation from zero 
(Subramanian et al. 2005). LEM is useful for identifying the core genes that account 
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for the gene set’s enrichment signal. Therefore in the investigation of the effects of 
histamine on placental gene expression, downstream analysis of the gene set 
enrichment results with GSEA leading edge metagene (LEM) method was performed 
to identify groups of genes that were co-regulated by histamine, and are likely to 
form the core sub-signatures of genes that accounts for the gene set’s enrichment 
signal to establish the distinct biological processes or pathways in PE placentae. 
 
3.4.5.5 Pareto Analysis for Vital Few Genes (#11) 
The Pareto Principle was applied to identify the "vital few" genes responsible for 
producing most of histamine effects. The principle as originally applied to quality 
improvement suggests that a great majority of effects (80%) are produced by a few 
key causes (20%) (Juran 1975). The importance of identifying the vital few histamine 
regulated genes lies in the plausibility that nothing of significance can happen in 
response to histamine unless these vital few genes are regulated. The analysis 
involved rank ordering of the frequency of involvement of a particular gene in 
multiple biological functions or ontologies, and applied the Lorenz (Lorenz 1905) 
cumulative curve to depict the distribution of the vital few genes. 
 
3.5 Conclusion 
There were many challenges for studying histamine effects on the placenta. The 
challenges ranged from using an appropriate ex vivo model that limited iatrogenic 
inflammation to tissues that are primed for or are already pro-inflammatory to 
maintaining maximal concentration of histamine introduced to experimental samples. 
These experimentations made substantial contributions to these areas of placental 
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research by showing that inflammatory effects can be controlled to investigate the 
effects of histamine on placenta that have undergone Syncytiotrophoblast 
degeneration and regeneration. These studies also showed that it is possible to 
obtain high quality RNA akin to pre-culture quality from micro explants cultured for 6 
days at the liquid-gas interface. These studies also confirmed that placental explants 
are viable after 6 days culture but the explant size affects the viability and integrity 
after culture. These studies further showed that morphological assessment of the 
degree of STB degeneration is parallel to explant RIN and could be used as proxy 
measure for explant viability. These investigations further contributed to the 
knowledge of placental tissue culture by providing genomic evidence to confirm that 
placental explant culture at atmospheric oxygen was pathological and that culture 
per se triggered the expression of cathartic genes, and the effect is worsened by 
culture in atmospheric oxygen. In contrast, explant culture in an optimum hypoxic 
condition (8% oxygen) was physiological and optimum for term placental explant 
culture. The discussion of the rationale underpinning the bioinformatics approach 
that incorporated absolute gene expression modelling to uncover PE pathways and 
the complexity of histamine pathways in PE placentae demonstrated additions to 
knowledge about novel methods to architype intra-phenotype significant gene 
expressions. 
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                                                                                         Chapter 4
Theme 3: Understanding causes of elevated Histamine in 
Pregnancy and Pre-eclampsia 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In this chapter: 
The commentary is based on publication items, #5, #6 and #7: 
 (#5) Brew O, Lakasing L, Sullivan M. (2007) Differential Activity of Histidine 
Decarboxylase in Normal and Pre-eclamptic Placentae. Placenta. May-Jun; 
28(5-6):585-7. 
 
 (#6) Brew O, Sullivan, M. H., & Roller S 2005, "Regulatory loops between 
cytokines and histamine in the human placenta", Placenta, vol. 26, no. 8-9, 
p. A.52  
 
  (#7) Brew, OB & Sullivan MH (2001) Localisation of mRNAs for diamine 
oxidase and histamine receptors H1 and H2, at the foeto-maternal interface 
of human pregnancy, Inflammation Research, 50(9): 449-452 
 
 
The focus of the commentary is to discuss the investigations that broadened our 
understanding of the causes of elevated histamine in pregnancy, with emphasis on 
histamine synthesis, production and metabolism in PE placenta. 
 
Highlights: 
 Histamine synthesis based on de novo HDC activity is higher in PE placentae 
than in normal placentae 
 The cytokines IL-10, IL-1β and INF- time dependently regulated histamine 
production in human placenta, inducing both rapid (30 minute) and prolonged 
(24h) increases in histamine. 
 Th1 (INF-) and Th2 (IL-10) like cytokines, pro-inflammatory (IL-1β) cytokines 
and endotoxins induce biphasic histamine increase in placenta. The responses 
are suggestive of both histamine release from storage and de novo histamine 
synthesis.  
 Histamine receptors are expressed in human placenta.  
 The co-expression of histamine receptors and DAO is consistent with a role for 
histamine at the foeto-maternal interface of human pregnancy 
 There was a regulatory feedback loop between histamine, cytokines and DAO 
expression in human placenta. 
 The expression of DAO in the decidua is widespread, indicating that the enzyme 
could also function to prevent prolonged exposure of decidual cells to bioactive 
histamine. 
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4.1 Introduction: 
PE is a complex disorder of pregnancy that involves a systemic inflammatory 
response, endothelial activation within the maternal vascular system, increased 
maternal blood histamine and decreased histamine metabolism (Kapeller-Adler 
1941, Redman et al. 1999, Chambers et al. 2001, Sargent et al. 2003). A number of 
the features of PE (hypertension, proteinuria, oedema, nausea, and headaches) as 
outlined in publication item #1 also mimic those of hyperhistaminemia (hypertension, 
proteinuria, oedema, nausea and vomiting, headaches, tachycardia, palpitation, 
convulsions, metallic taste). Normally, maternal plasma DAO levels increase up to 
1000-fold during pregnancy (Southren et al. 1966a, Beaven et al. 1975), but this 
increase in DAO is attenuated in PE, with a resultant high blood histamine (Kapeller-
Adler 1944, Achari et al. 1971).   
 
The placenta is the primary source of histamine and DAO in pregnancy. However, 
the human placenta functions both to produce nutrition and remove waste products 
for the developing foetus (Lyall 2002), thus suggesting that histamine as found in the 
placenta with increased levels in PE placentae could be a mere by-product of foetal 
development and hence may not have functional roles in the placenta. Therefore it 
was hypothesised that (1) for histamine to have functional roles in the placenta it 
must express receptors at the foeto-maternal interface; (2) that placental HDC 
activity did differ between normal and PE tissues; and (3) that pro-inflammatory 
cytokines and endotoxins would increase histamine synthesis in the placenta. 
 
Using DNA and RNA extraction, gene cloning, gene amplification and in situ 
hybridization technologies, the expression of mRNAs for histamine receptors H1 and 
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H2, and for diamine oxidase at the foeto-maternal interface were localised. Similarly, 
using enzyme assays including fluorometric and chemiluminescent methodologies 
and RNA amplification with reverse transcription polymerase chain reactions (RT-
PCR) HDC activity and the effect of histamine on cytokines expression in the 
placenta were investigated. The commentary will critically reflect on the relative 
contribution made by these findings to the knowledge and understanding of 
molecular functions of histamine in human placenta.  
 
4.2 HDC activity in PE placentae (Publication #5) 
 
In theme 1, it was established that maternal histamine levels in PE increases above 
levels found in normal pregnancies, and the difference is significant (Figure 2-6).  It 
was also established that the placenta is the source of the elevated histamine in 
human pregnancy and that nascent or de novo histamine rather than pre-formed 
histamine is the most likely source of the elevated histamine in PE. In order to 
increase our understanding of the source of the elevated histamine in PE, an 
enzyme assay study using fluorometric, ELISA,  and chemiluminescent 
methodologies was conducted to test the hypothesis that placental HDC activity did 
not differ between normal and PE tissues and histamine. 
 
The findings showed that HDC activity was present in all placental tissues tested, 
and normal placentae produced histamine at the rate of 4.77 ± 0.87 ng/g/hr, 
compared with 5.49 ± 0.52 ng/g/hr from the pre-eclamptic tissue (p<0.05, ANOVA).  
The work also showed that histamine production varied substantially between 
tissues, so the net rate of production for each placenta (Histamine level after 1 hour 
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of incubation – histamine level in corresponding control tissue) was compared using 
log ratios.  In normal tissues this was -0.37 ± 0.26 ng/g/hr, compared with 1.86 ± 0.5 
ng/g/hr from pre-eclamptic tissue (means ± s.e.m.), a significant difference (p = 
0.0003 ANOVA).  Thus confirming that histamine synthesis based on de novo HDC 
activity is higher in PE placentae than in normal placentae, and could contribute to 
the increased levels of histamine in maternal blood in pre-eclamptic pregnancies.   
 
This finding did not identify whether the change in pre-eclamptic placental histamine 
is a cause of the disorder, or an effect of it, but it made it clear that the placenta can 
contribute to the pathology.  Although this study showed that the rate of histamine 
synthesis is increased in PE placentae, it could not confirm previous report that 
histamine content may be increased in pre-eclamptic placentae (Szukiewicz et al., 
1999a). This observation was congruent because the study was intended to 
investigate synthesis rather than storage which may explain the difference. The 
findings however confirmed that the placenta contains histamine (Kapeller-Adler, 
1952; Purcell, 1992), which would be produced by HDC. It was therefore suggested 
that in normal pregnancy histamine is stored in the placenta but the synthetic 
capacity may be relatively low compared to pre-eclamptic placentae.   
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4.3 Effects of Cytokines and Endotoxins on Histamine Production in the 
Placenta (Publication #6) 
 
In attempts to investigate the causes of elevated histamine in PE, the effects of index 
cytokines for inflammation and endotoxins on histamine production in the placenta 
were examined. In this work, a total of six placental samples were collected from 6 
different normal pregnancies. Three placental explants per sample were used to 
investigate the effect of key cytokines and endotoxins on histamine production in the 
placenta.  Index cytokines Interleukin 1 beta (IL-1), Interferon gamma (IFN-), 
Interleukin 10 (IL-10) respectively for pro-labour, Th-1, Th-2 cytokines families and 
endotoxin lipopolysaccharide (LPS) were tested. 
 
Tissues in triplicates were stimulated with IL-1 (1 ng/ml), LPS (10 ng/ml), IL-10 (10 
ng/ml), IFN- (100 U/ml) in the presence of aminoguanidine (10-4 M final conc.) and 
cultured to different time courses (30min, 1hr, 2hr, 4hr, 8hr & 24hr). Histamine was 
then measured with histamine ELISA (IBL, Hamburg) and corrected for tissue 
weight. The difference in histamine production in response to the stimulant over the 
specified time course were statistically analysed with ANOVA and Bonferroni/Dunn 
post hoc to determine significance difference. The analysis showed that histamine 
was produced with a mean baseline (time zero) value of 31.1± 4.4 nmol/L (mean ± 
SEM, n = 6), and IL-10, IL-1beta and INF- time dependently regulated histamine 
production in human placenta (Figure 4-1).  
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Figure 4-1: Cytokines and Endotoxin effect on Placental Histamine Production 
Figures A – D show the effects of the index cytokines Interleukin 1 beta (IL-1), Interferon gamma 
(IFN- = INF-gama), Interleukin 10 (IL-10) and Lipopolysaccharides (LPS) on histamine production in 
normal placenta respectively at times 30 mins, 1, hour, 2 hours and 4 hours. * = significant difference 
between control and stimulant induced histamine levels.  
 
 
Figure 4-1A – D showed that IL-1, IFN-, IL-10 and LPS up-regulated short term 
histamine production in human placenta. All stimulants used significantly (overall 
p<0.0001 Bonferroni/Dun test) increased histamine levels after 30 minutes of culture 
(Figure 4-1A). DAO activity was blocked during culture. This implies histamine levels 
would naturally rise during culture. Therefore stimulant induced histamine production 
was compared with time-matched control (non-treated) samples. While the effects of 
the endotoxin (LPS), pro-labour (IL-1,) and Th-1 cytokines (IFN-) on histamine 
production were transient with maximal response at 2 hours (Figure 4-1C), the effect 
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of the Th-2 cytokine (IL-10) was sustained at the end of the 4 hours of culture (Figure 
4-1D).  
The transient effect observed at the end of 4 hours was reversed after 24 hours 
culture (Figure 4-2). All cytokines and the endotoxin tested significantly increased 
histamine levels after 24 hours culture (Figure 4-2). Thus, indicating that the index 
cytokines and endotoxin could both release histamine from storage (effect at 30 
minutes) and induce histamine synthesis (effect after 24 hours).  
 
 
Figure 4-2: Effects of Cytokines and Endotoxin on Placental histamine 
production after 24 hours of culture 
Figure shows the effects of the index cytokines Interleukin 1 beta (IL-1), Interferon gamma (IFN- = 
INF-gama), Interleukin 10 (IL-10) and Lipopolysaccharides (LPS) on histamine production in normal 
placenta after 24 hours. * = significant difference between control and stimulant induced histamine 
levels. 
 
These results showed that IL-1, IL10 and LPS overall increased histamine levels at 
the 0.1 µmolar range, and that in the short term the pro-labour cytokines, Th-2 like 
cytokines and endotoxins could stimulate histamine production in the placenta at 
concentrations similar to levels expected to mediate physiological functions such as 
p =0.0088 
p = 0.0027 
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such tissue remodelling, and cell proliferation while the INF  (TH-1 cytokine index) 
produced histamine in the range normally associated with pathophysiology. 
 
4.4 Histamine receptors and DAO mRNA are expressed in human placenta 
(Publication #7) 
 
To determine whether the histamine thus produced in the placenta has functional 
roles in the placenta, DNA and RNA extraction, gene cloning, gene amplification and 
in situ hybridization technologies were used to examine and localise the expression 
of mRNAs for histamine receptors H1 and H2, and for diamine oxidase at the foeto-
maternal interface. The results showed that co-expression of histamine receptors 
and DAO is consistent with a role for histamine at the foeto-maternal interface of 
human pregnancy.  
 
These findings are important, not only for the understanding of possible role of 
histamine in human pregnancy but also showed for the first time that H1R, H2R and 
DAO mRNAs are expressed in juxtaposed positions in the placental and decidual 
components of the foeto-maternal interface of human pregnancy.  The expression of 
mRNAs for histamine receptors H1 and H2 in human amnion, chorion, decidua and 
villous cytotrophoblast and stromal cells was novel. Previous studies at the time of 
publication had reported on finding the genes for histamine receptors 1 and 2 in 
human placenta tissues (Murakami et al. 1999) but not on the expression of the 
genes for the receptors in the specific tissues. Subsequent studies built upon this 
work to examine the expression of receptors in the syncytiotrophoblast cell layers 
(Matsuyama et al. 2004, Matsuyama et al. 2006).  
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The presence of mRNA for DAO in human placenta was documented previously 
(Zhang et al., 1995; Zhang & McIntire, 1996), but the localisation of mRNA 
expression had not been previously reported at the time of going to press. Therefore 
this work was significant in that it extended the understanding and knowledge of the 
expression site of the enzyme in the syncytium. The work further provided insight 
into the plausible role of DAO as a metabolic barrier to prevent excessive entry of 
active histamine into the maternal or foetal circulations. Similarly, the widespread 
expression of the enzyme in the decidua showed that it could also function to 
prevent prolonged exposure of decidual cells to bioactive histamine. 
 
4.5 Conclusion 
As the expression of histamine receptors is generally required for any functional 
effects of the amine in tissues, the localisation of histamine receptors in human 
amnion and chorion as well as in decidua and villous trophoblast cells was a crucial 
discovery. The findings clearly showed that these tissues could be targets for the 
histamine thus produced de novo in the placenta, and therefore enhances our 
knowledge and understanding of the molecular functions of histamine in human 
placenta. These studies further showed that products of inflammation, tissue 
remodelling, cell proliferation as normal placentation processes could trigger 
increased production of histamine. The findings therefore demonstrate the 
contribution made to the knowledge and understanding of the mechanisms that may 
underlie the regulation of histamine production in human placenta; a breakdown of 
which could contribute to elevated histamine associated with pre-eclampsia. 
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                                                                                         Chapter 5
Theme 4: Effects of histamine on placental genes expression: 
Implications for pre-eclampsia  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In this chapter: 
The commentary is based on the publication items #2, #6, #8 - #11 
 (#2) Brew, O., Sullivan, M.H. & Woodman, A. (2016) Comparison of Normal and 
Pre-Eclamptic Placental Gene Expression: A Systematic Review with Meta-
Analysis. PloS One, 11(8), p.e0161504. 
 (#6) Brew O, Sullivan, M. H., & Roller S (2005), "Regulatory loops between 
cytokines and histamine in the human placenta", Placenta, vol. 26, no. 8-9, p. A.52   
 (#8) Brew, O. & Sullivan, M.H.F. (2007) Histamine regulates placental diamine 
oxidase mrna expression - Evidence for a feedback loop decreasing histamine 
production in pregnancy? Placenta, 28(8 - 9), p.A71. 
 (#9) Brew OB, Sullivan MHF (2015) Placental Gene Expression in Response to 
Histamine and Oxygen, Gene Expression Omnibus. Series accession number 
GSE74446 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE74446) 
 (#10) Brew O, Sullivan M. (2017) Elevated Histamine Model: A Protocol for an ex 
vivo model for in vitro study of histamine effect on placenta. Protocols.io 
dx.doi.org/10.17504/protocols.io.jigckbw 
 (#11) Brew O, Sullivan MHF. Comparison of elevated histamine model and pre-
eclamptic placental gene expression, 
Highlights: 
 Histamine and DAO: two major biomarkers implicated in pre-eclampsia form a bi-
directional regulatory negative feed-forward relationship in the placenta. 
 Increasing histamine down-regulates DAO mRNA expression and this could lead to 
diminished DAO activity in the placenta. 
 Histamine up-regulated IL-1b, IL-10 and INF- production term placentae and this was 
reflected in increased long-term changes in mRNA levels.  
 The relative up-regulation of Th-1 cytokine INF- in response to prolonged exposure of 
high dose histamine is greater than that of IL-10 (Th-2 type cytokine). 
 Pre-eclamptic (PE) placentae express unique set of genes that are not significantly 
expressed in Normal (NP), but retain its ability to express the genes associated with in 
NP. 
 NP and PE placentae both share common biological pathways but additional pathways 
that are not significantly affected in NP are uniquely enriched in PE placentae. 
 Multiple Over-Represented genetic pathways underpin the aetiology of PE. 
 The natural process by which pre-eclampsia develops is affected by the amount of 
histamine in the maternal blood and placenta. 
 The natural process by which pre-eclampsia develops is indirectly affected by histamine 
via covariate functional groups regulated by specific PE placental genes. 
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5.1 Introduction  
Several studies have demonstrated that histamine signalling through HRH1 
generally activates cGMP, Ca2+fluxes, CaMKII, NFκB, Phospholipase A2, and 
Phospholipase D (Hill 1990, Jutel et al. 2001, Bakker et al. 2004, Matsubara et al. 
2006). In contrast, HRH2 activates cAMP, PKC-  PKC-1 adenylate cyclase, c-Fos, 
c-Jun, and Ca2+ fluxes in the placenta (Beaven 1982, McMillan et al. 1985, Hill 1990, 
Ghosh et al. 2001, Jutel et al. 2001, Davio et al. 2002). These histamine signalling 
pathways have been linked to regulation of placental cytokines, trophoblast 
proliferation, differentiation, inflammation, placental growth and cervical remodelling 
(Falus & Meretey 1992, Hamano et al. 1998, Jutel et al. 2001, Ma et al. 2002, Liu et 
al. 2004, Cricco et al. 2006, Matsubara et al. 2006, Matsuyama et al. 2006, Fukuda 
et al. 2007). Nonetheless, knowledge on placental gene expression in response to 
histamine was limited.  
 
With the advent of molecular and genomic data and complementary analytical tools, 
the possibility of going beyond the traditional index gene finding to a more complex 
investigation of the genomic architecture of the placenta was deemed feasible. 
Therefore, a comprehensive analysis of the placental gene expression in response 
to histamine was conducted with a combination of gene expression analysis 
technology including multiplex RT-qPCR and microarray technologies to provide 
better understanding of the effects of histamine in normal and pre-eclamptic 
placentae.  
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5.2 Histamine has regulatory feedback loop with Placental DAO (Publication 
#6 & #8) 
A relationship between histamine concentration and diamine oxidase activity has 
been known for sometimes. It was reported as far back in the 60s that histamine in 
high concentration inhibits intestinal diamine oxidase activity in animal models 
(Mondovi et al. 1965, Sasiak et al. 1975). Yet, this relationship was not tested in 
human placenta even though there was increasing evidence that maternal plasma 
diminished DAO activity concur with increasing maternal blood histamine (Section 
2.2.4). Perhaps, this scarcity of evidence could or may have been partly due to lack 
of clarity on the source of increasing blood histamine and DAO in maternal blood. In 
an attempt to increase knowledge and our understanding of the relationship between 
histamine and DAO in the placenta, the effect of histamine on DAO mRNA 
expression was examined. 
 
The study was guided by the hypothesis that increasing histamine concentration had 
inhibitory effect on placental DAO mRNA expression in placental explants. Therefore 
in a time series experiment, placental explants were treated with histamine at varying 
concentrations 0.01µM, 1µM and 100µM and cultured for 24 hours. Total RNA was 
extracted from time zero controls, time course histamine treated and non-treated 
(negative controls) cultured placental explants and analysed with multiplex real time 
RT-qPCR for DAO mRNA expression. Fold change expression relative to time zero 
samples was determined with ΔCT method using beta-actin as reference gene. 
 
The findings showed that histamine regulated DAO mRNA expression, and the 
response was time and concentration dependent. Overall, 0.01µM histamine 
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concentration induced exponential increase in DAO expression with highest 
response occurring after 24 hours. The findings also showed that prolonged 
exposure to 1µM histamine concentration up-regulated DAO but not as strong as 
0.01µM, whereas response to 100µM histamine was biphasic. At the high 
concentration (100µM), there was an immediate strong up-regulation followed by 
complete down-regulation after 24 hours.  
 
Interestingly, the findings confirmed the previously identified (Mondovi et al. 1965, 
Sasiak et al. 1975) dose dependent histamine inhibition of DAO activity and further 
showed that the effect could suggestively be intrinsically linked to histamine 
regulative effect on DAO gene expression in human placenta. Furthermore, the 
findings suggested that histamine appears to induce immediate concentration 
dependent increase in DAO mRNA expression, which if translated to protein would 
accelerate histamine metabolism. And while physiological levels of histamine 
(0.01µM) increase placental DAO expression, long term exposure of placental 
explants to increasing histamine concentration appears to diminish DAO mRNA 
expression. These findings also showed a bi-directional feed-forward loop between 
histamine and DAO: two major biomarkers implicated in pre-eclampsia. In this loop, 
increasing histamine levels appear to trigger DAO mRNA expression which could 
lead to increased DAO protein activity and subsequent deamination and removal of 
accumulating histamine in the placenta. The findings also showed that excess 
production of histamine could down-regulate DAO mRNA expression leading to 
diminished DAO activity and further elevation of histamine levels in the placenta.  
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5.3 Histamine regulates placental Th-1/Th-2 regulation (Publication #6) 
 
Human CD4+ and CD8+ T lymphocytes, macrophages, stromal cells express HDC, 
H1R and H2R mRNA, and produce endogenously synthesised histamine (van der 
Pouw Kraan et al. 1998, Hellstrand et al. 2000). Thus, changes in histamine 
concentration have been linked to activation of human T cells synthesis of Th-2 type 
cytokines, and down regulation of Th-1 cytokines (van der Pouw Kraan et al. 1998). 
Typically, histamine through receptor H2 activation inhibits IL-12 mRNA synthesis, 
while up regulating IL-10 in monocytes or macrophages (van der Pouw Kraan et al. 
1998, Packard & Khan 2003). Histamine also inhibits IL-2 and INF- synthesis in 
mice T lymphocytes (Kubo & Nakano 1999) and IL-1 production in mice macrophage 
(Falus & Meretey 1992, Kubo & Nakano 1999). It is also shown that specific 
cytokines including IL-3 and GM-CSF regulate T cell production of histamine (Falus 
& Meretey 1992, Kubo & Nakano 1999).  
 
Relative synthesis of Th-1 and Th-2 type cytokines are implicated in the regulation of 
maternal immune response at the Foeto-Maternal Interface (FMI) (Wegmann et al. 
1993). In this mechanism, it is suggested the foeto-placental unit redirects maternal 
immunity away from cell mediated immunity towards enhanced humoral 
responsiveness. In this case, it is observed that the balance between Th-1 and Th-2 
cytokines is switched in favour of Th-2 cytokines (Wegmann et al. 1993) as 
activation of cell mediated immunity is usually harmful to the foetus (Rukavina & G 
2000). CD4+ T helper Th-1 cells are known to secrete IL-2, IFN and TNF , where 
IL-2 and TNF  in turn activates NK cells towards cell directed lysis (Rukavina & 
Vince G, 2000; El et al., 2008; Laskarin et al., 2008). Both murine and human 
pregnancies with increased expression of Th-1 cytokines are highly unsuccessful 
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(Lin et al., 1993; Wegmann et al., 1993). Conversely, successful pregnancies tend to 
have increased expression of Th-2 cytokines (IL-4, IL-5, IL-10 and IL-13) (Rukavina 
& Vince G, 2000).  
 
Therefore, it was hypothesized that during normal pregnancy, histamine once 
produced could regulate Th- like cytokines in the placenta to modulate maternal 
immune response in favour of protecting the allogeneic foeto-placental allograft.  
 
The effects of increasing histamine concentrations (10-7, 10-5, 10-3 M/L) respectively 
for low, medium and high dose on placental synthesis and production of cytokines 
were therefore evaluated. RNA was extracted from the control and histamine treated 
explants cultured for up to 24 hours and subsequently analysed with real time RT-
qPCR.  Gene expression was calculated with Pfaffl equation for the expression of 
IL1beta, IL-10 and INF-γ, with beta-actin as housekeeping gene. The respective 
proteins were assayed with ELISA. Figure 5-1 A, C and E show the effects of 
histamine on IL1beta, IL-10 and INF-γ mRNA expression respectively. The 
corresponding protein levels are shown in Figure 5-1 B, D and F respectively.  
 
The results showed that overall, histamine in low dose up-regulated (Figure 5-1) the 
expression of IL-10, IL-1β and INF- mRNA in term placenta after prolonged 
exposure, although there was an immediate inhibitory effect within 2 hours of IL-10, 
and INF- gene expressions. In contrast, high dose histamine inhibited the mRNA 
expression of IL-10 and INF- transcriptomic expression after prolonged exposure. In 
the case of IL-1β, the low dose histamine had minimal effect on the mRNA 
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expression after 24 hours but high concentration transiently increased the 
expression levels with peak effect occurring after 12 hours.  
 
 
Figure 5-1: Effects of Histamine and Cytokine Synthesis and Production 
Figures A, C and E represent effects of histamine on IL1beta, IL-10 and INF-γ mRNA expression respectively. 
Figures B, D and F show the respective protein synthesis for IL1beta, IL-10 and INF-γ after 24 hours. 
Expression and protein levels are baseline (time zero) normalized.  
 
The changes in the transcriptomic expression were reflected in the message 
translation into protein. As shown in Figure 5-1 B, D and F, the most persistent 
change in response to low dose histamine was observed after 24 hours of culture: 
low dose histamine caused gradual, yet sustained increase in IL-1beta, IL-10 and 
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INF-γ levels while high dose transiently increased the protein levels with peak effect 
occurring after 6 hours. 
 
Also, while the individual gene expression data appeared to suggest that the effect of 
histamine on the respective genes after 24 hours could be minimal, analysis of the 
relative expression of INF- to IL-10 representing TH-1/Th-2 index (Figure 5-2) 
revealed a contrasting outcome. These findings (Figure 5-2) showed that the relative 
up-regulation of the Th-1 cytokine INF- in response to prolonged exposure of high 
dose histamine was greater (p< 0.001) than that of IL-10 (Th-2 type cytokine). In 
contrast, the relative expression of INF- to IL-10 mRNA expression at low dose 
histamine was significantly (p=0.018) decreased (i.e., Th-1/Th-2 ratio), therefore 
skewing the balance of the Th-1/Th-2 ratio in favour of Th-2 response in low dose 
histamine.  
 
Figure 5-2: Ratio of INF-γ and IL-10 Expression in the Placenta 
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These findings suggested that low dose histamine relatively up-regulated both Th-
1/Th-2 response in the placenta but favoured relative abundance of Th-2 response. 
These findings also confirmed previous reports that physiological levels of histamine 
support humoral immune response in the placenta, in favour of Th-2 up-regulation 
towards positive pregnancy outcome (Falus & Meretey 1992, Wegmann et al. 1993, 
van der Pouw Kraan et al. 1998, Weetman 1999, Lim et al. 2000, Pap et al. 2007). 
 
 
5.4 Uncovering the complexities of PE genetic pathways (Publication #2) 
Having established that there was a clear distinction between the levels of maternal 
blood histamine in PE and in normal pregnancy (Section 2.2.3); it was felt necessary 
to ascertain the extent to which placental gene expression differed between normal 
and pre-eclamptic placentae. A systematic review with meta-analysis of placental 
transcriptomic expression arrays was therefore conducted: first, to define the gene 
sets associated with normal and PE placentae; and secondly, to ascertain whether 
there was any relationship between the genes associated with PE and the clinical 
and or pathological presentation of the condition.  
 
Using Absolute Gene Expression (AGE) methodology (section 3.4.5.1), significant 
genes defined as genes that were consistently up-regulated or down-regulated in PE 
and normal placentae (NP) were identified. Out of a total of 16,701, 5146 (31%) and 
4394 (26%) placental genes were respectively identified as significantly down-
regulated and up-regulated in the PE placentae (Table 5-1). In contrast, 846 and 
1076 genes were respectively down-regulated and up-regulated in normal placentae 
(Table 5-1). The expression levels of 14779 and 7161 genes respectively in NP and 
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PE placentae were inconsistent and thus were classified as non-significant (Table 
5-1).  
Table 5-1: Differentially Expressed Genes in NP and PE Placentae 
  Absolute PE only Absolute NP only 
Negatively Significant Genes # of down-regulated Significant Genes 5146 846 
 % of down-regulated Significant Genes 31% 5% 
Positively Significant Genes # of up-regulated Significant Genes 4394 1076 
 % of up-regulated Significant Genes 26% 6% 
Non-Significant Genes # of Non-Significant Genes 7161 14779 
 % of Non-Significant Genes 43% 88% 
A total of 167 microarray samples (PE = 68; NP = 99) were meta-analysed as case-to-control 
matched samples with Fisher’s method or as case (PE) only and control (NP) only with RankProd 
analysis. About 31% more genes were identified as differentially expressed (DE) in PE only than in 
case matched baseline (NP) subtraction PE. RankProd analysis Confidence at (1 - alpha): 95.0%; 
False Significant Proportion: 0.05 or less; p value threshold for fisher’s metaP = 0.05. PE = Pre-
eclampsia Placentae; NP = Normal Placentae.  
 
Bioinformatics analyses of the significantly regulated genes showed that the genes 
were involved in 207 and 126 biological pathways respectively for PE and NP. 
Interestingly, all the 126 pathways enriched by the NP placental genes were also 
enriched in PE, but with higher enrichment ratios. A further 81 biological pathways 
were significantly enriched by PE placental genes only. Crucially, a number of 
pathways that have been associated with clinical manifestation of PE, including 
allograft rejection, apoptosis, VEGF signalling pathway, notch signalling pathway, 
and p53 signalling pathway, were significantly enriched in PE only. In addition, 
pathways such as histidine metabolism pathway and Fc epsilon RI-mediated 
signalling pathway were also significantly enriched in PE placentae only. These 
pathways have known histamine mediated functions. Thus, suggesting that 
histamine has some functional roles in the placenta and could be involved in the 
pathogenesis of PE.   
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For example, Fc epsilon RI-mediated signalling pathway is a pathway in mast cells. 
Mast cell concentration is significantly increased in PE placentae (Purcell 1992, 
Szewczyk et al. 2005). Fc epsilon RI-mediated signalling in mast cell is initiated by 
interaction of multivalent allogens with the extracellular domain of the alpha chain of 
Fc epsilon RI to release pre-formed histamines, proteoglycans (especially heparin), 
phospholipase A2 and subsequently, leukotrienes (LTC4, LTD4 and LTE4), 
prostaglandins (especially PDG2), and cytokines including TNF-alpha, IL-4 and IL-5 
(Kambayashi & Koretzky 2007). These mast cell activated mediators and cytokines 
levels are increased in PE, and increasing levels of these products have been 
associated with inflammatory responses.  
 
Inflammation pathways have been strongly linked to the pathophysiology of PE 
(Ilekis et al. 2016), and it has been suggested that the nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-κB) pathway mediates excessive maternal 
intravascular inflammation that leads to endothelial dysfunction (Aban et al. 2004, 
Redman et al. 1999). In this context, it has been hypothesised that PE arises as a 
result of an excessive maternal intravascular inflammatory response to pregnancy, 
and that it involves the activation of both innate and the adaptive immune system, 
neutrophil, and the complement system pathways which involve both histamine and 
mast cell signalling (Greer et al. 1991, Falus & Meretey 1992, Prieto et al. 1997, 
Redman et al. 1999, Belo et al. 2003, Lynch et al. 2008).  
 
Similarly, allograft rejection, graft vs. host disease, and primary immunodeficiency 
pathways were significantly enriched in PE. This observation is consistent with 
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previous opinions that heightened immune responses in PE pregnancies could be a 
consequence of chronic foeto-allograft rejection reaction (Martinez-Varea et al. 
2014). Accordingly, PE shares similarities with graft rejection linked to over activation 
of immune pathways (Wegmann et al. 1993, Weetman 1999, Raghupathy 2001, 
Saito & Sakai 2003, Dong et al. 2005, Wilczynski 2006). Integral to this is the 
argument that disequilibrium of Th-1/Th-2 cytokine balance in favour of Th-1 (IL-2, 
IL-12, IL-15, IL-18, IFNgamma, TNFalpha vs. IL-4, IL-10, TGFbeta); precipitation of 
subsets of immunocompetent cells (T CD4, suppressor gammadeltaT, cytotoxic T 
CD8, Treg, Tr1, uterine NK cells); innate immunity (NK cytotoxic cells, macrophages, 
neutrophils and complement); adhesion molecules; fgl2 prothrombinase activation 
(Wegmann et al. 1993, Weetman 1999, Raghupathy 2001, Saito & Sakai 2003, 
Dong et al. 2005, Wilczynski 2006) and under-expression of Heme oxygenase-1 
(HO-1) (Linzke et al. 2014) underpin the development of PE. 
 
These findings not only confirmed the previous reports that inflammation and 
immunologic pathways are involved in PE pathophysiology, but also made major 
contributions to the knowledge and understanding of PE by providing evidence for a 
comprehensive database of gene sets with impacts on biomarker synthesis and 
early screening for PE. The PE immuno-inflammatory paradigm is however not 
universally supported as a recent review by Ahmed and Ramma (Ahmed & Ramma 
2015) appears to down-play the roles of inflammatory, hypoxia and immunologic 
pathways in favour of angiogenic response as the cause of PE.  
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Ahmed and Ramma (Ahmed & Ramma 2015) argued that recent work supports the 
hypothesis that PE arises because of the loss of vascular endothelial growth factor 
(VEGF) activity, which in turn is caused by increase in the levels of endogenous 
soluble fms-like tyrosine kinase-1 (sFlt-1), an anti-angiogenic factor (Ahmed & 
Ramma 2015). SFlt-1 binds and reduces free circulating levels of the pro-angiogenic 
factor VEGF, and thus inhibits the beneficial effects mediated by flt-1 (also known as 
vascular endothelial growth factor receptor 1 (VEGFR-1)) on maternal endothelium, 
with consequential maternal hypertension and proteinuria (Andraweera et al. 2012, 
Ahmed et al. 1997).  
 
It is further argued that altered balance of circulating pro-angiogenic/anti-angiogenic 
factors such sFlt-1, soluble endoglin, and placenta growth factor (PlGF) are unique 
to PE (Andraweera et al. 2012, Ahmed et al. 1995, Ramma et al. 2012, Ahmed & 
Ramma 2015, Ahmed et al. 1997). Interestingly, we also found evidence to support 
this view: for it was identified that VEGF signalling pathway was significantly 
enriched only by the PE placental genes. This therefore led to a conclusion that 
biological pathways affected in PE are complex, and instead of the uni-lateral 
conclusion drawn by Ahmed and Ramma (Ahmed & Ramma 2015), our findings 
offered more evidence to support the more global view that multiple and concurrent 
dysregulated pathways underpin the aetiology of PE (Ilekis et al. 2016), and no 
single pathway could be associated with the origins of PE. Thus, this work made 
major contributions to the knowledge and understanding of the molecular pathology 
or the genomic basis of PE, and provided further evidence for the links between 
histamine and PE. 
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5.5 Histamine regulates specific genes in pre-eclamptic placenta 
(Publications #9, 10 & #11) 
While it is widely accepted that the placenta is a major source of elevated histamine 
in the blood of women with PE (section 2.2.2), the placenta concurrently releases 
highly active diamine amine oxidase (DAO) enzymes into the maternal circulation to 
metabolise the histamine, thus forming histamine-DAO-Axis (HDA) (section 2.2.3). 
However, in contrast to the effective clearance of histamine in normal pregnancy, the 
histamine-DAO-axis in PE is defective (section 2.2.4). Yet, our understanding of the 
impact of the mechanistic failure of the HDA and the consequential effects of 
elevated histamine on placental gene expression in PE was tenuous.  
 
Therefore, an ex vivo elevated histamine model (EHM) in human placental explants 
with some parallel characteristic to in vivo defective histamine – DAO – axis (dHDA) 
system was developed (section 3.2.5 above) and used to examine the effects of 
elevated histamine on the placental gene expression. The work was supported by 
the hypotheses that (1) genes regulated by histamine in elevated histamine placental 
model would show similar changes in expression to PE specific placental genes and 
(2) genes regulated by elevated histamine in an EHM would have known functions 
that could be biologically relevant in PE placentae.  
 
5.5.1 Global Changes in EHM Gene Expression 
First, the gene expression patterns among histamine treated (also known as EHM) 
and control explants were compared to determine if the two classes differ with regard 
to expression profiles and whether the differences were significant. The BRB 
ArrayTools platform (Section 3.4.5) was used for the analyses. As reported in 
publications #3 and #4, quality control (QC) of the microarray raw data was 
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assessed with Expression Console (Affymetrix) for .CEL files integrity. Probes with 
unusual signal patterns or signal strength and arrays showing low correlation 
between hybridization controls thus failed this initial QC measures were excluded 
from further analysis. The .CEL raw data were imported and processed with Robust 
Multi-array Average (RMA) into BRB-Array Tools version 4.5.1 – Stable (Simon et al. 
2007), and further processed using the R bionconductor packages (including Affy, 
annotate, annaffy, gcrma, simpleaffy) into log2-transformed and quantile-normalised 
linear model expression matrix. Genes showing minimal variation across the set of 
arrays were excluded from the analysis. Genes whose expression differed by at least 
1.5 fold from the median in at least 20% of the arrays were retained. After reducing 
multiple probeset to singles using the most variable probeset measured by IQR 
across arrays, 20233 genes were used for further analyses. 
The changes in gene expression in response to histamine treatment relative to the 
control under Physiologic oxygen concentration (8% O2) were established. Increases 
were determined for mRNA that were considered present or absent in the control 
and present in the histamine treated sample. Similarly, decreases were determined 
for mRNA that were present in the control sample and present or absent in the 
histamine treated sample. Scatterplot of Phenotype Averages (SPA) and Class 
Comparison analyses (CCA) (Simon et al. 2007) were used to establish the 
difference in gene expression.  
For the SPA analysis, average log-ratios within one phenotype (control samples), 
were plotted on the x-axis against the average log-ratio within the other phenotype 
(histamine treated samples), on the y-axis in a scatterplot.  These averages were 
then taken on a gene-by-gene basis, and each gene was represented by a single 
point in the resulting scatterplot. The differentially expressed genes among the two 
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phenotypes were determined as genes whose fold-change between the geometric 
mean of the expression ratios within each of the two classes was greater than a fixed 
threshold (1.5-fold change). Fold-change was defined as the ratio of geometric mean 
of intensities in class 1 to geometric mean of intensities in class 2, where class 1 was 
the treatment group and class 2, the control group. Thus, fold-change of less than 1 
was regarded as down-regulation, and that greater than 1 as up-regulated. The SPA 
analysis identified (Figure 5-3A) a total of 494 differentially expressed genes (315 
up-regulated and 179 down-regulated) between the EHM and Control samples. 
 
Figure 5-3: Plots of differentially expressed among EHM and Control Samples 
Figure A shows the Scatterplot of differentially expressed genes with 1.5-fold change among 
elevated histamine model (EHM) control samples. Figure B shows a volcano plot of 
significant (p<0.05) differentially genes among EHM and control classes, identified with 
Class Comparison analysis. EHM = histamine treated samples. Appendix 3, 4 & 5 contain 
gene lists for both figures A and B. Expression patterns of the genes were confirmed by 
performing RT-qPCR on three randomly selected genes (AKR1C1, IGFBP5, and EREG 
relative to L19; Appendix 9). 
 
To determine whether the differences in expression observed among the EHM 
(histamine treated) and control classes were significant, class comparisons analysis 
using a random-variance t-test was performed (Figure 5-3B). Figure 5-3B shows the 
 97 
results of the Class comparison analysis as a Volcano Plot of the significantly 
expressed genes among EHM and the controls.  
In the Class comparison analysis, the purpose was to establish a general trend in the 
class differences with regard to expression profiles therefore a modest p value of 
less the 0.05 was deemed sufficient (Simon et al. 2007). The Class Comparison 
analysis was used because it is a powerful model that permits as was intended, the 
sharing of information among genes about within-class variation without assuming 
that all genes have the same variance (Wright & Simon, 2003).  
Three key facts were learnt from these analyses: 
1. That elevated histamine alters placental gene expression 
2. That the relative differences in expression of specific genes between elevated 
histamine model and control sample are significant. 
3. While the analyses identified specific genes with significant differential 
expression between the EHM and control samples, the information revealed 
very little insight into the plausible roles or effects of the elevated histamine 
regulated significant genes in the pathophysiology of PE placentae.   
Therefore further innovative bioinformatics analyses were undertaken to decipher the 
plausible effects of elevated histamine on the placenta in the pathophysiology of PE 
 
5.5.2 Determination of the plausible effects of histamine in PE Placentae 
In the preceding section, the point was raised that the mere comparison of 
differential gene expression between EHM and control samples provided limited 
insight into the plausible role of placental histamine in PE pathophysiology. This view 
was drawn from the fact that in addition to PE, defective histamine – DAO – Axis 
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leading to elevated histamine occurs in other trophoblast related complications of 
human pregnancy such as pre-term labour and spontaneous abortion. Therefore, in 
order to determine the effects or roles of elevated histamine in PE placentae, 
innovative yet robust down-stream analyses were performed. The purpose of these 
down-stream analyses was to identify specific elevated histamine regulated placental 
genes relevant to PE.  
 
To achieve this, intra-class absolute gene expression analysis (Section 3.4.5.1) and 
In Vivo Validation of In vitro Expression protocols were developed. PE placental 
genes were identified from the pool of genes regulated in EHM.  The In Vivo 
validation of In vitro Expression is a complex bioinformatics workflow involving a 
systematic review process, meta-analysis, comparison analysis and confusion matrix 
analysis.  
 
First, GEO and ArrayExpress databases were systematically searched for case 
control pre-eclampsia OR histamine AND Placenta Homo sapiens RNA array 
assays. Multiple RNA array assays for PE matched with NP placentae were 
retrieved. Intra-class Absolute Gene Expression analysis using RankProd statistics 
was applied to identify significant genes in EHM model, PE placentae and normal 
placentae respectively. The PE genes were defined as a set of specific genes that 
are consistently expressed exclusively in PE placentae but not in normal placenta. A 
variant definition for PE genes in EHM model was given as the set of consistently 
expressed genes in response to elevated histamine in EHM that mapped to genes 
consistently expressed in PE placentae but not to consistent significantly expressed 
genes in normal placentae, or to cultured control sample. 
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The analyses identified 270 genes that were consistently expressed in the elevated 
histamine model and mapped to PE placental specific genes. That is, these genes 
were not consistently expressed in normal pregnancy placentae or cultured explants 
without histamine treatment, and thus was classified as histamine regulated specific 
genes in PE (HSPE). The overall concordance between the expression pattern of the 
HSPE genes and the PE specific genes, measured as accuracy and intra-class 
correlation coefficient were 92%, Kappa = 0.836 respectively. Also, 94.3% of the 
down-regulated HSPE genes were down-regulated in PE placentae. Similarly, 90% 
of the up-regulated HSPE genes were up-regulated in PE placentae. These 
suggested that the pattern of expression of the HSPE genes closely mimicked gene 
expression pattern of the in vivo PE placentae.  
 
With this clarity, the biological functions of the HSPE genes were examined with in-
depth bioinformatics pipeline including Over-representation of Gene Ontologies, 
Pareto Analysis for vital few genes and GSEA Leading Edge Metagene (LEM) 
analyses of biological pathways for leading edge genes. The analyses uncovered 
complex gene ontologies (Table 5-2) that offered stronger elucidation of plausible 
histamine functions in PE placentae. Analysis for the vital few genes revealed that 51 
(vital few) of the 270 HSPE genes (Table 5-3) were involved in 80% of the 
associated biological functions. Downstream analysis with leading edge meta-genes 
analysis further identified 24 enriched pathways (Table 5-4) from 4 databases 
(KEGG, Reactome, Wikipathways and Panther) that histamine specific consistent 
regulated genes could play significant roles.  
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Table 5-2: Histamine Specific Genes in PE Ontologies 
GO 
Category 
GO Term ID Name C O E R Pvalue 
MF GO:0002474 antigen processing and 
presentation of peptide 
antigen via MHC class I 
87 9 1.17 7.71 2.46E-06 
MF GO:0002064 epithelial cell development 195 12 2.61 4.59 1.30E-05 
MF GO:0060684 epithelial-mesenchymal cell 
signaling 
7 3 0.09 31.96 8.00E-05 
MF GO:0060710 chorio-allantoic fusion 7 3 0.09 31.96 8.00E-05 
MF GO:0048002 antigen processing and 
presentation of peptide 
antigen 
173 10 2.32 4.31 1.16E-04 
MF GO:0006397 mRNA processing 463 17 6.21 2.74 1.75E-04 
MF GO:0003334 keratinocyte development 11 3 0.15 20.34 3.62E-04 
MF GO:0010608 posttranscriptional regulation 
of gene expression 
454 16 6.09 2.63 4.26E-04 
MF GO:0001738 morphogenesis of a polarized 
epithelium 
134 8 1.8 4.45 4.51E-04 
MF GO:0071456 cellular response to hypoxia 136 8 1.82 4.39 4.98E-04 
CC GO:0005913      cell-cell adherens junction 318 16 2.9 5.51 3.65E-08 
CC GO:0015629      actin cytoskeleton  456 16 4.16 3.84 4.46E-06 
CC GO:0044297      cell body  472 16 4.31 3.71 6.89E-06 
CC GO:0005925      focal adhesion  390 14 3.56 3.93 1.41E-05 
CC GO:0005924      cell-substrate adherens 
junction 
393 14 3.59 3.9 1.53E-05 
CC GO:0030055      cell-substrate junction 398 14 3.63 3.85 1.76E-05 
CC GO:0043292      contractile fiber  209 10 1.91 5.24 2.26E-05 
CC GO:0098858      actin-based cell projection 180 9 1.64 5.47 4.16E-05 
CC GO:0043025       neuronal cell body  411 13 3.75 3.46 1.05E-04 
CC GO:0005681      spliceosomal complex 173 8 1.58 5.06 1.92E-04 
MF GO:0098641      cadherin binding involved in 
cell-cell adhesion 
277 14 3.24 4.32 4.85E-06 
MF GO:0098632      protein binding involved in cell-
cell adhesion 
288 14 3.37 4.16 7.58E-06 
MF GO:0098631      protein binding involved in cell 
adhesion 
293 14 3.42 4.09 9.22E-06 
MF GO:0045296      cadherin binding  294 14 3.44 4.07 9.59E-06 
MF GO:0045505      dynein intermediate chain 
binding 
7 3 0.08 36.66 5.32E-05 
MF GO:0003779      actin binding  390 15 4.56 3.29 5.60E-05 
MF GO:0050839      cell adhesion molecule binding 445 16 5.2 3.08 7.02E-05 
MF GO:0005520      insulin-like growth factor 
binding 
28 4 0.33 12.22 2.97E-04 
MF GO:0031994      insulin-like growth factor I 
binding 
12 3 0.14 21.39 3.20E-04 
MF GO:0010385      double-stranded methylated 
DNA binding 
5 2 0.06 34.22 1.33E-03 
C: the number of reference genes in the category; O: the number of genes in the user gene list and also in the 
category; E: The expected number in the category; R: ratio of enrichment; PValue: p value from hyergeometric 
test.  
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Table 5-3:  Histamine Regulated Genes Performing 80% of Histamine Mediated 
Functions in PE  
Rank GeneSymbol Name Count of 
Functions 
Sign 
1 FLNB filamin B, beta (actin binding protein 278) 14 (+ve) 
2 ITGA6* integrin, alpha 6 12 (+ve) 
3 HSPA1A heat shock 70kDa protein 1A 11 (+ve) 
4 MPRIP myosin phosphatase Rho interacting protein 11 (+ve) 
5 CDC42 cell division cycle 42 (GTP binding protein, 25kDa) 10 (+ve) 
6 PHLDB2 pleckstrin homology-like domain, family B, member 2 9 (+ve) 
7 CALD1 caldesmon 1 9 (+ve) 
8 PICALM phosphatidylinositol binding clathrin assembly protein 8 (+ve) 
9 RAN RAN, member RAS oncogene family 8 (+ve) 
10 PALLD palladin, cytoskeletal associated protein 8 (+ve) 
11 TJP1 tight junction protein 1 (zona occludens 1) 7 (+ve) 
12 RAB1A RAB1A, member RAS oncogene family 7 (+ve) 
13 LARP1 La ribonucleoprotein domain family, member 1 7 (+ve) 
14 KIF5B kinesin family member 5B 6 (+ve) 
15 GJA1 gap junction protein, alpha 1, 43kDa 6 (+ve) 
16 TPM4 tropomyosin 4 6 (+ve) 
17 PAFAH1B1 platelet-activating factor acetylhydrolase, isoform Ib, alpha subunit 
45kDa 
6 (+ve) 
18 BZW1* basic leucine zipper and W2 domains 1 6 (+ve) 
19 OPRM1 opioid receptor, mu 1 5 (-ve) 
20 ACTR3 ARP3 actin-related protein 3 homolog (yeast) 5 (+ve) 
21 PDIA3* protein disulfide isomerase family A, member 3 5 (+ve) 
22 SEPT2 septin 2 5 (+ve) 
23 ARF1 ADP-ribosylation factor 1 5 (+ve) 
24 PSMD14 proteasome (prosome, macropain) 26S subunit, non-ATPase, 14 4 (+ve) 
25 PSMA2 proteasome (prosome, macropain) subunit, alpha type, 2 4 (+ve) 
26 PSMD4 proteasome (prosome, macropain) 26S subunit, non-ATPase, 4 4 (+ve) 
27 PSME4 proteasome (prosome, macropain) activator subunit 4 4 (+ve) 
28 ZFP36L1 zinc finger protein 36, C3H type-like 1 4 (+ve) 
29 ABRA actin-binding Rho activating protein 3 (-ve) 
30 RALA v-ral simian leukemia viral oncogene homolog A (ras related) 3 (+ve) 
31 APP amyloid beta (A4) precursor protein 3 (+ve) 
32 IQGAP2** IQ motif containing GTPase activating protein 2 3 (-ve) 
33 TPM2 tropomyosin 2 (beta) 3 (+ve) 
34 ADAR adenosine deaminase, RNA-specific 3 (+ve) 
35 FOXA1 forkhead box A1 3 (-ve) 
36 TRPC5 transient receptor potential cation channel, subfamily C, member 5 3 (-ve) 
37 GPM6A glycoprotein M6A 3 (-ve) 
38 MPL myeloproliferative leukemia virus oncogene 3 (-ve) 
39 CYR61 cysteine-rich, angiogenic inducer, 61 3 (+ve) 
40 SYNCRIP synaptotagmin binding, cytoplasmic RNA interacting protein 3 (+ve) 
41 MTPN myotrophin 2 (+ve) 
42 ANXA3 annexin A3 2 (+ve) 
43 HNRNPH3 heterogeneous nuclear ribonucleoprotein H3 (2H9) 2 (+ve) 
44 MYO3B myosin IIIB 2 (-ve) 
 102 
45 GLRA3 glycine receptor, alpha 3 2 (-ve) 
46 ARPC4 actin related protein 2/3 complex, subunit 4, 20kDa 2 (+ve) 
47 SEC13 SEC13 homolog (S. cerevisiae) 2 (+ve) 
48 DLG5 discs, large homolog 5 (Drosophila) 2 (+ve) 
49 SLC5A7 solute carrier family 5 (choline transporter), member 7 2 (-ve) 
50 DNAJB6 DnaJ (Hsp40) homolog, subfamily B, member 6 2 (+ve) 
51 KHDRBS1 KH domain containing, RNA binding, signal transduction associated 1 2 (+ve) 
Count = number of GO terms gene is involved; (+ve) = consistently expressed at High 
levels; (-ve) = consistently expressed at low levels. Levels of expression of all genes 
matched the expression levels in PE placentae except where indicated: * signifies genes that 
are expressed at high levels in EHM but at low levels in PE placentae; ** genes expressed at 
low levels in EHM but at high levels in PE placentae. 
 
Table 5-4: Histamine Mediated Pathways with Leading Edge Genes 
ID Name Size L ES NES 
WP455 GPCRs, Class A Rhodopsin-like 8 8 -0.62 -1.71 
hsa04080 Neuroactive ligand-receptor interaction - Homo 
sapiens (human) 
8 8 -0.62 -1.84 
hsa05200 Pathways in cancer - Homo sapiens (human) 9 8 0.61 1.4 
R-HSA-500792 GPCR ligand binding 10 8 -0.32 -0.97 
WP2431 Spinal Cord Injury 7 6 0.43 0.95 
hsa04144 Endocytosis - Homo sapiens (human) 6 6 0.69 1.47 
WP2377 Integrated Pancreatic Cancer Pathway 6 5 0.56 1.18 
WP411 mRNA Processing 5 5 0.48 0.97 
hsa04260 Cardiac muscle contraction - Homo sapiens 
(human) 
5 5 0.75 1.54 
hsa04932 Non-alcoholic fatty liver disease (NAFLD) - Homo 
sapiens (human) 
5 5 0.81 1.64 
hsa04072 Phospholipase D signaling pathway - Homo 
sapiens (human) 
5 5 0.7 1.41 
hsa04015 Rap1 signaling pathway - Homo sapiens (human) 6 5 0.64 1.35 
hsa05132 Salmonella infection - Homo sapiens (human) 5 5 0.68 1.37 
P00034 Integrin signalling pathway 6 5 0.56 1.19 
R-HSA-425407 SLC-mediated transmembrane transport 5 5 -0.62 -1.42 
R-HSA-418555 G alpha (s) signalling events 5 5 -0.56 -1.28 
WP138 Androgen receptor signaling pathway 5 4 0.71 1.46 
WP481 Insulin Signaling 6 4 0.69 1.48 
WP306 Focal Adhesion 5 4 0.43 0.86 
hsa05010 Alzheimer's disease - Homo sapiens (human) 6 4 0.73 1.57 
hsa04022 cGMP-PKG signaling pathway - Homo sapiens 
(human) 
5 4 0.78 1.59 
hsa04010 MAPK signaling pathway - Homo sapiens 
(human) 
5 4 0.64 1.29 
P00016 Cytoskeletal regulation by Rho GTPase 5 4 0.43 0.89 
WP2380 Brain-Derived Neurotrophic Factor (BDNF) 
signaling pathway 
5 2 0.4 0.81 
Table is sorted according to L. Size: the number of genes in the user gene list and also in the 
category; L: the number of leading edge genes; ES: Enrichment Score; NES: Normalized Enrichment 
Score; (-) = down-regulated pathway 
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This work showed a strong correlation between significantly enriched GOs (Table 
5-2) and the pathways identified with leading edge meta-gene analysis (Table 5-4). 
For example, pathways including Insulin Signaling, Focal Adhesion, mRNA 
Processing, Salmonella infection and muscle contraction are very closely related to 
GO terms such as insulin-like growth factor I binding, focal adhesion, mRNA 
processing, antigen processing and presentation of peptide antigen, dynein 
intermediate chain binding, and actin binding. Thus, confirming that genes 
consistently regulated by elevated histamine in an EHM model had functional roles 
that were biologically relevant in PE placentae. 
 
5.5.3 Identification of causal effect of histamine specific genes in PE  
In order to determine plausible causal effect of the histamine regulated genes in PE, 
Directed acyclic graphs (DAGs) causal analysis was performed using dagitty.net 
(Textor et al. 2011). This study was aimed at (1) identifying the minimal sufficient 
adjustment sets of information from the GOs and biological pathways enriched by 
histamine regulated genes in PE; (2) to identify the Instruments and conditional 
variables, the adjustments necessary to estimate the total effect, and the minimal 
sufficient adjustment sets for estimating the direct effect of elevated histamine on 
pre-eclampsia to derive testable implications.  
 
To achieve these, extensive literature review using thematic analysis was firstly 
conducted on the functions of the genes enriching the significant GOs and pathways 
to document the covariates’ associations with the elevated histamine (exposure) and 
PE (outcome). DAG tool was then used to identify the minimal adjustment set of 
covariate to minimize the magnitude of bias (Figure 5-4A).  
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Figure 5-4: Causal effect identification of Elevated Histamine on Pre-eclampsia 
DAG Direct Acrylic Graph for the 9 major functional groupings for histamine regulated genes in PE 
(Figure A). Figure B shows the DAG causal pathways between histamine and PE and regulated 
genes functions covariates.  exposure;  outcome;  ancestor of exposure;  ancestor of 
outcome;  causal path 
 
 
 
The analysis enabled the identification of 9 minimal sufficient adjustment functional 
group covariates (Figure 5-4A) with 54 sub-functional group covariates and 45 
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causal paths (Figure 5-4B) to estimate direct effect of ‘Elevated Histamine’ on Pre-
eclampsia. The analysis also revealed that no adjustment to the minimum functional 
groups was necessary to estimate the total effect. Nonetheless, it clarified the roles 
of DAO and HDC in PE by predicting that defective DAO and increased HDC 
activities are instrumental and conditional variables for the estimating the causal 
effect of elevated histamine in PE.  
 
Also, the analysis clarified that the likelihood that elevated histamine will directly 
cause PE is nominal but greatly through the regulation of specific genes that activate 
minimal sufficient functional covariate and sub-functional groups. The minimal but 
major covariate functional groups included: Cell Signalling, Gene Regulation, 
Inflammation and Immune regulation, Junctional proteins regulation, Oxygen 
Sensing, Placental Innervation, Placental contractile activity, Placental growth, 
Tissue proliferation and morphogenesis.  
 
This study was very important to furthering our understanding of the relationship 
between histamine and PE. In that, in addition to generating 57 testable implications 
for future work, it refined our knowledge that (1) the natural process which 
determines the amount of histamine in the placental and maternal blood is affected 
by DAO and HDC activity; (2) the natural process by which pre-eclampsia develops 
is affected by the amount of histamine in the maternal blood and placenta; (3) the 
natural process by which pre-eclampsia develops is not affected by the DAO and 
HDC activities other than indirectly via the histamine deposit; and finally (4) the 
natural process by which pre-eclampsia develops is indirectly affected by histamine 
via functional group covariates, and  causal paths. 
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5.6 Discussions and Conclusion 
Data mining for the functions and relevance of the enriched biological pathways 
revealed a complex network of functions, yet a better understanding of the effects of 
elevated histamine in the placenta. While histamine is generally known to regulate 
several physiological processes, including neurotransmission, gastric acid secretion, 
inflammation, and smooth muscle tone, elevated histamine in the placenta through 
this cluster of studies have been shown to regulate the expression of vital genes with 
complex functions that are implicated in PE.  
 
The study examining the relationship between histamine and DAO was the first to 
demonstrate that these biomarkers implicated in pre-eclampsia form a bi-directional 
regulatory negative feed-forward relationship in the placenta. The causal effect 
analysis clarified that the decreased activity of DAO and increased HDC activity are 
actually instrumental and conditional variables that are expected for elevated 
histamine to occur in PE placentae. Using a self-validating gene pool, our 
understanding of the effect of histamine in the pathophysiology of PE was further 
broadened. The study of the effect of elevated histamine on placental explants was 
the first to successfully model ex vivo defective histamine-DAO-axis to provide an in 
vitro culture model to investigate the effect of elevated histamine in parallel with in 
vivo PE placentae. From these works, it was also shown for the first time that PE 
placentae express unique set of significant genes in addition to the significant genes 
expressed in NP, and that elevated histamine regulated a subset of these PE 
specific genes in vitro.  
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This revelation provided further unique insight into the biological pathways through 
which elevated histamine would seem to exert effects in the pathophysiology of PE. 
For example, the identification of the functional group covariate ‘Placental 
Innervation’ consisted of leading edge genes that formed the sub-functional 
covariates including Neuroactive ligand-receptor interaction - Homo sapiens 
(human), Brain-Derived Neurotrophic Factor (BDNF) signalling pathway and Spinal 
Cord Injury regulating.  The Placental contractile activity functional covariate group 
consisted of sub-groups including: muscle contraction including Cardiac muscle 
contraction - Homo sapiens (human) pathway, actin cytoskeleton, contractile fiber, 
actin-based cell projection, dynein intermediate chain binding, actin binding and 
Cytoskeletal regulation by Rho GTPase pathways.  
 
These findings were fascinating, nonetheless unexpected because the placenta is 
currently recognised as not an innervated organ (Walker & McLean 1971, Khong et 
al. 1997, Marzioni et al. 2004). The findings therefore provided new opportunity to re-
evaluate this long-held view that the placenta is de-innervated. The outcome of this 
re-evaluation was that currently, based on limited publications there is no evidence 
that the placenta is innervated. However, our work provided fresh evidence to justify 
further studies to examine whether elevated histamine levels in placentae destined 
to develop PE could regulate subsets of genes that might preserve innervation and 
contractility associated with PE placental vasculature (Reilly & Russell 1977, 
Szukiewicz et al. 1999, Pijnenborg et al. 2006b). Alternatively, the findings offered 
the opportunity to ask whether there is yet an un-identified pathway in PE placentae 
that mimics Neuroactive ligand-receptor interaction - Homo sapiens (human), Brain-
Derived Neurotrophic Factor (BDNF) signaling pathway and Spinal Cord Injury 
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smooth muscle contraction pathways in the placenta, and thus warrant further 
investigation.  
 
In addition to the generation of new theories about the functions of the placenta, the 
studies confirmed previous observations of the effects of histamine. It was previously 
reported that increasing histamine causes placental microvascular endothelial 
damage through redistribution of PECAM-1 and VE-cadherin molecules to non-
junctional regions, thus inducing vascular permeability and exposure of the 
basement membrane and vascular muscles to vasoactive ligands (Leach et al. 1995, 
Leach & Firth 1997, Chambers et al. 2001). It is also established that endothelial cell 
activation and dysfunction are also strongly associated with PE (Roberts et al. 1989, 
Taylor et al. 1998). Our work not only confirmed these previous reports but provided 
further insight into the complex network of genetic pathways including cell-cell 
adherens junction, focal adhesion, cadherin binding involved in cell-cell adhesion, 
and protein binding involved in cell-cell adhesion through which elevated histamine 
could function to precipitate endothelial dysfunction in PE. 
 
Notwithstanding the effect of histamine on inflammatory pathways in the placenta, 
the studies on the relationship between histamine and index cytokines provided both 
quantitative RNA and protein assays to confirm that histamine regulate pro-
inflammatory cytokines including IL-1b, IL-10 and INF- in the placenta, and elevated 
histamine tended to favour PE linked Th-1 cytokine INF- response. 
 
Taken together, the studies not only elaborated on the complexity of histamine’s 
function in the placenta, but added to our knowledge and understanding of the 
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pathogenesis of PE by showing that elevated histamine could significantly precipitate 
PE through the regulation of key placental genes involved in inflammation and 
immune system regulation; tissue proliferation and morphogenesis; regulation of 
junctional proteins; maintenance of placental contractile activity; regulation of growth; 
impairment of cell signalling; and regulation of placental gene expression. Thus, 
confirming that histamine has significant mediating and or sustaining functions in the 
placenta, and that further studies to confirm causal effect of elevated histamine in PE 
pathophysiology is warranted.   
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                                                                                             Chapter 6
Final Conclusion  
6.1 Reflection on contributions made by the publications to the knowledge 
and Science of Placental Genomics and Pre-eclampsia 
 
In this commentary, I have critically reflected on the rationale for investigating the 
functional roles of histamine in human placenta with a focus on pre-eclampsia. I 
have also critically reflected on the suitability of the methods, results and the relative 
contribution made by the series of publications to the knowledge and understanding 
of placental genomics with reference to the effects of histamine in human placenta. 
 
6.1.1 The placenta expresses histamine receptors, and histamine production and 
elimination in the PE placentae are impaired 
Prior to the onset of my research, it was known that maternal blood histamine levels 
are elevated during PE (Figure 2-4). However, due to lack of evidence for histamine 
functionality in the placenta, very limited progress was made to advance our 
understanding on the causal effects of the amine on PE. Most importantly, 
knowledge about the topological distribution of histamine receptor expression in 
human placenta was extremely limited. Nonetheless, through the preceding 
discussions, I have shown that one of my publications (Section 4.4) was the first to 
report that histamine receptors H1R and H2R are expressed in juxtaposed positions 
with DAO message at the foeto-maternal interface in the villous parenchyma.  
 
Prior to this discovery, it was known that histamine receptors H1R and H2R have 
both constitutive and inductive activities in other systems, and the constitutive activity 
was associated with a basal whole blood histamine concentration within the 0.1M 
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range (plasma equivalent in 2.0 nM range) (Kahlson et al., 1960b; Kahlson & 
Rosengren, 1971; Beaven, 1982; Bakker et al., 2000; Alewijnse et al., 2000). This 
view was postulated as a physiological switch for fine tuning specific cellular 
activities including tissue remodelling, immuno-modulation, cell proliferation and 
differentiation, tissue growth and wound healing (Kahlson, 1960; Kahlson et al., 
1960a; Kahlson & Rosengren, 1968; Kahlson & Rosengren, 1971; Kahlson & 
Rosengren, 1972; Beaven, 1978; Erlik et al., 1979; Krishna et al., 1986; Krishna et 
al., 1989; Tetlow & Woolley, 2003). Nonetheless, the extent to which histamine 
modulates human placental tissue remodelling was unclear. Therefore, I undertook 
subsequent studies to generate new knowledge to enhance our understanding on 
the effects of histamine in human placenta and PE. 
 
Importantly, with meticulous examination of the literature, I provided coherent 
knowledge and additional insight into the understanding of the profile and dynamics 
of maternal blood histamine levels in both normal and pre-eclamptic pregnancies 
(section 2.2). I thus contributed to further our understanding of the nature of maternal 
blood histamine level profiling that while maternal blood histamine levels in the 
course of normal pregnancy generally fall below pre-pregnancy levels (Figure 2-2), 
the levels remain elevated in PE (Figure 2-4). I have also contributed to clarifying 
that the elevated histamine levels in PE are due to a defective histamine-DAO-axis 
(section 2.2.4), which in turn could be caused by increased histamine synthesis 
(section 4.2) and diminished DAO activity (section 5.2).  
 
I provided specific evidence to contribute to knowledge on this matter by examining 
factors that could affect histamine production and elimination in the placenta, and 
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thus impact on PE. I showed that placental histidine decarboxylase activity is 
increased in PE placentae, and cytokines and mitogens increase histamine 
production in the placenta. I also showed that histamine has a feedforward 
regulatory loop with DAO, where increasing histamine levels cause down-regulation 
of DAO gene expression. 
 
6.1.2 Elevated histamine in the placenta has functional roles: it regulates production of 
Th-1/Th-2 like cytokines in the placenta 
The immune-modulative effect of histamine was previously demonstrated in other 
systems to be dependent on the concentration of bioactive histamine. For example, 
increasing histamine concentration inhibited macrophage ROS production and thus 
reversed NK cells and CTL deactivation by macrophage (Mellqvist et al., 2000; 
Hellstrand et al., 2000b). This was consistent with the clinical observations where 
decreased or falling DAO activity led to increased bioactive histamine and resultant 
spontaneous abortions (Southren et al. 1966b).  
 
Therefore, I examined and generated further knowledge on placental histamine 
physiology that provided evidence to support the claims that histamine dose 
dependently activates Th-1/Th-2 response in the placenta (Figure 5-2). Here, I 
demonstrated that low dose histamine up-regulates Th-2-type cytokine responses, 
and that this fine tuning could sustain successful foetal allograft and pregnancy 
(Wegmann et al., 1993) while high dose histamine up-regulated Th-1-type cytokine 
responses with potential to cause foetal demise (Weetman 1999). This contribution 
first and foremost, confirmed previous reports of Th-1/Th-2 switches in human 
placenta (Darmochwal-Kolarz et al. 1999, Saito et al. 1999, Saito & Sakai 2003). The 
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work further showed that the observed histamine dose dependent regulation of Th-
1/Th-2 response in peripheral tissues (Packard & Khan 2003) was also present in 
human placenta and that, varying concentrations of FMI circulating histamine does 
have key regulatory roles on the expression of the local Th-1/Th-2 cytokine genes. 
 
6.1.3 Optimum culture condition is fundamental for appropriate investigation of 
histamine effect in human placenta and implications in PE 
Having established that the placenta expresses histamine receptors and histamine 
has bi-directional regulatory effect with DAO and key index cytokines (sections 4.3 
and 5.3), further investigations involving genome wide transcriptomic expression 
analyses were used to study the effects of histamine on the global expression of 
placental gene with a focus on PE. In the first instance, an ex vivo defective 
Histamine-DAO-axis also referred to elevated histamine model was developed 
(section 3.2.5). In course of this investigation, I provided new evidence to confirm 
that matching in vitro oxygen tension with in vivo conditions (which vary with 
gestational age) was a key component for optimal condition for placental explant 
culture (section 3.2.4). And that oxygen levels could have marked effects on for 
example, trophoblast apoptosis during the placental explant cultures (Damsky et al. 
1993, Genbacev et al. 1996, Caniggia et al. 2000, Burton & Caniggia 2001, Huppertz 
et al. 2003). I contributed further knowledge to provide clarity on the extent to which 
tissue culture per se, culture oxygen concentration and culture duration affect 
placental gene expression. I provided genetic evidence to confirm previous 
morphological observations (Burton & Caniggia 2001, Burton & Jauniaux 2004, 
Burton et al. 2006) that high oxygen, i.e, atmospheric oxygen concentration (AOC) 
was not physiological for term placental culture. In this evidence, I showed that micro 
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explants were viable after 6 days culture in both AOC and Physiological Oxygen 
Concentration (POC). However, there was marked difference in tissue morphology 
between explants cultured in POC and AOC. I provided new evidence that while the 
explants were viable after 6 days culture, there was more syncytial detachment and 
loss in explants cultured in AOC; and that the tissue morphology and RNA quality in 
explants cultured in POC was akin to pre-culture explants. I also showed for the first 
time that placental RNA quality decline in tandem with STB degeneration and 
syncytial damage and loss. Hence, I provided new knowledge to further our 
understanding that micro explants cultured at POC have the best mRNA quality and 
tissue structure after long-term culture to support high throughput experiments. 
 
Regarding knowledge and understanding of the effects of placental explant culture 
on placental gene expression, I provided comprehensive new evidence to show that 
the observable morphological changes and differences in RNA quality between the 
POC and AOC cultured explants transcended beyond morphology to deeper 
changes in the biological and molecular pathways in the placenta; and that the 
changes impacted on interpretations of studies that have used explants cultured in 
AOC. I demonstrated further that explant culture in AOC not only affects individual 
gene expression but also induce relative changes to the enrichment of specific 
transcription factor targets, placental molecular functions, cellular components, 
biological processes and functional pathways.  
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6.1.1 Histamine has complex functions in the placenta: it regulates genetic pathways 
that have implications in PE placentae 
I then undertook further work to extend our knowledge and understanding of gene 
expression in normal and PE placentae (Section 5.4). This work was an extension to 
a previous report on PE gene expression meta-analysis, which explored the relative 
relationship between NP and PE gene expression. In this work, I broadened the 
coverage to examine the roles of genes with consistent low or high level expressions 
in the placenta. One key finding was the identification for the first time, of subsets of 
genes that are consistently up or down-regulated in PE but not in NP placentae. This 
enabled the identification of specific biochemical pathways that characterises the 
contributory roles or causal effects of elevated histamine in the pathogenesis of PE. 
Through this work, I further showed that about 30% of genes currently published as 
being investigated for possible roles in the molecular pathology of PE were not 
consistently expressed in the PE placentae.  
 
The work had interesting impact on further studies in PE. For, it not only provided a 
unique opportunity for researchers in the field to re-evaluate the relevance and focus 
of their investigations of PE, it offered further opportunities to refine the studies 
designed for molecular bio-markers for early detection of women at risk of 
preeclampsia. The work also developed on the framework for absolute gene 
expression analysis into modelling the baseline genomic blueprint for normal 
placental gene expression for comparison with expressions in complicated 
placentae.  
 
Thus, this work was further extended to examine the effect of elevated histamine on 
placental gene expression in parallel with effect of PE on the placenta (Section 5.5). 
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In this extension work, new evidence was added to the knowledge and 
understanding of the roles of specific placental genes regulated by histamine and 
their implications in PE. The key finding was Histamine regulated a subset of 
placental genes that were significantly expressed in PE placentae but not in normal 
pregnancy placentae or cultured explants without histamine treatment. I provided 
evidence that the elevated histamine regulates specific genes in pre-eclampsia, and 
that the genes are involved in inflammation and immune system regulation; tissue 
proliferation and morphogenesis; regulation of junctional proteins; maintenance of 
placental contractile activity; regulation of growth; impairment of cell signalling; and 
regulation of placental gene expression. These suggested that histamine has 
significant mediating and or sustaining functions in the placenta, and that elevated 
levels do play key roles in the pathophysiology of pre-eclampsia.  
 
6.1.2 Is histamine the missing link in PE pathophysiology? 
In the introduction, it was stated that if histamine receptors are expressed in the 
placenta, then elevated histamine would have functional roles, and if the effects of 
elevated histamine were similar to the pathophysiological changes observed in PE 
placentae, then histamine could be the missing link that precipitates or 
decompensate PE pathophysiology. In the course of these discussions, I have 
provided evidence through the series of publication submitted here for consideration 
that: histamine receptor genes are expressed at the foeto-maternal interface; DAO 
genes are expressed in the placenta; HDC activity levels are increased in PE 
placentae; there is cross-talk between histamine, DAO and cytokines in the placenta; 
elevated histamine in dHDA regulated the expression of specific genes in the 
placenta and these genes are abnormally expressed in PE placentae; the functions 
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of these elevated histamine regulated genes also expressed in PE are involved in 
tissue morphology and possibly poor placentation, metabolic defects, endothelia 
dysfunction, inflammation, immunologic response, angiogenic and anti-angiogenic 
response in PE placentae.  It is therefore suffice to suggest that elevated histamine 
fits the role of the missing link (Figure 6-1) in PE pathophysiology and that elevated 
histamine has causal effects on PE and is plausibly, the missing link that perpetuates 
the pathophysiological changes in the placental and maternal systems to culminate 
in pre-eclampsia complication.  Therefore it is reasonable to conclude that the 
elevated histamine observed in PE would have pathophysiological roles in PE and 
early detection leading to effective control of maternal blood histamine levels could 
save lives and it’s thus recommended. 
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 Figure 6-1: Histamine fits the missing link in Pre-eclampsia Pathogenesis 
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6.2 Reflection on my contributions and my professional development as a 
research practitioner 
My contributions to the listed publications are described in Table 6-1 below 
according the CRediT Taxonomy of author contributions (Brand et al. 2015). My 
contributory role is described in column 1, followed by the role definition in column 2. 
The respective publications are numbered from 1 – 11 in line with the publication 
portfolio listing. The listings and completion (√) of this information with copies of the 
published author contribution accurately reflect my contributions to the works 
submitted here for the award.  
Table 6-1: Summary of My Contributory  
My 
Contributory 
Roles 
Role Definition 1 2 3 4 5 6 7 8 9 10 11 
Conceptualisation Ideas; formulation or 
evolution of overarching 
research goals and 
aims. 
√ √ √ √ √ √ √ √ √ √ √ 
Data Curation Management activities 
to annotate (produce 
metadata), scrub data 
and maintain research 
data for initial use and 
later reuse. 
√* √* √* √* √* √* √* √* √* √* √* 
Formal Analysis Application of statistical, 
mathematical, 
computational, or 
bioinformatics to analyse 
or synthesize study 
data. 
√ √ √ √ √ √ √ √ √ √ √ 
Investigation** Conducting research 
and investigation 
process, specifically 
performing the 
experiments 
√ √ √* √ √* √ √ √ √ √ √ 
Methodology Development or design 
of methodology; creation 
of models 
√ √ √* √* √* √* √* √* √* √* √* 
Project 
Administration 
Management and 
coordination 
responsibility for the 
research activity 
planning and execution. 
√* √* √* √* √* √* √* √* √* √* √* 
Resources Provision of study 
materials, reagents, 
materials, patients, 
√* √* √* √* √* √* √* √* √* √* √* 
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laboratory samples, 
animals, 
instrumentation, 
computing resources, or 
other analysis tools. 
Validation Verification, whether as 
a part of the activity or 
separate, of the overall 
replication/reproducibility 
of results/experiments 
and other research 
outputs. 
√ √ √* √ √* √ √ √ √ √ √ 
Visualization Preparation, creation 
and/or presentation of 
the published work, 
specifically 
visualization/data 
presentation. 
√ √ √ √ √ √ √ √ √ √ √ 
Writing – Original 
Preparation 
Creation and/or 
presentation of the 
published work, 
specifically writing the 
initial draft (including 
substantive 
interpretation). 
√ √ √ √ √ √ √ √ √ √ √ 
Review & Editing Presentation of the 
published work, 
specifically critical 
review, commentary or 
revision – including pre- 
or post-publication 
stages. 
√* √§ √§ √§ √§ √§ √§ √§ √§ √§ √§ 
√* = joint activity; √
§
 = I performed activity but consulted with named others; ** = list of specific 
experiments or investigations I performed (tissue dissection, tissue culture, protein and amine assays 
with ELISA, gene cloning, immuno-histochemistry; in situ hybridisation, RNA and DNA extraction, 
PCR, RT-PCR, real time RT-qPCR, systematic review, meta-analysis, all statistical analysis, all 
bioinformatics analysis) 
 
Over the course of this work, it was a primary desire to improve on my skills for 
conceptualising research ideas. To achieve this, I used a 3Cs (Curiosity, Critical 
thinking, and Courage for idea generations) prong approach to improve on my 
conceptualisation skills. Development, harnessing and control of my curiosity for 
good research were particularly important for me. In the Old Man's Advice to Youth: 
"Never Lose a Holy Curiosity," LIFE magazine (2 May 1955, p. 64) Einstein is 
famously quoted as saying: “The important thing is not to stop questioning. Curiosity 
has its own reason for existence. One cannot help but be in awe when he 
contemplates the mysteries… of life, of the marvellous structure of reality. It is 
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enough if one tries merely to comprehend a little of this mystery each day. Never 
lose a holy curiosity”. Thus, I desired to develop a higher sense of curiosity, a holy 
curiosity to continue to question, control my curiosity, amass courage to entertain 
and refine scientific questions including those others considered “bad ideas or red 
herrings” through critical thinking into clearly stated researchable ideas. The 
outcome for this is clearly outlined in Table 6-1, row 1. The ideas for all the studies 
underpinning the publications submitted here originated from my desire not to stop 
questioning.  
Of course, my development was not limited to conceptualisation of good research 
ideas. I used the opportunities available to develop across all areas as an academic 
researcher. In Table 6-1, I also show that over the period of the studies, I developed 
quite considerable skills to position myself towards internationally and publicly 
renowned publications. I aligned my development with the UK workforce Researcher 
Development Framework (RDF) for researcher development. My primary goal for 
this initiative was to enhance my capacity to develop as a world-class researcher. I 
therefore took the initiatives to lead and manage the activities to annotate and 
produce metadata for initial use and later reuse. Some of the activities were more 
complex, for example, the curation, management and publication of raw data on 
public databases such as GEO required several standards to be met. Each stage of 
the material preparation was associated with critical learning that I found extremely 
helpful. 
Similarly, I performed all statistical, mathematical, computational, and bioinformatics 
analyse or syntheses outlined in the studies underpinning the publications presented 
here. These processes involved determination and openness to extend my reach 
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and develop high throughput skills in computational biology and statistical analyses. 
Consequently, I over the period of investigations improved my knowledge, skills and 
capabilities in areas beyond biology, genetics and genomics to computer 
programming, data mining, complex statistics and bioinformatics. These culminated 
in the design and development of methodology; the creation of novel models, leading 
and conducting high throughput research and investigation, and in performing both 
wet and dry-laboratory experiments. Clearly, I received support and guidance and I 
made a very conscious effort to use every opportunity offered to develop as an all-
round researcher in genomics and bioinformatics with core knowledge in human 
reproduction; and thus, actively contributed to all aspects of the research activities 
required for recognition as a publisher. 
Also, I made conscious efforts during the studies to recognise, create and confidently 
act on opportunities with the potential to develop my career within both academia 
and industry. Therefore, I made it a career ambition to actively create and champion 
opportunities for others within my scope of practice. Hence, I developed a sense of 
responsiveness towards collaborative opportunities across research disciplines and 
with non-academic organisations. While I sought to develop substantial ability and 
confidence to set expectations, I also developed the courage and competence to 
advise peers and less experienced members of staff to engage in research and 
scholarly publications. In brief, the journey to develop as a research practitioner has 
been onerous but worthwhile. I still aspire to develop further to direct not just local 
policy, but enhance my contributions to shape wider policy and procedures within the 
HE sector and professional associations or bodies because human development is 
intrinsically linked to creation of new knowledge emanating from prudent questioning, 
and I believe I can still contribute.  
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6.3 Suggestions for future developments 
The findings from the preceding studies have provided substantial insight into the 
roles of histamine in the human placenta and the ensuing effect on PE 
pathophysiology. While the studies have provided closure to some questions, they 
have also opened up novel areas for further investigations. In this section I outline 
new areas of investigations that have arisen from above studies. 
6.3.1 Early Maternal Blood Pregnancy Histamine and links with Preeclampsia 
In chapter 1, it was shown that PE is a major cause of perinatal mortality and it 
complicates up to 8% of all pregnancies in Western countries. In chapter 2, it was 
also shown that mothers who develop PE present with clinical symptoms akin to 
experimentally induced elevated histamine and the elevated histamine is harmful to 
the placenta. While it is widely accepted that the levels and activity of DAO in 
maternal blood rise a 100 and 1000 fold respectively during normal pregnancy, but 
diminishes after gestational week 10 in pregnancies that result in PE, the cause of 
the diminished DAO levels and activity in early pregnancy is unclear. It was further 
shown in chapter 4 that histamine production is increased in PE placentae, and 
increasing histamine levels diminishes DAO mRNA expression in placentae. Figure 
2-4 further demonstrates that while maternal blood histamine levels in normal 
pregnancy and late PE pregnancy are well characterised, early maternal blood 
histamine levels in women who later develop PE remain unelucidated. Therefore, we 
are currently testing the hypothesis that maternal blood histamine in early pregnancy 
(first trimester) are elevated above normal pregnancy levels and the elevated 
histamine in early pregnancy is associated with diminished maternal serum DAO 
levels in mothers who later develop PE.  
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We are thus conducting a prospective association study to examine serial assay of 
maternal blood for histamine and serum for DAO levels of (1) women with no history 
of PE, (2) women with history of PE and (3) primigravid women with history of 
histamine intolerance. We anticipate that the findings from this investigation could 
provide evidence to show for the first time, differences in early pregnancy maternal 
blood histamine in mothers who later develop PE and those that do not. The findings 
are also expected to help determine the levels of maternal blood histamine that 
coincide with diminished maternal serum DAO. Thirdly, with predictive modelling the 
findings are also expected to suggest maternal histamine and DAO level cut-off 
points that could be used for early detection of PE. 
 
6.3.2 Histamine Intolerance and Pregnancy Outcome 
It was shown through the systematic reviews that maternal blood histamine is well 
controlled in normal pregnancy, and in such instances atopic women who usually 
have histamine intolerance symptoms fare well during normal pregnancy. In contrast, 
women whose blood histamine levels are poorly controlled during pregnancy or 
plausibly elevated from early pregnancy suffer from PE and experience most of the 
symptoms associated with histamine intolerance. The commentaries summarised 
the evidence that high blood and urine histamine occur in PE. It is established that 
placental HDC activity is increased while DAO activity is decreased in PE. It is also 
established that histamine intolerance can be triggered by certain foods such as 
beans and pulses, tomatoes, canned fish, cheese, cocoa and chocolate and other 
histamine releasing foods.  
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It is further established that maternal nutrient deficiency in copper and ascorbic acid 
increases maternal risk for PE. Copper and ascorbic acid are co-factors for 
histamine synthesis and metabolism. However, it is not known whether histamine 
releasing foods or deficiencies in copper and ascorbic acid have effects on the 
diminished DAO activity in maternal blood. It also uncertain which foods induce 
histamine elevation in pregnancy so that pregnant women can avoid such foods. We 
are therefore conducting further studies in this area to investigate the effect of 
environmental histamine releasers on pregnancy outcome. Specifically, the studies 
are focused to:  
 prospectively survey the dietary type of a cohort of pregnant women and 
correlate with the outcome of pregnancy 
 assay blood histamine, ascorbic acid and DAO levels and determine their 
relation with dietary intake and pregnancy outcome 
 determine frequency of exposure to environmental histamine releasers such 
as ‘cigarette smoking’ alcohol, and lack of sleep that induce elevated blood 
histamine and how these correlate with  symptoms of histamine intolerance 
during pregnancy. 
These studies will have clear impact on maternal health and pregnancy outcomes. 
The information thus gained is expected to provide useful dietary and environmental 
advice to pregnant women who may be at a higher risk of developing trophoblastic 
diseases such as preeclampsia. It is also expected that the study will yield results to 
inform a predictive tool for early diagnosis of preeclampsia. 
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6.3.3 Genetic Variations in histamine pathways and Pregnancy Outcomes 
It has been recognised that single nucleotide polymorphisms in key genes in 
histamine pathways including Methylenetetrahydrofolate reductase (MTHFR), DAO 
(also known as AOC1), Monoamine Oxidase (MAO), HNMT, and 
Phosphatidylethanolamine N-Methyltransferase (PEMT) are strongly linked with 
defective regulation of blood histamine with and histamine intolerance. Epigenetic 
regulation of histamine synthesis and metabolic genes has also been associated 
with defective histamine metabolism and elevated blood histamine. Although the 
placenta is the root cause of PE, previous studies examining variations in these 
genes in relation to PE have focused on the mother instead of the placenta. We have 
therefore adopted an integrated approach to examine the variations in these genes 
in the placenta in the context of clinical changes in maternal health. Currently we are 
focusing on characterising the genetic variations of these genes in placenta with high 
therapeutic potentials to develop and test a multi-sensory diagnostic intervention for 
early detection and management of PE. 
 
6.3.4 Validation of HSPE genes and curation of histamine regulated pathways in PE 
placentae 
A total of 270 significant genes were identified as consistently expressed, specifically 
in response to elevated histamine treatment in the placenta. These genes were 
observed to have functional effects that could have implications in the placental 
pathophysiology of PE. In order to establish the roles of elevated histamine in PE 
placental pathophysiology and curate the respective pathways, the expression of the 
HSPE genes require further validation assessment. It is therefore proposed to 
undertake further work using RT-qPCR to confirm the expression of the HSPE 
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genes. This validation study could confirm the effects of elevated histamine in the 
pathophysiology of PE and authenticate subsequent analysis to curate the pathways 
enriched by the elevated histamine in PE placentae. 
6.3.5 Histamine effects on CD3 signal transduction in placental T and NK cells 
Regulatory loops between histamine and cytokines in human placenta were 
confirmed in these studies. INF-gamma, IL-1beta and IL-10 transiently induced 
histamine production. The histamine thus produced was shown to sustain the 
production of pro-inflammatory and extra-thymus-like cytokines in placenta. 
Prolonged exposure of the placental tissues to higher histamine concentration up-
regulates TH-1 like cytokine in human placenta explants. There is also emerging 
evidence that high histamine concentration up-regulates Th-1 response by reversing 
monocytes or macrophage down regulation of CD3 signal transduction on T and NK 
cells thereby allowing IL-2 and other Th-1 cytokines to potently sustain the Th-1 
cytolytic response (Hellstrand et al. 2000, Johansson et al. 2000). I would like to 
conduct further studies on this subject to delineate the relationships between 
histamine receptors and the regulations of CD3 signal transduction in placental T 
and NK cells. 
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Appendix 
Appendix 1: Statistical Analysis results of maternal blood and urine histamine 
Table A-1: Maternal Blood Histamine Levels 
Condition N Mean Std. Deviation Std. Error 
95% Confidence Interval for Mean 
Minimum Maximum Lower Bound Upper Bound 
NP Trimester 1 2 64.0000 8.48528 6.00000 -12.2372 140.2372 58.00 70.00 
NP Trimester 2 3 43.3333 11.54701 6.66667 14.6490 72.0177 30.00 50.00 
NP Trimester 3 38 52.9108 8.80811 1.42886 50.0156 55.8059 35.00 74.30 
PE 31 63.5613 10.49342 1.88467 59.7123 67.4103 49.10 94.30 
Eclampsia 14 69.6714 10.03145 2.68102 63.8794 75.4634 54.20 87.30 
Total 88 59.2547 11.86594 1.26491 56.7405 61.7688 30.00 94.30 
 
Table A-2: Maternal Blood Histamine Trimester Multiple Comparisons 
Dependent Variable:   BloodHA   
Bonferroni   
(I) Condition (J) Condition Mean Difference (I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
NP Trimester 1 NP Trimester 2 20.66667 8.86125 .221 -4.8893 46.2226 
NP Trimester 3 11.08921 7.04221 1.000 -9.2206 31.3990 
PE .43871 7.08185 1.000 -19.9854 20.8628 
Eclampsia -5.67143 7.33781 1.000 -26.8338 15.4909 
NP Trimester 2 NP Trimester 1 -20.66667 8.86125 .221 -46.2226 4.8893 
NP Trimester 3 -9.57746 5.82137 1.000 -26.3663 7.2114 
PE -20.22796* 5.86926 .009 -37.1550 -3.3009 
Eclampsia -26.33810* 6.17569 .001 -44.1488 -8.5273 
NP Trimester 3 NP Trimester 1 -11.08921 7.04221 1.000 -31.3990 9.2206 
NP Trimester 2 9.57746 5.82137 1.000 -7.2114 26.3663 
PE -10.65050* 2.34930 .000 -17.4259 -3.8751 
Eclampsia -16.76064* 3.03481 .000 -25.5131 -8.0082 
PE NP Trimester 1 -.43871 7.08185 1.000 -20.8628 19.9854 
NP Trimester 2 20.22796* 5.86926 .009 3.3009 37.1550 
NP Trimester 3 10.65050* 2.34930 .000 3.8751 17.4259 
Eclampsia -6.11014 3.12570 .540 -15.1247 2.9044 
Eclampsia NP Trimester 1 5.67143 7.33781 1.000 -15.4909 26.8338 
NP Trimester 2 26.33810* 6.17569 .001 8.5273 44.1488 
NP Trimester 3 16.76064* 3.03481 .000 8.0082 25.5131 
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PE 6.11014 3.12570 .540 -2.9044 15.1247 
*. The mean difference is significant at the 0.05 level. 
 
 
Table A-3: Maternal Urine Histamine after Aminoguanidine Treatment 
Gestational Age Mean HA before AG Mean HA after AG Significance 
Non-Pregnant Mean (µg/24h) 6.6667 7.8333 p>0.05 
N 3 3  
Std. Deviation 5.13160 8.80814  
Std. Error of Mean 2.96273 5.08538  
Minimum (µg/24h) 2.33 2.50  
Maximum (µg/24h) 12.33 18.00  
Range (µg/24h) 10.00 15.50  
Trimester 1 Mean (µg/24h) 44.1333 52.4000 p=0.137 
N 5 5  
Std. Deviation 18.31605 17.67201  
Std. Error of Mean 8.19119 7.90316  
Minimum (µg/24h) 17.67 21.00  
Maximum (µg/24h) 61.00 62.00  
Range (µg/24h) 43.33 41.00  
 
Percentage (%) rise 
in urine histamine 
   
An analysis of maternal urine histamine (HA) levels after inhibition of Diamine oxidase (DAO) with 
aminoguanidine (AG) based on Bjuro et al 1964. Percentage (%) rise in urine histamine in pregnancy 
from non-pregnant = 562.00%. Percentage rise in maternal urine histamine after inhibition of DAO 
with aminoguanidine = 18.73%. 
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Appendix 2: Causal effect identification-Testable Implications  
A.  Adjustment for Total effect: 
No adjustment is necessary to estimate the total effect of Elevated 
Histamine on Pre-eclampsia. 
 
Adjustments for Direct Effect: 
Minimal sufficient adjustment sets for estimating the direct effect of Elevated 
Histamine on Pre-eclampsia: 
 Cell Signalling, Gene Regulation, Inflammation and Immune regulation, 
Junctional proteins regulation, Oxygen Sensing, Placental like 
Innervation, Placental like contractile activity, Placental growth, Tissue 
proliferation and morphogenesis 
Instrumental and conditional Covariates: 
 Defective_DAO_Activity 
 Increased_HDC_Activity 
B.  Testable implications- The model implies the following conditional 
independences: 
1.  Cell_Signaling ⊥ Defective_DAO_Activity | Elevated Histamine 
2.  Cell_Signaling ⊥ Gene_Regulation | Elevated Histamine 
3.  Cell_Signaling ⊥ Increased_HDC_Activity | Elevated Histamine 
4.  Cell_Signaling ⊥ Inflammation_and_Immune_regulation | Elevated Histamine 
5.  Cell_Signaling ⊥ Junctional_proteins_regulation | Elevated Histamine 
6.  Cell_Signaling ⊥ Oxygen_Sensing | Elevated Histamine 
7.  Cell_Signaling ⊥ Placental_Innervation | Elevated Histamine 
8.  Cell_Signaling ⊥ Placental_contractile_activity | Elevated Histamine 
9.  Cell_Signaling ⊥ Placental_growth | Elevated Histamine 
10.  Cell_Signaling ⊥ Tissue_proliferation_and_morphogenesis | Elevated Histamine 
11.  Defective_DAO_Activity ⊥ Gene_Regulation | Elevated Histamine 
12.  Defective_DAO_Activity ⊥ Increased_HDC_Activity 
13.  Defective_DAO_Activity ⊥ Inflammation_and_Immune_regulation | Elevated 
Histamine 
14.  Defective_DAO_Activity ⊥ Junctional_proteins_regulation | Elevated Histamine 
15.  Defective_DAO_Activity ⊥ Oxygen_Sensing | Elevated Histamine 
16.  Defective_DAO_Activity ⊥ Placental_Innervation | Elevated Histamine 
17.  Defective_DAO_Activity ⊥ Placental_contractile_activity | Elevated Histamine 
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18.  Defective_DAO_Activity ⊥ Placental_growth | Elevated Histamine 
19.  Defective_DAO_Activity ⊥ Pre-eclampsia | Elevated Histamine 
20.  Defective_DAO_Activity ⊥ Tissue_proliferation_and_morphogenesis | Elevated 
Histamine 
21.  Gene_Regulation ⊥ Increased_HDC_Activity | Elevated Histamine 
22.  Gene_Regulation ⊥ Inflammation_and_Immune_regulation | Elevated 
Histamine 
23.  Gene_Regulation ⊥ Junctional_proteins_regulation | Elevated Histamine 
24.  Gene_Regulation ⊥ Oxygen_Sensing | Elevated Histamine 
25.  Gene_Regulation ⊥ Placental_Innervation | Elevated Histamine 
26.  Gene_Regulation ⊥ Placental_contractile_activity | Elevated Histamine 
27.  Gene_Regulation ⊥ Placental_growth | Elevated Histamine 
28.  Gene_Regulation ⊥ Tissue_proliferation_and_morphogenesis | Elevated 
Histamine 
29.  Increased_HDC_Activity ⊥ Inflammation_and_Immune_regulation | Elevated 
Histamine 
30.  Increased_HDC_Activity ⊥ Junctional_proteins_regulation | Elevated Histamine 
31.  Increased_HDC_Activity ⊥ Oxygen_Sensing | Elevated Histamine 
32.  Increased_HDC_Activity ⊥ Placental_Innervation | Elevated Histamine 
33.  Increased_HDC_Activity ⊥ Placental_contractile_activity | Elevated Histamine 
34.  Increased_HDC_Activity ⊥ Placental_growth | Elevated Histamine 
35.  Increased_HDC_Activity ⊥ Pre-eclampsia | Elevated Histamine 
36.  Increased_HDC_Activity ⊥ Tissue_proliferation_and_morphogenesis | Elevated 
Histamine 
37.  Inflammation_and_Immune_regulation ⊥ Junctional_proteins_regulation | 
Elevated Histamine 
38.  Inflammation_and_Immune_regulation ⊥ Oxygen_Sensing | Elevated 
Histamine 
39.  Inflammation_and_Immune_regulation ⊥ Placental_Innervation | Elevated 
Histamine 
40.  Inflammation_and_Immune_regulation ⊥ Placental_contractile_activity | 
Elevated Histamine 
41.  Inflammation_and_Immune_regulation ⊥ Placental_growth | Elevated 
Histamine 
42.  Inflammation_and_Immune_regulation ⊥ 
Tissue_proliferation_and_morphogenesis | Elevated Histamine 
43.  Junctional_proteins_regulation ⊥ Oxygen_Sensing | Elevated Histamine 
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44.  Junctional_proteins_regulation ⊥ Placental_Innervation | Elevated Histamine 
45.  Junctional_proteins_regulation ⊥ Placental_contractile_activity | Elevated 
Histamine 
46.  Junctional_proteins_regulation ⊥ Placental_growth | Elevated Histamine 
47.  Junctional_proteins_regulation ⊥ Tissue_proliferation_and_morphogenesis | 
Elevated Histamine 
48.  Oxygen_Sensing ⊥ Placental_Innervation | Elevated Histamine 
49.  Oxygen_Sensing ⊥ Placental_contractile_activity | Elevated Histamine 
50.  Oxygen_Sensing ⊥ Placental_growth | Elevated Histamine 
51.  Oxygen_Sensing ⊥ Tissue_proliferation_and_morphogenesis | Elevated 
Histamine 
52.  Placental_Innervation ⊥ Placental_contractile_activity | Elevated Histamine 
53.  Placental_Innervation ⊥ Placental_growth | Elevated Histamine 
54.  Placental_Innervation ⊥ Tissue_proliferation_and_morphogenesis | Elevated 
Histamine 
55.  Placental_contractile_activity ⊥ Placental_growth | Elevated Histamine 
56.  Placental_contractile_activity ⊥ Tissue_proliferation_and_morphogenesis | 
Elevated Histamine 
57.  Placental_growth ⊥ Tissue_proliferation_and_morphogenesis | Elevated 
Histamine 
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Appendix 3: Scatterplot Up-regulated Genes 
ProbeSet Accession UGCluster Symbol 
1552509_a_at NM_145273 Hs.657365 CD300LG 
1552575_a_at NM_153344 Hs.485528 C6orf141 
1553151_at AY079172 Hs.436360 ATP6V0D2 
1553482_at NM_153040 Hs.367879 C15orf32 
1553574_at NM_176891 Hs.682604 IFNE 
1553789_a_at NM_058180 Hs.236572 C21orf58 
1553973_a_at BC032003 Hs.334274 SPINK6 
1554020_at BC010091 Hs.505202 BICD1 
1554097_a_at BC021861 Hs.458096 LOC554202 
1554640_at BC039306 Hs.591908 PALM2 
1554663_a_at BC043499 Hs.325978 NUMA1 
1554906_a_at BC029395 Hs.344400 MPHOSPH6 
1554997_a_at AY151286 Hs.196384 PTGS2 
1555758_a_at AF213040 Hs.84113 CDKN3 
1556364_at AK057923 Hs.660881 LOC730057 
1556409_a_at AF086184 Hs.103068 LOC100129932 
1556423_at BE220445 Hs.525479 VASH1 
1556695_a_at AK095719 Hs.457407 FLJ42709 
1556698_a_at AI819722 Hs.605082 GPRIN3 
1558075_at BM989131 Hs.619009 LOC339047 
1558834_s_at AL832216 Hs.716732 C1orf62 
1558930_at BC009533 Hs.559194 LOC728192 
1559277_at AK093019 Hs.78061 FLJ35700 
1560558_at BC013097 Hs.658575 C9orf80 
1561171_a_at AK093450 Hs.569472 LOC727832 
1561720_at BC042989 Hs.632229 RECQL5 
1562102_at BC014579 Hs.460260 AKR1C1 
1562337_at AK095468 Hs.531755 OR7D2 
1562591_a_at AF548116 Hs.532138 OFCC1 
1564231_at AK025109 Hs.478095 IFT80 
1564315_at AK055534 Hs.545529 C8orf49 
1564474_at AK055144 Hs.161338 LOC728723 
1565716_at BE930017 Hs.513522 FUS 
1566785_x_at AK025172 Hs.646586 LOC728806 
1568638_a_at BQ024836 Hs.676257 IDO2 
1570515_a_at BC029425 Hs.696158 FILIP1 
201430_s_at W72516 Hs.519659 DPYSL3 
201508_at NM_001552 Hs.462998 IGFBP4 
201820_at NM_000424 Hs.433845 KRT5 
201860_s_at NM_000930 Hs.491582 PLAT 
202273_at NM_002609 Hs.509067 PDGFRB 
202291_s_at NM_000900 Hs.365706 MGP 
202363_at AF231124 Hs.643338 SPOCK1 
202465_at NM_002593 Hs.202097 PCOLCE 
202709_at NM_002023 Hs.519168 FMOD 
202834_at NM_000029 Hs.19383 AGT 
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202936_s_at NM_000346 Hs.647409 SOX9 
203083_at NM_003247 Hs.371147 THBS2 
203085_s_at BC000125 Hs.645227 TGFB1 
203151_at AW296788 Hs.194301 MAP1A 
203153_at NM_001548 Hs.20315 IFIT1 
203263_s_at AI625739 Hs.54697 ARHGEF9 
203325_s_at AI130969 Hs.210283 COL5A1 
203649_s_at NM_000300 Hs.466804 PLA2G2A 
203886_s_at NM_001998 Hs.198862 FBLN2 
204114_at NM_007361 Hs.369840 NID2 
204301_at NM_014867 Hs.5333 KBTBD11 
204337_at AL514445 Hs.386726 RGS4 
204411_at NM_017596 Hs.169182 KIF21B 
204533_at NM_001565 Hs.632586 CXCL10 
204596_s_at U46768 Hs.25590 STC1 
204719_at NM_007168 Hs.58351 ABCA8 
204733_at NM_002774 Hs.79361 KLK6 
204749_at NM_004538 Hs.21365 NAP1L3 
204818_at NM_002153 Hs.162795 HSD17B2 
204932_at BF433902 Hs.81791 TNFRSF11B 
204945_at NM_002846 Hs.89655 PTPRN 
204951_at NM_004310 Hs.654594 RHOH 
205048_s_at NM_003832 Hs.512656 PSPH 
205051_s_at NM_000222 Hs.479754 KIT 
205112_at NM_016341 Hs.655033 PLCE1 
205236_x_at NM_003102 Hs.2420 SOD3 
205267_at NM_006235 Hs.654525 POU2AF1 
205290_s_at NM_001200 Hs.73853 BMP2 
205347_s_at NM_021992 Hs.56145 TMSB15A 
205364_at NM_003500 Hs.444959 ACOX2 
205404_at NM_005525 Hs.195040 HSD11B1 
205447_s_at BE222201 Hs.713539 MAP3K12 
205475_at NM_007281 Hs.7122 SCRG1 
205481_at NM_000674 Hs.77867 ADORA1 
205499_at NM_014467 Hs.306339 SRPX2 
205500_at NM_001735 Hs.494997 C5 
205624_at NM_001870 Hs.646 CPA3 
205660_at NM_003733 Hs.118633 OASL 
205680_at NM_002425 Hs.2258 MMP10 
205695_at NM_006843 Hs.439023 SDS 
205767_at NM_001432 Hs.115263 EREG 
205782_at NM_002009 Hs.567268 FGF7 
205801_s_at NM_015376 Hs.143674 RASGRP3 
205870_at NM_000623 Hs.654542 BDKRB2 
205890_s_at NM_006398 Hs.44532 UBD 
206224_at NM_001898 Hs.123114 CST1 
206227_at NM_003613 Hs.442180 CILP 
206304_at NM_004997 Hs.927 MYBPH 
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206481_s_at NM_001290 Hs.714330 LDB2 
206510_at AF332197 Hs.101937 SIX2 
206574_s_at NM_007079 Hs.43666 PTP4A3 
206618_at NM_003855 Hs.469521 IL18R1 
206637_at NM_014879 Hs.2465 P2RY14 
206806_at NM_004717 Hs.242947 DGKI 
206924_at NM_000641 Hs.467304 IL11 
206994_at NM_001899 Hs.654549 CST4 
207016_s_at AB015228 Hs.643455 ALDH1A2 
207191_s_at NM_005545 Hs.699822 ISLR 
207276_at NM_004065 Hs.446675 CDR1 
207387_s_at NM_000167 Hs.1466 GK 
207510_at NM_000710 Hs.525572 BDKRB1 
207889_at NM_007101 Hs.198003 SARDH 
208307_at NM_005058 Hs.380450 RBMY1A1 
208851_s_at AL161958 Hs.644697 THY1 
209047_at AL518391 Hs.660192 AQP1 
209198_s_at BC004291 Hs.32984 SYT11 
209335_at AI281593 Hs.718429 DCN 
209396_s_at M80927 Hs.382202 CHI3L1 
209496_at BC000069 Hs.647064 RARRES2 
209560_s_at U15979 Hs.533717 DLK1 
209596_at AF245505 Hs.369422 MXRA5 
209747_at J03241 Hs.592317 TGFB3 
209914_s_at AW149405 Hs.637685 NRXN1 
209955_s_at U76833 Hs.654370 FAP 
210029_at M34455 Hs.840 IDO1 
210119_at U73191 Hs.411299 KCNJ15 
210140_at AF031824 Hs.143212 CST7 
210145_at M68874 Hs.497200 PLA2G4A 
210401_at U45448 Hs.41735 P2RX1 
210605_s_at BC003610 Hs.3745 MFGE8 
210619_s_at AF173154 Hs.75619 HYAL1 
210632_s_at L35853 Hs.463412 SGCA 
210687_at BC000185 Hs.503043 CPT1A 
211617_at M21191 Hs.652473 ALDOAP2 
211743_s_at BC005929 Hs.512633 PRG2 
211958_at R73554 Hs.607212 IGFBP5 
212134_at AB014538 Hs.504062 PHLDB1 
212354_at BE500977 Hs.409602 SULF1 
212358_at AL117468 Hs.466539 CLIP3 
212624_s_at BF339445 Hs.654534 CHN1 
212670_at AA479278 Hs.647061 ELN 
212713_at R72286 Hs.296049 MFAP4 
212736_at BE299456 Hs.401798 C16orf45 
212865_s_at BF449063 Hs.409662 COL14A1 
212942_s_at AB033025 Hs.459088 KIAA1199 
213001_at AF007150 Hs.653262 ANGPTL2 
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213075_at AL050002 Hs.357004 OLFML2A 
213249_at AU145127 Hs.433057 FBXL7 
213265_at AI570199 Hs.601055 PGA3 
213280_at AK000478 Hs.499659 GARNL4 
213422_s_at AW888223 Hs.558570 MXRA8 
213800_at X04697 Hs.363396 CFH 
213820_s_at T54159 Hs.513075 STARD5 
213832_at AA530995 Hs.666367 KCND3 
213974_at AB033059 Hs.459162 ADAMTSL3 
214022_s_at AA749101 Hs.458414 IFITM1 
214079_at AK000345 Hs.272499 DHRS2 
214236_at AA166684 Hs.463295 CDC27 
214761_at AW149417 Hs.530930 ZNF423 
214951_at AL050358 Hs.159481 SLC26A10 
214978_s_at AK023365 Hs.153648 PPFIA4 
215002_at BE000837 Hs.552700 LOC100132247 
215184_at AK026801 Hs.237886 DAPK2 
215192_at D38500 Hs.712714 PMS2L4 
215388_s_at X56210 Hs.575869 CFHR1 
215543_s_at AB011181 Hs.474667 LARGE 
215646_s_at R94644 Hs.643801 VCAN 
215856_at AK025833 Hs.287692 SIGLEC15 
216176_at AK025343 Hs.675399 HCRP1 
217525_at AW305097 Hs.503500 OLFML1 
217590_s_at AA502609 Hs.716816 TRPA1 
217897_at NM_022003 Hs.714294 FXYD6 
218285_s_at NM_020139 Hs.124696 BDH2 
218332_at NM_018476 Hs.334370 BEX1 
218484_at NM_020142 Hs.718455 NDUFA4L2 
218638_s_at NM_012445 Hs.302963 SPON2 
218729_at NM_020169 Hs.478067 LXN 
218820_at NM_020215 Hs.6434 C14orf132 
218950_at NM_022481 Hs.25277 ARAP3 
219025_at NM_020404 Hs.195727 CD248 
219054_at NM_024563 Hs.13528 C5orf23 
219059_s_at AL574194 Hs.655332 LYVE1 
219087_at NM_017680 Hs.435655 ASPN 
219230_at NM_018286 Hs.173233 TMEM100 
219315_s_at NM_024600 Hs.459652 TMEM204 
219359_at NM_025092 Hs.353181 ATHL1 
219407_s_at NM_006059 Hs.201805 LAMC3 
219478_at NM_021197 Hs.36688 WFDC1 
219500_at NM_013246 Hs.502977 CLCF1 
219554_at NM_016321 Hs.459284 RHCG 
219602_s_at NM_022068 Hs.585839 FAM38B 
219629_at NM_017911 Hs.265018 FAM118A 
219689_at NM_020163 Hs.59729 SEMA3G 
219700_at NM_020405 Hs.125036 PLXDC1 
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219743_at NM_012259 Hs.144287 HEY2 
219837_s_at NM_018659 Hs.13872 CYTL1 
219855_at NM_018159 Hs.200016 NUDT11 
220092_s_at NM_018153 Hs.165859 ANTXR1 
220116_at NM_021614 Hs.98280 KCNN2 
220191_at NM_019617 Hs.69319 GKN1 
220301_at NM_024781 Hs.280781 CCDC102B 
220480_at NM_021973 Hs.388245 HAND2 
220872_at NM_018547 Hs.621377 PRO2964 
221305_s_at NM_019076 Hs.554822 UGT1A8 
221572_s_at AF288410 Hs.631925 SLC26A6 
221730_at NM_000393 Hs.445827 COL5A2 
221914_at H19843 Hs.225936 SYN1 
221992_at AI925734 Hs.448833 NPIPL2 
222253_s_at AL117484 Hs.534980 POM121L9P 
222379_at AI002715 Hs.348522 KCNE4 
222450_at AL035541 Hs.517155 PMEPA1 
223316_at AL136562 Hs.498720 CCDC3 
223467_at AF069506 Hs.25829 RASD1 
223499_at AF329841 Hs.632102 C1QTNF5 
223618_at AF225426 Hs.24889 FMN2 
223672_at AL136561 Hs.132121 SGIP1 
223816_at AF242557 Hs.512668 SLC46A2 
223987_at AF332891 Hs.432379 CHRDL2 
224212_s_at AF169689 Hs.199343 PCDHA10 
224339_s_at AB056476 Hs.591474 ANGPTL1 
224403_at AF343661 Hs.120260 FCRL4 
224976_at R37335 Hs.191911 NFIA 
226069_at AA404269 Hs.524348 PRICKLE1 
226304_at AA563621 Hs.534538 HSPB6 
226408_at AA905942 Hs.515534 TEAD2 
226474_at AA005023 Hs.528836 NLRC5 
226571_s_at N38920 Hs.712625 PTPRS 
226614_s_at BE856336 Hs.124299 FAM167A 
226658_at AW590196 Hs.468675 PDPN 
226677_at AF141339 Hs.116935 ZNF521 
226766_at AB046788 Hs.13305 ROBO2 
226814_at AI431730 Hs.656071 ADAMTS9 
226828_s_at AL040198 Hs.472566 HEYL 
226847_at BF438173 Hs.9914 FST 
226971_at AI678057 Hs.521178 CCDC136 
226997_at W74476 Hs.12680 ADAMTS12 
227006_at AA156998 Hs.631569 PPP1R14A 
227058_at AW084730 Hs.646647 C13orf33 
227059_at AI651255 Hs.444329 GPC6 
227099_s_at AW276078 Hs.714890 LOC387763 
227154_at AL566367 Hs.212511 IGSF21 
227289_at AU119437 Hs.106511 PCDH17 
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227300_at AL521682 Hs.449718 TMEM119 
227475_at AI676059 Hs.591352 FOXQ1 
227557_at AI127800 Hs.474251 SCARF2 
227566_at AW085558 Hs.504352 NTM 
227654_at AI056877 Hs.372578 FAM65C 
227688_at AK022128 Hs.65366 LRCH2 
227850_x_at AW084544 Hs.415791 CDC42EP5 
227923_at BF439330 Hs.149035 SHANK3 
227946_at AI955239 Hs.463320 OSBPL7 
227984_at BE464483 Hs.371980 LOC650392 
228384_s_at AI690274 Hs.238303 C10orf33 
228537_at AI797248 Hs.111867 GLI2 
228554_at AL137566 Hs.32405 PGR 
228580_at AI828007 Hs.479119 HTRA3 
228593_at AI271425 Hs.471067 LOC339483 
228608_at N49852 Hs.525146 NALCN 
228617_at AA142842 Hs.441975 XAF1 
228875_at AI540210 Hs.126712 FAM162B 
229019_at AI694320 Hs.655005 ZNF385B 
229088_at BF591996 Hs.527295 ENPP1 
229151_at BE673587 Hs.101307 SLC14A1 
229158_at AW082836 Hs.105448 WNK4 
229177_at AI823572 Hs.11782 C16orf89 
229288_at BF439579 Hs.73962 EPHA7 
229529_at AI827830 Hs.78061 TCF21 
229678_at AA418402 Hs.380738 LOC728431 
229902_at AW083785 Hs.646917 FLT4 
230015_at AV729651 Hs.634380 PRCD 
230109_at AI638433 Hs.594417 PDE7B 
230204_at AU144114 Hs.2799 HAPLN1 
230453_s_at AW188009 Hs.513870 ATP2A3 
231358_at BE465760 Hs.30495 MRO 
231406_at AW205664 Hs.363308 ORAI2 
232001_at AW193600 Hs.590987 LOC439949 
232224_at AI274095 Hs.89983 MASP1 
232313_at AL122107 Hs.49599 TMEM132C 
232570_s_at AL356755 Hs.173716 ADAM33 
232602_at AL050348 Hs.419126 WFDC3 
232645_at AW665885 Hs.259625 LOC153684 
232686_at AI801574 Hs.132045 SIGLECP3 
233092_s_at AL133561 Hs.648234 LOC100271840 
233947_s_at U47671 Hs.567915 LOC255480 
234994_at AA088177 Hs.591341 TMEM200A 
235126_at N51468 Hs.552649 LQK1 
235334_at AW963951 Hs.337040 ST6GALNAC3 
235521_at AW137982 Hs.659337 HOXA3 
235548_at BG326592 Hs.119286 APCDD1L 
235588_at AA740849 Hs.99480 ESCO2 
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235874_at AL574912 Hs.98381 PRSS35 
235944_at BF446673 Hs.58877 HMCN1 
236044_at BF130943 Hs.40479 PPAPDC1A 
236141_at AA156933 Hs.61435 NBLA00301 
236738_at AW057589 Hs.710781 LOC401097 
236918_s_at AW975772 Hs.591289 LRRC34 
237721_s_at BE220587 Hs.666357 ASB4 
238370_x_at AI252081 Hs.515329 RPL22 
238542_at AA831769 Hs.656778 ULBP2 
238577_s_at AA628481 Hs.271605 TSHZ2 
238654_at W79425 Hs.293236 LOC147645 
239077_at W81648 Hs.657569 CSGALNACT2 
239286_at AI038737 Hs.116471 CDH11 
239580_at BF724601 Hs.24258 GUCY1A3 
239627_at BG034114 Hs.279929 TMED9 
239739_at AW452218 Hs.483200 SNX24 
240068_at H08345 Hs.106234 C21orf130 
241221_at BE644691 Hs.505601 SEC14L3 
241394_at AA213799 Hs.464224 LOC284120 
241926_s_at AA296657 Hs.473819 ERG 
242100_at AI076484 Hs.213137 CHSY3 
242625_at AW189843 Hs.17518 RSAD2 
243526_at AI968904 Hs.647083 WDR86 
244413_at AW237307 Hs.560087 CLECL1 
244723_at BF510430 Hs.656497 LOC100129488 
336_at D38081 Hs.442530 TBXA2R 
37408_at AB014609 Hs.7835 MRC2 
40687_at M96789 Hs.296310 GJA4 
61734_at AI797684 Hs.567550 RCN3 
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Appendix 4: Scatterplot Down-regulated Genes 
ProbeSet Accession UGCluster Symbol 
1553243_at NM_032817 Hs.498586 ITIH5 
1553333_at NM_152367 Hs.376194 C1orf161 
1553352_x_at AF513360  ERVWE1 
1553405_a_at NM_033225 Hs.571466 CSMD1 
1553698_a_at NM_145257 Hs.715507 C1orf96 
1553986_at BC023566 Hs.657750 RASEF 
1554036_at BC036731 Hs.409876 ZBTB24 
1554099_a_at BC032490 Hs.522672 SPIN3 
1554122_a_at BC012536 Hs.132513 HSD17B12 
1554195_a_at BC021680 Hs.660038 C5orf46 
1554737_at AF193046 Hs.519294 FBN2 
1554875_at BC029359 Hs.468349 C2orf34 
1554916_a_at BC043351 Hs.535903 JRK 
1555038_at BC031042 Hs.584954 EPB41L4A 
1556200_a_at BC021140 Hs.587663 C10orf90 
1557047_at BC032368 Hs.632575 YEATS2 
1557161_at BC039503 Hs.62646 LOC100132735 
1557321_a_at AA743820 Hs.468059 CAPN14 
1557636_a_at BC031107 Hs.258357 C7orf57 
1558212_at BC004474 Hs.416043 FLJ35024 
1558451_at AK094945 Hs.435077 LOC285500 
1558523_at AJ420563 Hs.443789 FAM184A 
1559254_at BI826147 Hs.534828 NCRNA00162 
1560932_at AK055918 Hs.562970 FLJ31356 
1561514_at BC034583 Hs.579378 LOC400655 
1562054_at BF377197 Hs.350673 SMEK3P 
1562966_at BC017424 Hs.445885 KIAA1217 
1563900_at AK055204 Hs.657974 FAM83B 
1563933_a_at AK091691 Hs.672452 PLD5 
1564166_s_at AK098276 Hs.406395 PRKRIP1 
1568849_at BC009635 Hs.382029 C21orf135 
1568882_at BC035223 Hs.317243 LRTOMT 
1569112_at AW020413 Hs.654821 SLC44A5 
1569464_at BC001560 Hs.172445 PPFIBP1 
1569555_at BC012859 Hs.494163 GDA 
1569723_a_at BC011119 Hs.461786 SPIRE2 
1570394_at BC039314 Hs.435103 XRN1 
201909_at NM_001008 Hs.282376 RPS4Y1 
202203_s_at NM_001144 Hs.295137 AMFR 
202966_at NM_014289 Hs.496593 CAPN6 
203589_s_at NM_006286 Hs.379018 TFDP2 
203591_s_at NM_000760 Hs.524517 CSF3R 
203815_at NM_000853 Hs.268573 GSTT1 
203824_at NM_004616 Hs.170563 TSPAN8 
203949_at NM_000250 Hs.458272 MPO 
204154_at NM_001801 Hs.442378 CDO1 
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204199_at NM_014636 Hs.648175 RALGPS1 
204359_at NM_013231 Hs.533710 FLRT2 
204409_s_at BC005248 Hs.461178 EIF1AY 
204529_s_at AI961231 Hs.491805 TOX 
204548_at NM_000349 Hs.521535 STAR 
204614_at NM_002575 Hs.594481 SERPINB2 
204624_at NM_000053 Hs.492280 ATP7B 
204750_s_at BF196457 Hs.95612 DSC2 
204844_at L12468 Hs.435765 ENPEP 
205000_at NM_004660 Hs.99120 DDX3Y 
205073_at NM_000775 Hs.152096 CYP2J2 
205190_at NM_002670 Hs.203637 PLS1 
205287_s_at NM_003222 Hs.473152 TFAP2C 
205363_at NM_003986 Hs.591996 BBOX1 
205543_at NM_014278 Hs.135554 HSPA4L 
205916_at NM_002963 Hs.112408 S100A7 
205922_at NM_004665 Hs.293130 VNN2 
206239_s_at NM_003122 Hs.407856 SPINK1 
206424_at NM_000783 Hs.150595 CYP26A1 
206605_at NM_006025 Hs.997 P11 
206698_at NM_021083 Hs.78919 XK 
206700_s_at NM_004653 Hs.80358 JARID1D 
206801_at NM_002521 Hs.219140 NPPB 
206882_at NM_005071 Hs.515217 SLC1A6 
207111_at NM_001974 Hs.2375 EMR1 
207220_at NM_021071 Hs.591158 ART4 
207291_at NM_024081 Hs.471695 PRRG4 
207423_s_at AF029899 Hs.177984 ADAM20 
207790_at NM_025168 Hs.646997 LRRC1 
208607_s_at NM_030754 Hs.1955 SAA2 
209521_s_at AF286598 Hs.528051 AMOT 
209686_at BC001766 Hs.422181 S100B 
209757_s_at BC002712 Hs.25960 MYCN 
210141_s_at M13981 Hs.407506 INHA 
210172_at D26121 Hs.502829 SF1 
210437_at BC002351 Hs.512582 MAGEA9 
210548_at U58913 Hs.169191 CCL23 
210984_x_at U95089 Hs.488293 EGFR 
211149_at AF000994 Hs.115277 UTY 
211170_s_at AF127480 Hs.348762 PDE10A 
211469_s_at U73531 Hs.34526 CXCR6 
213307_at AF131790 Hs.268726 SHANK2 
213816_s_at AA005141 Hs.132966 MET 
213849_s_at AA974416 Hs.655213 PPP2R2B 
214051_at BF677486 Hs.675540 TMSB15B 
214357_at AL035295 Hs.517991 C1orf105 
214397_at AI827820 Hs.25674 MBD2 
214920_at R33964 Hs.120855 THSD7A 
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214983_at AL080135 Hs.433656 TTTY15 
214998_at AF090100 Hs.468878 AAK1 
215047_at AL080170 Hs.323858 TRIM58 
215153_at AF037070 Hs.655000 NOS1AP 
215491_at AI273812 Hs.437922 MYCL1 
216213_at AF155113 Hs.481181 NEK1 
217477_at U78581 Hs.534371 PIP5K1B 
217589_at AW300309 Hs.27453 RAB40A 
218182_s_at NM_021101 Hs.439060 CLDN1 
218701_at NM_016027 Hs.118554 LACTB2 
219263_at NM_024539 Hs.496542 RNF128 
219304_s_at NM_025208 Hs.352298 PDGFD 
219424_at NM_005755 Hs.501452 EBI3 
219756_s_at NM_024921 Hs.267038 POF1B 
219768_at NM_024626 Hs.546434 VTCN1 
219814_at NM_018388 Hs.105134 MBNL3 
220100_at NM_018484 Hs.220844 SLC22A11 
220196_at NM_024690 Hs.432676 MUC16 
220410_s_at NM_018627 Hs.522493 CAMSAP1 
220528_at NM_018399 Hs.183656 VNN3 
222456_s_at BF197289 Hs.525419 LIMA1 
224168_at AL136742 Hs.98712 TXNDC2 
224482_s_at BC006240 Hs.406788 RAB11FIP4 
226665_at AI986239 Hs.655602 AHSA2 
227128_s_at AI345950 Hs.23582 TACSTD2 
227174_at Z98443 Hs.122125 WDR72 
227241_at R79759 Hs.407152 MUC15 
228212_at AL574699 Hs.29742 ISM2 
228236_at AA903862 Hs.283865 C20orf54 
228492_at AV681765 Hs.598540 USP9Y 
229215_at AI393930 Hs.152475 ASCL2 
229403_at AI572046 Hs.272011 B4GALT1 
229546_at AI378035 Hs.657296 LOC653602 
229599_at AA675917 Hs.390599 LOC440335 
230760_at BF592062 Hs.522845 ZFY 
230763_at AA905508 Hs.171130 SPATA17 
230792_at BE671210 Hs.496205 FAAH2 
230863_at R73030 Hs.657729 LRP2 
230882_at AA129217 Hs.34969 FLJ34048 
230910_s_at AI828018 Hs.69517 LY6K 
231186_at AI184196 Hs.445241 FLJ43390 
231240_at AI038059 Hs.202354 DIO2 
231569_at N58489 Hs.98843 TMEM31 
232056_at AW470178 Hs.534699 SCEL 
232124_at AL117530 Hs.146346 LOC729085 
232170_at AJ243672 Hs.442337 S100A7A 
232388_at AB051550 Hs.461389 CNTNAP4 
232452_at AI808477 Hs.23491 OR2C3 
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232771_at Z83850 Hs.209527 NRK 
232849_at AI761436 Hs.204945 LOC100128988 
233520_s_at AL359338 Hs.482625 CMYA5 
233737_s_at AK023548 Hs.504540 LOC284561 
233830_at AK023635 Hs.635164 LOC90246 
234766_at AF162668 Hs.504212 OR8D2 
235382_at AI246369 Hs.98288 LVRN 
235942_at AI272059 Hs.568127 LOC401629 
236255_at BG026457 Hs.535800 PLEKHG4B 
236518_at BE208843 Hs.370555 C9orf86 
236707_at AA521016 Hs.436271 DAPP1 
237229_at AI268287 Hs.145717 JMJD5 
237265_at BF062257 Hs.662737 C16orf73 
237449_at BF447038 Hs.195922 SP8 
237577_at BE465316 Hs.545311 PCNP 
238263_at AW590543 Hs.642649 LOC285965 
238763_at AI539118 Hs.715766 RBM20 
238778_at AI244661 Hs.499159 MPP7 
238790_at BE738988 Hs.659158 LOC374443 
239186_at AI347139 Hs.8162 MGC39372 
239243_at AA279654 Hs.434401 ZNF638 
239398_at AI743156 Hs.131064 KLHL31 
239430_at AA195677 Hs.546554 IGFL1 
239921_at AA995791 Hs.491104 COL28A1 
240091_at AI001156 Hs.464813 PSMA8 
240189_at BF064226 Hs.253320 ACOXL 
241111_at AI032819 Hs.364941 HSD3B1 
241782_at AI932350 Hs.5025 NEBL 
241881_at N54813 Hs.269151 OR2W3 
241931_at AI168338 Hs.179675 XG 
243541_at AI123586 Hs.55378 IL31RA 
243683_at H43976 Hs.326387 MORF4L2 
243709_at BG054799 Hs.649685 SLC38A9 
244198_at AA885461 Hs.410810 RANBP17 
244374_at N39767 Hs.515575 PLAC2 
244385_at AA766126 Hs.709425 JMJD2C 
244802_at AA909218 Hs.500409 GLUD1 
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Appendix 5: Differentially expressed genes among EHM and Control classes 
 ProbeSet Symbol P-value Fold-change 
1 220579_at FLJ14100 0.0003589 1.44 
2 221267_s_at FAM108A1 0.0011862 1.24 
3 235409_at MGA 0.001332 0.7 
4 201407_s_at PPP1CB 0.0014617 0.91 
5 217358_at DNAJC16 0.0017172 0.82 
6 202076_at BIRC2 0.0023647 0.93 
7 224151_s_at AK3 0.0026289 0.82 
8 205987_at CD1C 0.002642 0.75 
9 34689_at TREX1 0.0027493 1.15 
10 220410_s_at CAMSAP1 0.002781 0.66 
11 238790_at LOC374443 0.0028797 0.63 
12 214540_at HIST1H2BO 0.0028801 0.77 
13 1563933_a_at PLD5 0.0029399 0.56 
14 207423_s_at ADAM20 0.0030885 0.65 
15 212649_at DHX29 0.0030945 0.86 
16 236329_at FLJ33996 0.0031796 1.31 
17 244565_at HMX2 0.0032257 1.24 
18 225210_s_at FAM103A1 0.0032481 0.82 
19 1564240_at LOC100130856 0.003337 1.45 
20 237229_at JMJD5 0.0034946 0.62 
21 216203_at SPTLC2 0.0035257 0.75 
22 215248_at GRB10 0.0035407 0.67 
23 243406_at LOC440268 0.0036221 1.21 
24 207959_s_at DNAH9 0.0036241 1.21 
25 230015_at PRCD 0.0037443 1.7 
26 243238_at PYGB 0.0037485 1.26 
27 212420_at ELF1 0.0039983 0.84 
28 229941_at FAM166B 0.0042202 0.9 
29 216213_at NEK1 0.004344 0.59 
30 217486_s_at ZDHHC17 0.0044159 0.67 
31 237205_at C14orf53 0.0044451 1.15 
32 238600_at JAKMIP1 0.0044965 1.31 
33 240827_at FLJ45983 0.0046887 0.78 
34 232318_s_at LOC121838 0.0047704 0.73 
35 1553756_at C9orf70 0.0049188 1.28 
36 231667_at SLC39A5 0.0049354 1.18 
37 223120_at FUCA2 0.0050835 0.93 
38 220947_s_at TBC1D10B 0.0052046 0.89 
39 222438_at MED4 0.0052299 0.82 
40 232001_at LOC439949 0.005269 1.93 
41 229542_at C20orf85 0.0054122 1.24 
42 217803_at GOLPH3 0.0054213 0.88 
43 224827_at UBTD2 0.0055323 0.89 
44 212185_x_at MT2A 0.0056176 1.1 
45 228621_at HFE2 0.0058128 0.87 
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46 205500_at C5 0.0062228 1.59 
47 204638_at ACP5 0.0062257 1.34 
48 203250_at RBM16 0.0062952 0.93 
49 224069_x_at P2RX2 0.0063464 1.3 
50 202371_at TCEAL4 0.0064324 0.81 
51 218171_at VPS4B 0.0065387 0.85 
52 236918_s_at LRRC34 0.0065704 1.6 
53 205553_s_at CSRP3 0.0065788 1.14 
54 1566363_at DNTT 0.0067486 0.78 
55 229860_x_at C4orf48 0.0069419 1.26 
56 203167_at TIMP2 0.0071573 1.26 
57 218529_at CD320 0.0071899 1.29 
58 204617_s_at ACD 0.0071951 1.21 
59 244119_at LOC283483 0.0073746 0.85 
60 223579_s_at APOB 0.0073762 1.12 
61 228154_at C19orf44 0.0074435 0.8 
62 1561232_at LOC100270680 0.007454 1.11 
63 230012_at C17orf44 0.007469 1.41 
64 209300_s_at NECAP1 0.0076702 0.87 
65 46142_at LMF1 0.007714 1.42 
66 1558795_at LOC728052 0.0079144 0.87 
67 222742_s_at RABL5 0.0081637 1.22 
68 238644_at MYSM1 0.0082074 0.74 
69 239585_at KAT2B 0.0084524 0.84 
70 223430_at SIK2 0.0084569 1.16 
71 208308_s_at GPI 0.008541 1.13 
72 225603_s_at C8orf83 0.0086517 0.83 
73 1555343_at MEGF10 0.0088899 1.29 
74 209523_at TAF2 0.0089522 0.86 
75 204548_at STAR 0.0089635 0.66 
76 215452_x_at SUMO4 0.0090376 0.89 
77 240784_at C7orf52 0.0090543 0.86 
78 1554801_at C5orf40 0.0094134 0.88 
79 207403_at IRS4 0.0095524 1.24 
80 203593_at CD2AP 0.0095917 0.87 
81 236283_x_at LOC646214 0.0096327 0.87 
82 206875_s_at SLK 0.0098347 0.87 
83 1559682_at TRIM16L 0.0099596 1.27 
84 221336_at ATOH1 0.0100868 0.9 
85 221220_s_at SCYL2 0.010151 0.68 
86 233681_at KRTAP3-3 0.0106159 0.87 
87 203614_at UTP14C 0.0112371 0.94 
88 206355_at GNAL 0.0113893 1.39 
89 221005_s_at PTDSS2 0.0115387 1.18 
90 210033_s_at SPAG6 0.0115842 0.7 
91 1570394_at XRN1 0.0115887 0.56 
92 203686_at MPG 0.0116844 1.17 
93 220022_at ZNF334 0.0119879 0.78 
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94 204992_s_at PFN2 0.012005 0.91 
95 201348_at GPX3 0.0122545 0.78 
96 220971_at IL25 0.0122726 0.85 
97 216551_x_at PLCG1 0.0122809 1.26 
98 235261_at UNC45B 0.0123232 1.25 
99 230993_s_at C6orf118 0.0123761 0.91 
100 234617_at OR52D1 0.0126402 0.85 
101 210406_s_at RAB6C 0.0127851 0.95 
102 1564974_at KRTAP8-1 0.0129876 1.21 
103 206842_at KCND1 0.0130475 0.86 
104 200661_at CTSA 0.0130818 1.19 
105 236033_at ASB12 0.0130968 0.83 
106 234226_at OPN4 0.0131863 0.9 
107 237056_at INSC 0.0132595 1.4 
108 223816_at SLC46A2 0.0133179 1.8 
109 1563685_at LOC285422 0.0133496 0.8 
110 222705_s_at SLC25A15 0.0134727 0.72 
111 227120_at FOXP4 0.0134956 1.33 
112 216380_x_at RPS28P6 0.0135994 1.13 
113 233353_at FER1L5 0.013662 1.28 
114 243683_at MORF4L2 0.0137011 0.46 
115 1557296_at FLJ12825 0.0139896 1.27 
116 244132_x_at ZNF518A 0.0140383 0.8 
117 1558622_a_at ZNF548 0.0140483 1.23 
118 203982_s_at ABCD4 0.0141782 1.19 
119 238978_at LMBRD2 0.0143239 0.7 
120 225193_at KIAA1967 0.0143674 0.75 
121 210057_at SMG1 0.0144536 0.71 
122 238833_at LOC729088 0.0144885 1.36 
123 231791_at ASAH2B 0.0146016 0.68 
124 202600_s_at NRIP1 0.0149217 0.71 
125 212682_s_at LMF2 0.015119 1.19 
126 1554882_at ERCC8 0.0152081 0.71 
127 241736_at FBXW2 0.0152111 0.74 
128 206427_s_at MLANA 0.0152622 1.16 
129 1553106_at C5orf24 0.0153748 0.75 
130 227946_at OSBPL7 0.0153901 1.76 
131 1564660_at LOC100131864 0.0154189 1.09 
132 213303_x_at ZBTB7A 0.0154385 1.13 
133 215244_at DGCR5 0.0157839 1.28 
134 209112_at CDKN1B 0.0158879 0.88 
135 209752_at REG1A 0.0159607 1.22 
136 229458_s_at GALK1 0.0161022 1.24 
137 208551_at HIST1H4G 0.0161741 0.85 
138 227617_at TMEM201 0.0161898 1.14 
139 232810_at AIG1 0.016286 0.73 
140 216088_s_at PSMA7 0.0163512 1.11 
141 206505_at UGT2B4 0.0163536 0.9 
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142 222259_s_at SPO11 0.0164153 1.16 
143 225024_at RPRD1B 0.0167583 0.88 
144 216921_s_at KRT35 0.0168356 1.15 
145 224252_s_at FXYD5 0.016973 1.19 
146 205775_at FAM50B 0.0170546 1.43 
147 214432_at ATP1A3 0.0171428 1.19 
148 214903_at SYT2 0.0171937 0.9 
149 1567060_at OR8G1 0.0173169 0.75 
150 238577_s_at TSHZ2 0.0173521 2.59 
151 237619_at C6orf146 0.01744 1.12 
152 209705_at MTF2 0.0175313 0.87 
153 216699_s_at KLK1 0.0177079 1.2 
154 228026_at RP5-1000E10.4 0.0177405 0.84 
155 32209_at FAM89B 0.0177597 1.2 
156 240521_at NCRNA00153 0.0178521 1.4 
157 232486_at LRFN1 0.0180814 1.14 
158 215959_at PPFIBP2 0.0182769 0.78 
159 241256_at LOC100131283 0.0183674 1.21 
160 206424_at CYP26A1 0.0184207 0.6 
161 1561384_a_at LOC284661 0.0185284 1.17 
162 223273_at C14orf142 0.0186446 0.8 
163 205140_at FPGT 0.0189011 0.84 
164 233344_x_at KIAA1875 0.0191119 0.86 
165 1564435_a_at KRT72 0.0191456 1.18 
166 223780_s_at MED13 0.0192048 0.68 
167 214161_at OSGIN2 0.0192178 0.76 
168 241599_at LSM11 0.0192427 1.5 
169 1562209_at WDR21B 0.0192807 0.75 
170 226617_at ARL5A 0.0196498 0.87 
171 227637_at TFCP2 0.0196867 0.76 
172 219695_at SMPD3 0.0200129 0.88 
173 208745_at ATP5L 0.0200659 0.88 
174 231783_at CHRM1 0.0202329 0.8 
175 225028_at LOC550643 0.0203 0.82 
176 214995_s_at APOBEC3F 0.0203374 1.25 
177 204382_at NAT9 0.0204292 1.11 
178 227005_at RPP14 0.0206063 0.87 
179 226390_at STARD4 0.0206713 0.9 
180 1557146_a_at LOC146336 0.0207754 0.87 
181 200943_at HMGN1 0.0208001 0.9 
182 219273_at CCNK 0.0208133 0.73 
183 1553246_a_at SGK196 0.0210413 0.77 
184 220217_x_at SPANXC 0.0211315 1.13 
185 219443_at TASP1 0.0213244 0.8 
186 242685_at GTPBP8 0.0214123 0.77 
187 209361_s_at PCBP4 0.0215662 1.39 
188 217269_s_at PRSS7 0.0215683 1.34 
189 230418_s_at GALNTL1 0.021664 1.21 
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190 206080_at PLCH2 0.021834 1.15 
191 206358_at PRM1 0.0219524 1.19 
192 206872_at SLC17A1 0.0220032 1.08 
193 223754_at MGC13057 0.0220641 0.72 
194 215790_at AJAP1 0.0220801 1.31 
195 1552751_a_at CIB3 0.0221359 0.82 
196 1560932_at FLJ31356 0.0222339 0.66 
197 232039_at KIAA1383 0.0222371 0.85 
198 212440_at SNRNP27 0.0224666 0.92 
199 223752_at CFC1 0.02253 1.17 
200 220223_at ATAD5 0.0227945 1.27 
201 223506_at ZC3H8 0.022919 0.87 
202 238163_at LOC100133229 0.0231235 1.18 
203 1566524_a_at hCG_1986447 0.0231327 0.68 
204 206605_at P11 0.023154 0.64 
205 208093_s_at NDEL1 0.0237543 0.95 
206 206967_at CCNT1 0.0239101 0.78 
207 205948_at PTPRT 0.0239316 1.26 
208 1552602_at CACNG5 0.0240234 0.78 
209 209323_at PRKRIR 0.0240316 0.92 
210 232291_at MIRHG1 0.0240519 0.85 
211 205765_at CYP3A5 0.0241927 0.9 
212 244672_at WDR1 0.0242403 0.85 
213 203413_at NELL2 0.0242406 0.83 
214 1555330_at GCLC 0.0243718 0.76 
215 1564166_s_at PRKRIP1 0.024386 0.65 
216 223330_s_at SUGT1 0.0245407 0.82 
217 206151_x_at ELA3B 0.024579 1.14 
218 205350_at CRABP1 0.0246988 1.42 
219 226268_at RAB21 0.0247677 0.87 
220 213838_at NOL7 0.024782 0.83 
221 233229_at SCFD1 0.0251655 0.7 
222 237449_at SP8 0.0251984 0.65 
223 228139_at RIPK3 0.0252366 1.32 
224 212844_at RRP1B 0.025475 0.87 
225 238586_at LOC731489 0.025525 1.11 
226 210454_s_at KCNJ6 0.0255429 1.37 
227 208548_at IFNA6 0.0255546 1.17 
228 220627_at CST8 0.0258015 1.22 
229 236514_at ACOT8 0.0258242 0.8 
230 238893_at LOC338758 0.0258614 1.49 
231 209593_s_at TOR1B 0.0258656 1.07 
232 243362_s_at LOC641518 0.0258671 1.41 
233 219171_s_at ZNF236 0.025871 0.78 
234 221641_s_at ACOT9 0.0261025 1.07 
235 238135_at AGTRAP 0.0261472 0.8 
236 226167_at SYT7 0.0261505 1.36 
237 205475_at SCRG1 0.0263258 2 
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238 34225_at WHSC2 0.026431 0.84 
239 1563581_at LOC285456 0.0264972 1.32 
240 1553314_a_at KIF19 0.0265424 0.85 
241 220224_at HAO1 0.0265452 0.86 
242 226800_at EFCAB7 0.0265954 0.87 
243 1555238_at PTH2 0.0266333 1.13 
244 229566_at LOC645638 0.0266682 0.73 
245 216607_s_at CYP51A1 0.0267076 1.33 
246 209937_at TM4SF4 0.0267185 1.23 
247 241779_at MTX3 0.0268559 0.77 
248 238016_s_at LOC100129105 0.0268726 1.1 
249 201574_at ETF1 0.0270324 0.91 
250 232907_at UBR4 0.0270394 0.69 
251 1562966_at KIAA1217 0.027046 0.6 
252 229094_at LOC401431 0.0270462 1.22 
253 226962_at ZBTB41 0.0270543 0.82 
254 227365_at ATCAY 0.0273438 0.93 
255 230763_at SPATA17 0.0273701 0.61 
256 231731_at OTX2 0.0274355 0.88 
257 218760_at COQ6 0.0276837 1.11 
258 205364_at ACOX2 0.0277763 1.61 
259 225235_at TSPAN17 0.0277944 1.17 
260 1554339_a_at COG3 0.0279185 0.72 
261 225580_at MRPL50 0.0279466 0.85 
262 208440_at C3orf27 0.0280131 1.15 
263 208578_at SCN10A 0.0280748 1.2 
264 218174_s_at C10orf57 0.0281064 0.84 
265 227358_at ZBTB46 0.0281615 1.24 
266 235310_at GCET2 0.028259 0.79 
267 1558027_s_at PRKAB2 0.0282756 0.88 
268 237721_s_at ASB4 0.0283536 1.58 
269 205911_at PTH1R 0.0283936 1.28 
270 234979_at BCDIN3D 0.0284326 0.81 
271 233532_x_at IFT52 0.0285195 1.19 
272 208040_s_at MYBPC3 0.0287075 0.89 
273 220235_s_at C1orf103 0.0287579 0.77 
274 239492_at SEC14L4 0.0287998 1.4 
275 230839_at PRMT8 0.0289504 1.16 
276 209668_x_at CES2 0.0292073 1.13 
277 204951_at RHOH 0.0292183 1.62 
278 211646_at LOC100126583 0.0295025 0.88 
279 203924_at GSTA2 0.0295472 1.3 
280 218297_at C10orf97 0.0295589 0.84 
281 208953_at LARP5 0.0296576 0.84 
282 214411_x_at CTRB2 0.0297295 0.79 
283 207844_at IL13 0.0297325 0.86 
284 1553193_at ZNF441 0.0303803 0.73 
285 210753_s_at EPHB1 0.0303997 1.47 
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286 229422_at NRD1 0.0304688 0.71 
287 200627_at PTGES3 0.030551 0.93 
288 231765_at ZFYVE20 0.030568 1.25 
289 242284_at LOC199899 0.0305789 1.21 
290 203965_at USP20 0.0305844 1.14 
291 219916_s_at RNF39 0.0306563 1.32 
292 212339_at EPB41L1 0.0307202 1.18 
293 206578_at NKX2-5 0.0307973 1.21 
294 216460_at FLJ00049 0.030816 1.23 
295 210873_x_at APOBEC3A 0.0308197 1.11 
296 1559561_at FBXO18 0.0308873 1.18 
297 206411_s_at ABL2 0.0309285 1.36 
298 1564000_at ANKRD31 0.031043 0.84 
299 238061_at LGI3 0.0310584 0.83 
300 235588_at ESCO2 0.0314097 1.7 
301 210556_at NFATC3 0.0317492 1.39 
302 242441_at LOC646548 0.0318012 0.88 
303 221966_at GPR137 0.0318496 0.86 
304 227720_at ANKRD13B 0.032017 1.33 
305 244175_at RP3-439I14.1 0.0320294 1.11 
306 205271_s_at CCRK 0.0320322 0.84 
307 244198_at RANBP17 0.0320327 0.6 
308 1556266_a_at LOC400831 0.0320601 1.34 
309 243916_x_at UBLCP1 0.0321357 0.89 
310 227601_at METTL14 0.0323088 0.88 
311 230141_at ARID4A 0.0323968 0.82 
312 232570_s_at ADAM33 0.0324026 1.7 
313 1553191_at DST 0.0326154 0.71 
314 208259_x_at IFNA7 0.0326415 0.87 
315 215112_x_at MCF2L2 0.0326861 1.11 
316 218299_at C11orf24 0.0327883 1.13 
317 220077_at CCDC134 0.0328582 1.14 
318 234025_at LOC100129890 0.0329924 1.28 
319 223928_s_at GUCA1C 0.0331593 0.85 
320 235866_at C9orf85 0.033266 0.72 
321 228782_at SCGB3A2 0.0333221 0.88 
322 215324_at SEMA3D 0.0333565 0.84 
323 228001_at TMEM50B 0.0334288 1.2 
324 201822_at TIMM17A 0.0334318 0.74 
325 243268_at PATE2 0.0337116 0.85 
326 222792_s_at CCDC59 0.0337128 1.16 
327 230136_at LOC400099 0.0337718 0.8 
328 219833_s_at EFHC1 0.0338373 1.24 
329 242883_at OTOS 0.0338653 0.91 
330 217620_s_at PIK3CB 0.0338695 0.7 
331 1556133_s_at LOC100169752 0.0338836 1.12 
332 204501_at NOV 0.0339183 1.18 
333 237120_at KRT77 0.0339548 1.05 
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334 233171_at GRIN3A 0.0340149 0.84 
335 224846_at SHKBP1 0.0340186 1.16 
336 213322_at C6orf130 0.0340868 0.89 
337 224110_at LOC100133319 0.0342204 1.49 
338 242210_at ZNF24 0.034362 0.78 
339 236421_at ANKRD45 0.0343994 0.86 
340 239198_at EZH1 0.0345462 0.75 
341 237513_at TRYX3 0.0346088 0.9 
342 205044_at GABRP 0.0346971 0.81 
343 1567238_at OR2L2 0.0349928 0.77 
344 1553822_at RTP1 0.035195 1.21 
345 217515_s_at CACNA1S 0.0352024 0.87 
346 212160_at XPOT 0.0352788 0.89 
347 1569436_at LOC400128 0.0353156 1.38 
348 204030_s_at SCHIP1 0.0355554 0.91 
349 233913_at WFDC10A 0.035772 0.78 
350 205029_s_at FABP7 0.0359774 0.8 
351 235707_at LOC221710 0.0360783 0.74 
352 1552990_at LOC100133695 0.0363598 0.81 
353 239143_x_at RNF138 0.0363651 0.69 
354 218861_at RNF25 0.0367013 1.15 
355 215491_at MYCL1 0.0368251 0.62 
356 214554_at HIST1H2AL 0.0368598 1.22 
357 216937_s_at RS1 0.0369858 0.76 
358 219101_x_at ABHD8 0.0370082 0.9 
359 206612_at CACNG1 0.0370709 0.85 
360 200025_s_at RPL27 0.0370973 0.96 
361 243927_x_at KIAA1429 0.0371189 0.86 
362 1558584_at UBL4B 0.0371305 0.85 
363 1563696_at HSD17B4 0.0375333 0.83 
364 224436_s_at NIPSNAP3A 0.0376867 0.81 
365 1556472_s_at SCML4 0.0377806 1.13 
366 222949_at NXF3 0.0378359 0.86 
367 220186_s_at PCDH24 0.0379349 1.14 
368 222825_at OTUD6B 0.0379432 0.84 
369 231403_at TRIO 0.0380465 0.81 
370 1570006_at LOC400958 0.0380896 1.33 
371 204936_at MAP4K2 0.0381501 1.19 
372 237493_at IL22RA2 0.0382551 1.16 
373 231719_at IFRG15 0.0383874 0.67 
374 224311_s_at CAB39 0.0384198 0.86 
375 205984_at CRHBP 0.0385009 1.31 
376 219632_s_at TRPV1 0.0385879 1.25 
377 224242_at GALP 0.0386116 1.12 
378 223030_at TRAF7 0.0386461 0.84 
379 218164_at SPATA20 0.0387422 1.31 
380 217378_x_at LOC100130100 0.0389593 1.11 
381 226654_at MUC12 0.038983 1.34 
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382 225949_at NRBP2 0.0389924 1.31 
383 217731_s_at ITM2B 0.0390139 0.91 
384 207694_at POU3F4 0.0392589 1.14 
385 211339_s_at ITK 0.0392954 0.87 
386 223740_at C6orf59 0.0393114 1.15 
387 1562388_at LOC285819 0.0393585 1.11 
388 219345_at BOLA1 0.0393812 1.23 
389 224678_at KIAA1219 0.0394098 0.88 
390 220116_at KCNN2 0.0394641 1.56 
391 202941_at NDUFV2 0.0395118 1.07 
392 1560147_at LOC100131176 0.0395294 1.19 
393 203749_s_at RARA 0.0395419 1.3 
394 235469_at FAM133B 0.0395577 0.76 
395 1557571_at VPS13D 0.0397487 1.18 
396 230341_x_at ADAMTS10 0.0397793 1.4 
397 1559627_at LOC285941 0.0398172 1.12 
398 1556200_a_at C10orf90 0.0398429 0.59 
399 203253_s_at HISPPD1 0.0398832 0.87 
400 213589_s_at B3GNTL1 0.0399597 1.44 
401 205716_at SLC25A40 0.0399974 0.81 
402 205839_s_at BZRAP1 0.0400035 1.42 
403 210720_s_at NECAB3 0.0400495 1.28 
404 211147_s_at P2RX6 0.0403632 0.77 
405 215503_at SPINT3 0.0403652 0.88 
406 1560806_at LOC150527 0.0405062 1.29 
407 207849_at IL2 0.0405218 1.11 
408 220972_s_at KRTAP9-9 0.0406294 0.92 
409 210175_at C2orf3 0.0406319 0.69 
410 204611_s_at PPP2R5B 0.0406393 1.29 
411 232373_at NOXA1 0.0406835 1.08 
412 239243_at ZNF638 0.0407022 0.64 
413 211116_at SLC9A2 0.040738 1.17 
414 231068_at SLC47A2 0.0407413 1.09 
415 208479_at KCNA1 0.0408819 1.24 
416 237288_at TGM7 0.0409264 0.87 
417 223398_at C9orf89 0.0409987 1.16 
418 209497_s_at RBM4B 0.0410305 0.93 
419 1570128_at DDX19A 0.0411041 0.84 
420 244694_at IGLON5 0.0411146 1.45 
421 222040_at LOC728844 0.0411901 0.84 
422 225607_at CCDC43 0.0412916 0.93 
423 219359_at ATHL1 0.0412942 1.6 
424 1558292_s_at PIGW 0.0413222 0.83 
425 232143_at DNM1P41 0.0413762 1.26 
426 213526_s_at LIN37 0.0413856 1.11 
427 225844_at POLE4 0.0413904 1.15 
428 225455_at TADA1L 0.0414091 0.85 
429 238149_at ZNF818P 0.0414375 0.73 
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430 207557_s_at RYR2 0.0415176 1.48 
431 221240_s_at B3GNT4 0.0415369 1.23 
432 1564386_at TXNDC8 0.041683 0.85 
433 241955_at HECTD1 0.0418456 0.77 
434 219369_s_at OTUB2 0.0420378 0.75 
435 225277_at SLC39A13 0.042045 1.16 
436 212589_at RRAS2 0.0420794 0.86 
437 220573_at KLK14 0.0422841 0.86 
438 239802_at SAP30L 0.0423883 0.75 
439 221392_at TAS2R4 0.0423904 0.76 
440 1555240_s_at GNG12 0.042565 0.78 
441 218103_at FTSJ3 0.0425963 1.09 
442 232366_at KIAA0232 0.0426389 0.78 
443 205720_at POMC 0.042663 0.85 
444 207021_at ZPBP 0.0428135 1.1 
445 224553_s_at TNFRSF18 0.0429597 0.81 
446 209151_x_at TCF3 0.0429873 1.24 
447 219095_at JMJD7-
PLA2G4B 
0.0431288 1.17 
448 243311_at DEFB132 0.0431385 0.9 
449 219730_at MED18 0.0432211 1.2 
450 1563137_at MGAT5B 0.0432279 0.87 
451 1554875_at C2orf34 0.0432354 0.6 
452 214226_at POL3S 0.0434023 1.22 
453 216176_at HCRP1 0.0434029 1.77 
454 1554916_a_at JRK 0.043474 0.67 
455 211152_s_at HTRA2 0.0437694 1.09 
456 225076_s_at ZNFX1 0.0437904 1.21 
457 226325_at ADSSL1 0.0438138 1.25 
458 241963_at ZNF704 0.0439061 1.33 
459 229690_at FAM109A 0.0439114 1.15 
460 205447_s_at MAP3K12 0.0439787 1.91 
461 218458_at GMCL1 0.0440709 0.81 
462 207830_s_at PPP1R8 0.0441136 0.95 
463 222759_at SUV420H1 0.0443464 0.82 
464 203765_at GCA 0.0444953 0.85 
465 237021_at LOC144486 0.0445005 1.15 
466 207972_at GLRA1 0.044605 1.17 
467 226493_at KCTD18 0.0447031 0.71 
468 235619_at LOC285986 0.0447732 1.33 
469 202957_at HCLS1 0.0448217 0.9 
470 231197_at PPP1R3F 0.0449499 0.8 
471 228384_s_at C10orf33 0.0451921 1.53 
472 215567_at FCF1 0.0453041 0.88 
473 208244_at BMP3 0.0454621 1.15 
474 222817_at HSD3B7 0.0454939 1.15 
475 201467_s_at NQO1 0.0455492 1.4 
476 230076_at PITPNM3 0.0455623 1.23 
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477 208843_s_at GORASP2 0.0455965 0.83 
478 239894_at LOC100128511 0.0456483 0.82 
479 1561169_at LOC727818 0.0456823 1.2 
480 1555947_at FAM120A 0.0457091 0.71 
481 1553267_a_at CNOT6L 0.0457881 0.68 
482 234903_at OR2B3 0.0459378 0.89 
483 213866_at SAMD14 0.0459837 1.43 
484 219011_at PLEKHA4 0.0460468 1.41 
485 1562591_a_at OFCC1 0.0461233 1.62 
486 1565728_at LOC284630 0.0461407 1.18 
487 206915_at NKX2-2 0.0462666 1.18 
488 228880_at LOC339984 0.0465128 0.8 
489 220007_at METTL8 0.0465492 0.76 
490 223823_at KCNMB2 0.0465625 0.76 
491 218513_at C4orf43 0.0466076 0.84 
492 1553525_at NLRP13 0.0466533 1.4 
493 212713_at MFAP4 0.0467887 2.8 
494 1557864_x_at LOC100129266 0.0467995 1.31 
495 229451_at GALNT9 0.0468526 1.11 
496 1564785_at LOC196913 0.0468907 1.11 
497 211170_s_at PDE10A 0.0469142 0.55 
498 242200_at ADAMTSL5 0.0470495 1.27 
499 218745_x_at TMEM161A 0.047207 1.21 
500 1569974_x_at SEP13 0.0472981 1.14 
501 212391_x_at LOC100130107 0.0473749 0.97 
502 202412_s_at USP1 0.0474036 0.78 
503 229399_at C10orf118 0.0475045 0.81 
504 236055_at DQX1 0.0475116 0.67 
505 210380_s_at CACNA1G 0.0475193 1.29 
506 220347_at SMG6 0.0475337 1.2 
507 203983_at TSNAX 0.047564 0.94 
508 1553558_at TAS2R41 0.047615 1.23 
509 219751_at SETD6 0.0476513 0.79 
510 1554309_at EIF4G3 0.0478381 0.74 
511 242427_at WAC 0.0478621 0.88 
512 236675_at RPA1 0.0478876 0.71 
513 222220_s_at TSNAXIP1 0.0478912 1.25 
514 213200_at SYP 0.0479142 1.4 
515 1569468_at ZNF732 0.0479338 0.84 
516 231070_at IYD 0.0479356 1.13 
517 206020_at SOCS6 0.0479646 0.88 
518 1559252_a_at C20orf29 0.0479771 1.31 
519 227325_at LOC255783 0.0480529 1.23 
520 225754_at AP1G1 0.0481797 0.88 
521 230759_at SNX14 0.0482163 0.91 
522 218677_at S100A14 0.0483573 0.72 
523 218411_s_at MBIP 0.0483993 0.89 
524 235129_at PPP1R1A 0.0484194 1.31 
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525 221456_at TAS2R3 0.0488843 1.12 
526 210119_at KCNJ15 0.0489331 1.95 
527 209064_x_at PAIP1 0.0489473 0.83 
528 213611_at AQP5 0.0489659 0.86 
529 1555757_at C7orf34 0.0489967 0.9 
530 1552594_at TMEM190 0.0490474 1.23 
531 205014_at FGFBP1 0.04912 0.8 
532 204873_at PEX1 0.049123 0.8 
533 225883_at ATG16L2 0.0492266 1.33 
534 1554794_a_at UBE3C 0.0492977 1.27 
535 237002_at NCDN 0.0493018 1.16 
536 214237_x_at LOC100133105 0.0493116 1.21 
537 1568690_a_at LOC728853 0.0495655 0.88 
538 239594_at LOC145837 0.0496205 1.21 
539 202393_s_at KLF10 0.0498015 0.91 
540 226346_at MEX3A 0.0499647 1.42 
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Appendix 6: Up-regulated HSPE Genes 
Gene Symbol Gene Name EntrezGene Ensembl 
ACTR3 ARP3 actin-related protein 3 homolog (yeast) 10096 ENSG00000115091 
ADAR adenosine deaminase, RNA-specific 103 ENSG00000160710 
AFF1 AF4/FMR2 family, member 1 4299 ENSG00000172493 
AIDA axin interactor, dorsalization associated 64853 ENSG00000186063 
ANXA3 annexin A3 306 ENSG00000138772 
ANXA8L2 annexin A8-like 2 244 ENSG00000186807 
APP amyloid beta (A4) precursor protein 351 ENSG00000142192 
ARF1 ADP-ribosylation factor 1 375 ENSG00000143761 
ARPC4 actin related protein 2/3 complex, subunit 4, 20kDa 10093 ENSG00000241553 
ATP1B3 ATPase, Na+/K+ transporting, beta 3 polypeptide 483 ENSG00000069849 
ATP2A2 ATPase, Ca++ transporting, cardiac muscle, slow twitch 
2 
488 ENSG00000174437 
ATP6V1D ATPase, H+ transporting, lysosomal 34kDa, V1 subunit D 51382 ENSG00000100554 
BZW1 basic leucine zipper and W2 domains 1 9689 ENSG00000082153 
C15orf48 chromosome 15 open reading frame 48 84419 ENSG00000166920 
CALD1 caldesmon 1 800 ENSG00000122786 
CCDC6 coiled-coil domain containing 6 8030 ENSG00000108091 
CCND2 cyclin D2 894 ENSG00000118971 
CCT3 chaperonin containing TCP1, subunit 3 (gamma) 7203 ENSG00000163468 
CD164 CD164 molecule, sialomucin 8763 ENSG00000135535 
CDC42 cell division cycle 42 (GTP binding protein, 25kDa) 998 ENSG00000070831 
CDKN1A cyclin-dependent kinase inhibitor 1A (p21, Cip1) 1026 ENSG00000124762 
CKAP4 cytoskeleton-associated protein 4 10970 ENSG00000136026 
CLDND1 claudin domain containing 1 56650 ENSG00000080822 
CMTM6 CKLF-like MARVEL transmembrane domain containing 6 54918 ENSG00000091317 
COX7B cytochrome c oxidase subunit VIIb 1349 ENSG00000131174 
CYR61 cysteine-rich, angiogenic inducer, 61 3491 ENSG00000142871 
DEK DEK oncogene 7913 ENSG00000124795 
DLG5 discs, large homolog 5 (Drosophila) 9231 ENSG00000151208 
DNAJB6 DnaJ (Hsp40) homolog, subfamily B, member 6 10049 ENSG00000105993 
DYNLRB1 dynein, light chain, roadblock-type 1 83658 ENSG00000125971 
EGR1 early growth response 1 1958 ENSG00000120738 
ERGIC1 endoplasmic reticulum-golgi intermediate compartment 
(ERGIC) 1 
57222 ENSG00000113719 
ERP29 endoplasmic reticulum protein 29 10961 ENSG00000089248 
ETV5 ets variant 5 2119 ENSG00000244405 
FCER1G Fc fragment of IgE, high affinity I, receptor for; gamma 
polypeptide 
2207 ENSG00000158869 
FDFT1 farnesyl-diphosphate farnesyltransferase 1 2222 ENSG00000079459 
FLNB filamin B, beta 2317 ENSG00000136068 
GABARAP GABA(A) receptor-associated protein 11337 ENSG00000170296 
GJA1 gap junction protein, alpha 1, 43kDa 2697 ENSG00000152661 
H2AFY H2A histone family, member Y 9555 ENSG00000113648 
H3F3B H3 histone, family 3B (H3.3B) 3021 ENSG00000132475 
HDGF hepatoma-derived growth factor 3068 ENSG00000143321 
HMGB3 high mobility group box 3 3149 ENSG00000029993 
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HN1 hematological and neurological expressed 1 51155 ENSG00000189159 
HNRNPA3 heterogeneous nuclear ribonucleoprotein A3 220988 ENSG00000170144 
HNRNPH3 heterogeneous nuclear ribonucleoprotein H3 (2H9) 3189 ENSG00000096746 
HNRNPM heterogeneous nuclear ribonucleoprotein M 4670 ENSG00000099783 
HNRPDL heterogeneous nuclear ribonucleoprotein D-like 9987 ENSG00000152795 
HSPA1A heat shock 70kDa protein 1A 3303 ENSG00000204389 
IER2 immediate early response 2 9592 ENSG00000160888 
IL24 interleukin 24 11009 ENSG00000162892 
INHBC inhibin, beta C 3626 ENSG00000175189 
INSR insulin receptor 3643 ENSG00000171105 
IRS2 insulin receptor substrate 2 8660 ENSG00000185950 
ITGA6 integrin, alpha 6 3655 ENSG00000091409 
ITPRIPL2 inositol 1,4,5-trisphosphate receptor interacting 
protein-like 2 
162073 ENSG00000205730 
KARS lysyl-tRNA synthetase 3735 ENSG00000065427 
KHDRBS1 KH domain containing, RNA binding, signal transduction 
associated 1 
10657 ENSG00000121774 
KIF5B kinesin family member 5B 3799 ENSG00000170759 
LARP1 La ribonucleoprotein domain family, member 1 23367 ENSG00000155506 
LDHB lactate dehydrogenase B 3945 ENSG00000111716 
LGALS3 lectin, galactoside-binding, soluble, 3 3958 ENSG00000131981 
LHFPL2 lipoma HMGIC fusion partner-like 2 10184 ENSG00000145685 
LSM4 LSM4 homolog, U6 small nuclear RNA associated (S. 
cerevisiae) 
25804 ENSG00000130520 
MAP1LC3B microtubule-associated protein 1 light chain 3 beta 81631 ENSG00000140941 
MATR3 matrin 3 9782 ENSG00000015479 
MCL1 myeloid cell leukemia sequence 1 (BCL2-related) 4170 ENSG00000143384 
MGEA5 meningioma expressed antigen 5 (hyaluronidase) 10724 ENSG00000198408 
MLLT4 myeloid/lymphoid or mixed-lineage leukemia (trithorax 
homolog, Drosophila); translocated to, 4 
4301 ENSG00000130396 
MPRIP myosin phosphatase Rho interacting protein 23164 ENSG00000133030 
MRC1 mannose receptor, C type 1 4360 ENSG00000120586 
MRFAP1L1 Morf4 family associated protein 1-like 1 114932 ENSG00000178988 
MTPN myotrophin 136319 ENSG00000105887 
MYADM myeloid-associated differentiation marker 91663 ENSG00000179820 
NDUFB4 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 
4, 15kDa 
4710 ENSG00000065518 
NHP2L1 NHP2 non-histone chromosome protein 2-like 1 (S. 
cerevisiae) 
4809 ENSG00000100138 
NPTN neuroplastin 27020 ENSG00000156642 
NUB1 negative regulator of ubiquitin-like proteins 1 51667 ENSG00000013374 
NUCKS1 nuclear casein kinase and cyclin-dependent kinase 
substrate 1 
64710 ENSG00000069275 
OXSR1 oxidative-stress responsive 1 9943 ENSG00000172939 
PAFAH1B1 platelet-activating factor acetylhydrolase 1b, regulatory 
subunit 1 (45kDa) 
5048 ENSG00000007168 
PALLD palladin, cytoskeletal associated protein 23022 ENSG00000129116 
PDCD4 programmed cell death 4 (neoplastic transformation 
inhibitor) 
27250 ENSG00000150593 
 174 
PDGFA platelet-derived growth factor alpha polypeptide 5154 ENSG00000197461 
PDIA3 protein disulfide isomerase family A, member 3 2923 ENSG00000167004 
PDIA4 protein disulfide isomerase family A, member 4 9601 ENSG00000155660 
PFN2 profilin 2 5217 ENSG00000070087 
PGAM1 phosphoglycerate mutase 1 (brain) 5223 ENSG00000171314 
PHLDB2 pleckstrin homology-like domain, family B, member 2 90102 ENSG00000144824 
PICALM phosphatidylinositol binding clathrin assembly protein 8301 ENSG00000073921 
PIP4K2C phosphatidylinositol-5-phosphate 4-kinase, type II, 
gamma 
79837 ENSG00000166908 
POLR2B polymerase (RNA) II (DNA directed) polypeptide B, 
140kDa 
5431 ENSG00000047315 
PPIC peptidylprolyl isomerase C (cyclophilin C) 5480 ENSG00000168938 
PSMA2 proteasome (prosome, macropain) subunit, alpha type, 
2 
5683 ENSG00000106588,ENSG00000256646 
PSMD14 proteasome (prosome, macropain) 26S subunit, non-
ATPase, 14 
10213 ENSG00000115233 
PSMD4 proteasome (prosome, macropain) 26S subunit, non-
ATPase, 4 
5710 ENSG00000159352 
PSME4 proteasome (prosome, macropain) activator subunit 4 23198 ENSG00000068878 
PTGES prostaglandin E synthase 9536 ENSG00000148344 
PTGS2 prostaglandin-endoperoxide synthase 2 (prostaglandin 
G/H synthase and cyclooxygenase) 
5743 ENSG00000073756 
PURB purine-rich element binding protein B 5814 ENSG00000146676 
RAB1A RAB1A, member RAS oncogene family 5861 ENSG00000138069 
RALA v-ral simian leukemia viral oncogene homolog A (ras 
related) 
5898 ENSG00000006451 
RAN RAN, member RAS oncogene family 5901 ENSG00000132341 
RAP2A RAP2A, member of RAS oncogene family 5911 ENSG00000125249 
RBM39 RNA binding motif protein 39 9584 ENSG00000131051 
RBMS1 RNA binding motif, single stranded interacting protein 1 5937 ENSG00000153250 
RCAN1 regulator of calcineurin 1 1827 ENSG00000159200 
RDH10 retinol dehydrogenase 10 (all-trans) 157506 ENSG00000121039 
RPS21 ribosomal protein S21 6227 ENSG00000171858 
RREB1 ras responsive element binding protein 1 6239 ENSG00000124782 
RSL24D1 ribosomal L24 domain containing 1 51187 ENSG00000137876 
SAR1A SAR1 homolog A (S. cerevisiae) 56681 ENSG00000079332 
SEC13 SEC13 homolog (S. cerevisiae) 6396 ENSG00000157020 
SEPT2 septin 2 4735 ENSG00000168385 
SF3B14 splicing factor 3B, 14 kDa subunit 51639 ENSG00000115128 
SFPQ splicing factor proline/glutamine-rich 6421 ENSG00000116560 
SKP1 S-phase kinase-associated protein 1 6500 ENSG00000113558 
SKP2 S-phase kinase-associated protein 2, E3 ubiquitin 
protein ligase 
6502 ENSG00000145604 
SNRPE small nuclear ribonucleoprotein polypeptide E 6635 ENSG00000182004 
SNX3 sorting nexin 3 8724 ENSG00000112335 
SSB Sjogren syndrome antigen B (autoantigen La) 6741 ENSG00000138385 
SSR1 signal sequence receptor, alpha 6745 ENSG00000124783 
SSR2 signal sequence receptor, beta (translocon-associated 
protein beta) 
6746 ENSG00000163479 
 175 
STAT2 signal transducer and activator of transcription 2, 
113kDa 
6773 ENSG00000170581 
STC1 stanniocalcin 1 6781 ENSG00000159167 
SYNCRIP synaptotagmin binding, cytoplasmic RNA interacting 
protein 
10492 ENSG00000135316 
TALDO1 transaldolase 1 6888 ENSG00000177156 
TAPBP TAP binding protein (tapasin) 6892 ENSG00000231925 
TARS threonyl-tRNA synthetase 6897 ENSG00000113407 
TAX1BP3 Tax1 (human T-cell leukemia virus type I) binding 
protein 3 
30851 ENSG00000213977 
TFAP2A transcription factor AP-2 alpha (activating enhancer 
binding protein 2 alpha) 
7020 ENSG00000137203 
TJP1 tight junction protein 1 7082 ENSG00000104067 
TM2D3 TM2 domain containing 3 80213 ENSG00000184277 
TPBG trophoblast glycoprotein 7162 ENSG00000146242 
TPM2 tropomyosin 2 (beta) 7169 ENSG00000198467 
TPM4 tropomyosin 4 7171 ENSG00000167460 
TRIM8 tripartite motif containing 8 81603 ENSG00000171206 
TSPAN13 tetraspanin 13 27075 ENSG00000106537 
TUBB6 tubulin, beta 6 class V 84617 ENSG00000176014 
TXNL1 thioredoxin-like 1 9352 ENSG00000091164 
U2AF1 U2 small nuclear RNA auxiliary factor 1 7307 ENSG00000160201 
UBE2D3 ubiquitin-conjugating enzyme E2D 3 7323 ENSG00000109332 
VCAN versican 1462 ENSG00000038427 
YTHDC1 YTH domain containing 1 91746 ENSG00000083896 
YTHDF2 YTH domain family, member 2 51441 ENSG00000198492 
ZBTB4 zinc finger and BTB domain containing 4 57659 ENSG00000174282 
ZFAND6 zinc finger, AN1-type domain 6 54469 ENSG00000086666 
ZFP36L1 zinc finger protein 36, C3H type-like 1 677 ENSG00000185650 
    
HSPE = Histamine Specific genes in PE (elevated histamine regulated significant genes also expressed 
consistently in PE placentae); PE = Pre-eclampsia 
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Appendix 7: Down-Regulated HSPE genes 
Gene Symbol Gene Name EntrezGene Ensembl 
ABCB5 ATP-binding cassette, sub-family B (MDR/TAP), member 5 340273 ENSG00000004846 
ABRA actin-binding Rho activating protein 137735 ENSG00000174429 
ACSM2B acyl-CoA synthetase medium-chain family member 2B 348158 ENSG00000066813 
ADCYAP1R1 adenylate cyclase activating polypeptide 1 (pituitary) 
receptor type I 
117 ENSG00000078549 
APOF apolipoprotein F 319 ENSG00000175336 
ARG1 arginase, liver 383 ENSG00000118520 
ASB12 ankyrin repeat and SOCS box containing 12 142689 ENSG00000198881 
ASB5 ankyrin repeat and SOCS box containing 5 140458 ENSG00000164122 
B3GALT2 UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, 
polypeptide 2 
8707 ENSG00000162630 
BCL2L14 BCL2-like 14 (apoptosis facilitator) 79370 ENSG00000121380 
C12orf40 chromosome 12 open reading frame 40 283461 ENSG00000180116 
C14orf39 chromosome 14 open reading frame 39 317761 ENSG00000179008 
C15orf43 chromosome 15 open reading frame 43 145645 ENSG00000167014 
C1orf110 chromosome 1 open reading frame 110 339512 ENSG00000185860 
C3orf15 chromosome 3 open reading frame 15 89876 ENSG00000183833 
C6orf10 chromosome 6 open reading frame 10 10665 ENSG00000204296 
C8orf34 chromosome 8 open reading frame 34 116328 ENSG00000165084 
CA6 carbonic anhydrase VI 765 ENSG00000131686 
CADPS Ca++-dependent secretion activator 8618 ENSG00000163618 
CCDC67 coiled-coil domain containing 67 159989 ENSG00000165325 
CFTR cystic fibrosis transmembrane conductance regulator 
(ATP-binding cassette sub-family C, member 7) 
1080 ENSG00000001626 
CNBD1 cyclic nucleotide binding domain containing 1 168975 ENSG00000176571 
CNTNAP4 contactin associated protein-like 4 85445 ENSG00000152910 
CNTNAP5 contactin associated protein-like 5 129684 ENSG00000155052 
CPEB2 cytoplasmic polyadenylation element binding protein 2 132864 ENSG00000137449 
CRB1 crumbs homolog 1 (Drosophila) 23418 ENSG00000134376 
CRYGB crystallin, gamma B 1419 ENSG00000182187 
CSN2 casein beta 1447 ENSG00000135222 
DEFB126 defensin, beta 126 81623 NA 
EFCAB6 EF-hand calcium binding domain 6 64800 ENSG00000186976 
EMCN endomucin 51705 ENSG00000164035 
ENAM enamelin 10117 ENSG00000132464 
ESRRB estrogen-related receptor beta 2103 ENSG00000119715 
FABP6 fatty acid binding protein 6, ileal 2172 ENSG00000170231 
FCRL5 Fc receptor-like 5 83416 ENSG00000143297 
FLG filaggrin 2312 ENSG00000143631 
FOXA1 forkhead box A1 3169 ENSG00000129514 
FSTL5 follistatin-like 5 56884 ENSG00000168843 
GC group-specific component (vitamin D binding protein) 2638 ENSG00000145321 
GCM2 glial cells missing homolog 2 (Drosophila) 9247 ENSG00000124827 
GLRA3 glycine receptor, alpha 3 8001 ENSG00000145451 
GLYAT glycine-N-acyltransferase 10249 ENSG00000149124 
GPM6A glycoprotein M6A 2823 ENSG00000150625 
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GPR17 G protein-coupled receptor 17 2840 ENSG00000144230 
GPR22 G protein-coupled receptor 22 2845 ENSG00000172209 
GRIN2B glutamate receptor, ionotropic, N-methyl D-aspartate 2B 2904 ENSG00000150086 
HAL histidine ammonia-lyase 3034 ENSG00000084110 
HAO1 hydroxyacid oxidase (glycolate oxidase) 1 54363 ENSG00000101323 
HEPACAM2 HEPACAM family member 2 253012 ENSG00000188175 
HHLA2 HERV-H LTR-associating 2 11148 ENSG00000114455 
IGFBP1 insulin-like growth factor binding protein 1 3484 ENSG00000146678 
INTS4 integrator complex subunit 4 92105 ENSG00000149262 
IQGAP2 IQ motif containing GTPase activating protein 2 10788 ENSG00000145703 
KCNK10 potassium channel, subfamily K, member 10 54207 ENSG00000100433 
KLF12 Kruppel-like factor 12 11278 ENSG00000118922 
KRT38 keratin 38 8687 ENSG00000171360 
LAMA2 laminin, alpha 2 3908 ENSG00000196569 
LHX9 LIM homeobox 9 56956 ENSG00000143355 
LMO3 LIM domain only 3 (rhombotin-like 2) 55885 ENSG00000048540 
LOC400891 chromosome 14 open reading frame 166B pseudogene 400891 NA 
MAGEC2 melanoma antigen family C, 2 51438 ENSG00000046774 
MAGEE2 melanoma antigen family E, 2 139599 ENSG00000186675 
MC2R melanocortin 2 receptor (adrenocorticotropic hormone) 4158 ENSG00000185231 
MIPOL1 mirror-image polydactyly 1 145282 ENSG00000151338 
MPL myeloproliferative leukemia virus oncogene 4352 ENSG00000117400 
MTMR8 myotubularin related protein 8 55613 ENSG00000102043 
MYO3B myosin IIIB 140469 ENSG00000071909 
MYT1L myelin transcription factor 1-like 23040 ENSG00000186487 
NCAM1 neural cell adhesion molecule 1 4684 ENSG00000149294 
NCR2 natural cytotoxicity triggering receptor 2 9436 ENSG00000096264 
NDST4 N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 
4 
64579 ENSG00000138653 
NOVA1 neuro-oncological ventral antigen 1 4857 ENSG00000139910 
NPBWR2 neuropeptides B/W receptor 2 2832 ENSG00000125522 
OLFM3 olfactomedin 3 118427 ENSG00000118733 
OPRM1 opioid receptor, mu 1 4988 ENSG00000112038 
OR2J2 olfactory receptor, family 2, subfamily J, member 2 26707 ENSG00000204700 
OR5V1 olfactory receptor, family 5, subfamily V, member 1 81696 ENSG00000243729 
P2RY10 purinergic receptor P2Y, G-protein coupled, 10 27334 ENSG00000078589 
PCDH20 protocadherin 20 64881 ENSG00000197991 
PDE11A phosphodiesterase 11A 50940 ENSG00000128655 
PER3 period homolog 3 (Drosophila) 8863 ENSG00000049246 
PMS1 PMS1 postmeiotic segregation increased 1 (S. cerevisiae) 5378 ENSG00000064933 
POF1B premature ovarian failure, 1B 79983 ENSG00000124429 
POU1F1 POU class 1 homeobox 1 5449 ENSG00000064835 
PPP1R3A protein phosphatase 1, regulatory subunit 3A 5506 ENSG00000154415 
PPP3R2 protein phosphatase 3, regulatory subunit B, beta 5535 ENSG00000188386 
PREX2 phosphatidylinositol-3,4,5-trisphosphate-dependent Rac 
exchange factor 2 
80243 ENSG00000046889 
PTCHD1 patched domain containing 1 139411 ENSG00000165186 
PTH parathyroid hormone 5741 ENSG00000152266 
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PTN pleiotrophin 5764 ENSG00000105894 
RALYL RALY RNA binding protein-like 138046 ENSG00000184672 
RNF165 ring finger protein 165 494470 ENSG00000141622 
SCEL sciellin 8796 ENSG00000136155 
SCML4 sex comb on midleg-like 4 (Drosophila) 256380 ENSG00000146285 
SCN2B sodium channel, voltage-gated, type II, beta subunit 6327 ENSG00000149575 
SDR16C5 short chain dehydrogenase/reductase family 16C, 
member 5 
195814 ENSG00000170786 
SERPINB4 serpin peptidase inhibitor, clade B (ovalbumin), member 4 6318 ENSG00000206073 
SFRP4 secreted frizzled-related protein 4 6424 ENSG00000106483 
SIM1 single-minded homolog 1 (Drosophila) 6492 ENSG00000112246 
SLC13A1 solute carrier family 13 (sodium/sulfate symporters), 
member 1 
6561 ENSG00000081800 
SLC17A1 solute carrier family 17 (sodium phosphate), member 1 6568 ENSG00000124568 
SLC17A8 solute carrier family 17 (sodium-dependent inorganic 
phosphate cotransporter), member 8 
246213 ENSG00000179520 
SLC26A7 solute carrier family 26, member 7 115111 ENSG00000147606 
SLC5A7 solute carrier family 5 (choline transporter), member 7 60482 ENSG00000115665 
SOX6 SRY (sex determining region Y)-box 6 55553 ENSG00000110693 
SRP72 signal recognition particle 72kDa 6731 ENSG00000174780 
TAS2R16 taste receptor, type 2, member 16 50833 ENSG00000128519 
TCTE3 t-complex-associated-testis-expressed 3 6991 ENSG00000184786 
TMED5 transmembrane emp24 protein transport domain 
containing 5 
50999 ENSG00000117500 
TMEM67 transmembrane protein 67 91147 ENSG00000164953 
TPPP2 tubulin polymerization-promoting protein family member 
2 
122664 ENSG00000179636 
TRDN triadin 10345 ENSG00000186439 
TRPC5 transient receptor potential cation channel, subfamily C, 
member 5 
7224 ENSG00000072315 
TRPM1 transient receptor potential cation channel, subfamily M, 
member 1 
4308 ENSG00000134160 
TSHR thyroid stimulating hormone receptor 7253 ENSG00000165409 
UGT2A3 UDP glucuronosyltransferase 2 family, polypeptide A3 79799 ENSG00000135220 
UNC5C unc-5 homolog C (C. elegans) 8633 ENSG00000182168 
UPP2 uridine phosphorylase 2 151531 ENSG00000007001 
VASH2 vasohibin 2 79805 ENSG00000143494 
ZDHHC15 zinc finger, DHHC-type containing 15 158866 ENSG00000102383 
ZNF407 zinc finger protein 407 55628 ENSG00000215421 
ZNF780B zinc finger protein 780B 163131 ENSG00000128000 
HSPE = Histamine Specific genes in PE (elevated histamine regulated significant genes also expressed 
consistently in PE placentae); PE = Pre-eclampsia 
 
 
 
 
 
 
 179 
Appendix 8: Validation Genes Primer sequences for RT-qPCR 
Target Primer sequence (5’ to 3’) 
 
Product 
length (bp) 
GenBank ® 
accession 
number 
L19 F: GCGGAAGGGTACAGCCAAT 
R: GCAGCCGGCGCAAA 
140 NM_000981.3 
AKR1C1 F: ATTTGCCAGCCAGGCTAGTG 
R: ACTTTTAGGACCTCTGCAGGC 
122 NM_001353.5 
EREG F: CTGCCTGGGTTTCCATCTTCT 
R: GCCACACGTGGATTGTCTTC 
123 NM_001412.2 
IGFBP5 F: AAAGCAGTGCAAACCTTCCC 
R: CACTCAACGTTGCTGCTGTC 
138 NM_001353.5 
AKR1C1, aldo-ketose reductase family 1 member C1; EREG, epiregulin; IGFBP5, insulin-like growth factor 
binding protein 5; RT-qPCR, real-time quantitative polymerase chain reaction;  
 
 
Appendix 9: RT-qPCR Validation results relative to L19 
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